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AVANT-PROPOS 
Ce n’est pas pour rien  que le KCE consacre un quatrième rapport au cancer du 
rectum. Les cancers du colon et du rectum sont en effet parmi les cancers les plus 
fréquents, et leur impact est donc loin d’être négligeable. Mais en outre, voilà plus de 5 
ans que dans notre pays, un groupe enthousiaste et visionnaire de chirurgiens et autres 
cliniciens actifs, milite en faveur d’une amélioration radicale de la qualité des soins du 
cancer rectal. A travers des sensibilisations, des formations, un enregistrement de 
données avec feedback, l’initiative du groupe PROCARE apporte un soutien à un grand 
nombre de cliniciens, et mérite à juste titre l’appellation de travail de pionnier. 
Tout qui s’est déjà  frotté à la collecte de données cliniques sait combien c’est difficile. 
D’une part, enregistrer des données de manière précise et fiable sur le patient, sa 
maladie, le processus diagnostique et le traitement, exige un effort continu. D’autre 
part, il s’agit de données très sensibles, à la fois pour la vie privée du patient et  pour les 
intérêts professionnels du médecin. Enfin, la manière dont ces informations sont 
retransmises aux prestataires de soins concernés doit répondre aux règles de l’art.  
C’est ce dernier aspect qui a fait l’objet d’une étude approfondie dans ce rapport. La 
transformation de données cliniques brutes en un feedback éloquent n’est en effet pas 
une mince affaire. Il faut  soupeser  la valeur spécifique de l’information contenue dans 
chaque donnée enregistrée, et trouver la meilleure manière de les rassembler dans des 
indicateurs synthétiques.  
Il s’agit clairement d’un travail de spécialistes dans lequel le KCE a pu compter sur 
l’expertise de l’équipe de Stat-Crescendo de l’Université de Gand. Nous les remercions 
pour leur contribution  minutieuse. Les méthodes mises au point pourront être utiles 
dans d’autres projets à venir. Mais sans l’excellent soutien du Registre du Cancer, et 
sans l’enthousiasme et la confiance des cliniciens du groupe PROCARE, cette étude 
n’aurait pas été possible. Nos sincères remerciements leur sont également adressés. 
 
 
 
 
 
Jean Pierre CLOSON     Raf MERTENS 
Directeur général adjoint     Directeur général 
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Résumé  
INTRODUCTION 
En 2004, la Section de Chirurgie colorectale de la Société royale belge de Chirurgie a 
décidé de lancer le projet PROCARE (PROject on CAncer of the REctum), une 
initiative multidisciplinaire, pilotée par la profession et décentralisée, dont l’objectif 
principal visait à réduire la variabilité diagnostique et thérapeutique, de même qu’à 
améliorer les résultats des soins chez les patients souffrant d’un cancer du rectum. En 
2005, toutes les spécialités médicales impliquées dans la prise en charge du cancer du 
rectum ont créé un groupe de pilotage multidisciplinaire. Elles ont convenu 
d’appréhender l’objectif précité en normalisant le traitement grâce à des 
recommandations de bonne pratique, une mise en œuvre de ces recommandations et 
une garantie de qualité via un enregistrement de données et un feedback.  
En 2007, les recommandations de bonne pratique PROCARE ont été actualisées 
(Procare Phase I, rapport KCE 69). En 2008, un ensemble de 40 indicateurs de qualité 
clinique (IQC) (indicateurs de processus et de résultat) a été défini et subdivisé en 8 
domaines de soins : soins généraux, diagnostic/stadification, traitement néoadjuvant, 
chirurgie, traitement adjuvant, soins palliatifs, suivi et examen histopathologique. Ces 
IQC ont été testés sur la base de données prospective PROCARE ainsi que sur la base 
de données administratives (données de remboursement) (Procare Phase II, rapport 
KCE 81). Par la suite, quatre IQC ont été ajoutés par le groupe PROCARE.  
Les centres ont reçu un feedback du registre PROCARE sur ces IQC, avec une 
description de la distribution des moyennes non ajustées des centres, et de la position 
des centres dans cette distribution. Pour optimiser ce feedback, les centres devraient 
idéalement être informés de leurs résultats ajustés en fonction du case-mix, et disposer 
de certains points de repère. La phase III du projet PROCARE est consacrée à 
l’élaboration d’une méthodologie visant à réaliser ce feedback. 
OBJECTIF ET QUESTIONS DE RECHERCHE  
La présente étude a pour but de définir une méthodologie pour évaluer la qualité des 
soins cliniques dispensés aux patients atteints d’un cancer du rectum sur base de 
l’ensemble des IQC disponibles. Indépendamment de son application spécifique, la 
méthodologie définie devrait idéalement être de nature générique et applicable à 
d’autres cancers et à d’autres pathologies (chroniques).  
Les questions de recherche sont les suivantes:  
1. Quelles sont les caractéristiques cliniques des patients (facteurs pronostiques) 
qui doivent être prises en compte pour permettre une évaluation correcte de la 
qualité des soins chez les patients souffrant d’un cancer du rectum, sur la base de 
l’ensemble des IQC existants ?  
2. Quelle est la méthodologie statistique la mieux adaptée – en tenant compte de la 
faisabilité - pour identifier les centres dont les performances sont meilleures ou 
moins bonnes que les autres ? 
3. Comment combiner les indicateurs de résultat et les indicateurs de processus 
des 8 domaines de soins ?  Comment définir un score composite sur la base de 
ces 8 domaines de soins ? Peut-on faire l’impasse sur certains indicateurs? 
Autrement dit, quels indicateurs sont essentiels pour évaluer les performances 
des centres ?  
4. Comment présenter ces résultats dans un feedback individuel aux équipes ?  
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FACTEURS AYANT UN IMPACT SUR LES 
RÉSULTATS DANS LE CANCER DU RECTUM  
MÉTHODES 
Une revue de la littérature a été réalisée sur base de la littérature indexée. Des facteurs 
pronostiques ont été recherchés pour la survie globale et pour la récidive locale.  
RÉSULTATS  
Le principal facteur pronostique pour la survie globale est le stade au moment du 
diagnostic. Le pronostic est de loin plus mauvais pour les patients présentant une 
occlusion intestinale, une perforation, une invasion séreuse ou des métastases 
péritonéales, après avoir tenu compte des autres facteurs. A l’inverse de l’âge, le sexe 
ne constitue pas un facteur pronostique. Dans plusieurs études, le dénuement socio-
économique est également considéré comme pronostique de la survie au cancer 
colorectal. En outre, nous avons identifié un large éventail de variables de pronostic 
pathologique tant macroscopiques que microscopiques et moléculaires. Les facteurs 
pronostiques pour la récidive locale sont répertoriés à l’annexe 2. 
CADRE CONCEPTUEL POUR LA COMPARAISON 
DES CENTRES SUR BASE D’INDICES DE QUALITÉ  
Les méthodes proposées ici se fondent sur le précédent ensemble de 44 IQC.  
Les méthodes permettant de profiler les dispensateurs de soins comportent trois 
étapes : (1) une étape d’ajustement pour les différences de risque entre les patients, (2) 
le choix d’un IQC (il peut s’agir d’un score composite), et (3) la comparaison 
proprement dite. Chacune de ces étapes a fait l’objet d’une étude sur la base la 
littérature méthodologique et des résultats d’études de simulation.  
1ÈRE ÉTAPE: AJUSTEMENT POUR LE RISQUE  
Le but de cet ajustement est de corriger l’effet des centres sur les résultats du 
traitement des patients, en tenant compte des caractéristiques des patients. Il existe 
quatre types de méthodes statistiques pour réaliser cet ajustement.  
1. Les modèles de régression standard, avec ajustement pour les variables 
confondantes disponibles (aussi appelé modèle à effets fixes); 
2. Les modèles de régression qui intègrent des effets stochastiques pour tenir 
compte de la variabilité entre les centres  (aussi appelé modèle à effets aléatoires 
ou modèle hiérarchique); 
3. Les méthodes qui utilisent le score de propension (propensity score), càd qui 
corrigent pour la probabilité pour un patient présentant un ensemble donné de 
facteurs de risque, d’être traité dans chacun des hôpitaux considérés ; 
4. Les méthodes qui utilisent des variables instrumentales. La variable instrumentale 
qui prédit le choix de l’hôpital mais pas le résultat, est utilisée comme instrument 
pour estimer le véritable effet de l’hôpital. D’ordinaire, on utilise comme variable 
instrumentale la distance entre le domicile du patient et le centre où ce patient 
est traité.  
Cette dernière méthode n’a pas été utilisée dans le présent projet en raison de 
l’absence de données relatives à la distance entre le domicile du patient et le centre.  
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Les méthodes ont été évaluées sur des facteurs tels que les hypothèses du modèle, la 
précision et l’exactitude de l’estimation, l’interprétation des résultats, la faisabilité, 
l’influence de l'effet de recentrage sur la moyenne  (la tendance pour les institutions 
ayant été identifiées comme « extrêmes » de devenir moins extrêmes si elles font 
l’objet d’une surveillance future), l'atténuation des effets estimés du centre, la capacité 
du modèle à détecter les centres extrêmes, à gérer des tailles d'échantillon différentes, 
et à gérer la question des comparaisons multiples. Les résultats de nombreuses 
simulations ont montré qu'aucune des trois méthodes précitées ne génère 
systématiquement les meilleurs résultats.  
2E ÉTAPE: LES DIMENSIONS DES SOINS ET LEUR AGRÉGATION 
Il s’agit ici de ramener l’ensemble des 44 indicateurs à une taille plus facilement gérable. 
Il existe de nombreuses références méthodologiques sur la construction de scores 
agrégés permettant la comparaison des centres de chirurgie cardiaque aux États-Unis, et 
la présente étape s'appuie sur ces méthodes. 
La sélection des IQC à intégrer dans l'indice de qualité composite est régie par les 
grands principes suivants: les indicateurs sélectionnés doivent avoir une 
importance/pertinence clinique, doivent permettre de distinguer les centres sur base 
des variations observées, doivent se fonder sur des données fiables, et doivent montrer 
empiriquement une étroite corrélation avec les différentes dimensions couvertes par les 
IQC. 
Une fois que la sélection des indicateurs a été effectuée, il existe différentes méthodes 
pour les agréger en un score composite (indice de qualité): moyenne simple ou 
pondérée,  combinaisons graduées ou scoring 'tout ou rien'. En fonction des arguments 
développés dans le rapport scientifique, le choix s'est porté sur le scoring « tout ou 
rien ».  
Deux stratégies ont été proposées pour concevoir des indices de qualité:  
1. L'approche clinico-statistique, qui se fonde sur les IQC considérés comme les 
plus sélectifs et pertinents d'un point de vue clinique, et qui effectue ensuite une 
analyse en composantes principales et une analyse factorielle, visant à déterminer 
si les IQC sélectionnés intègrent l'éventail complet des IQC de bonne qualité; 
2. L'approche statistico-clinique, qui débute par une analyse en composantes 
principales et une analyse factorielle des IQC de bonne qualité, puis choisit les 
IQC les plus sélectifs et pertinents d'un point de vue clinique.  
Le consensus et la participation  des cliniciens sont essentiels dans les deux approches. 
Dans le cadre du présent projet, c'est la seconde approche (statistico-clinique) qui a été 
retenue.  
3E ÉTAPE: ANALYSE DES MÉTHODES STATISTIQUES DE PROFILAGE 
DES PRESTATAIRES  
Une fois qu'un score composite a été défini, l'étape suivante consiste à comparer les 
centres. Cette étape se fonde sur des travaux antérieurs menés sur la chirurgie 
cardiaque aux États-Unis et sur des audits de la chirurgie du cancer colorectal aux Pays-
Bas. La variation des indices de qualité entre les centres est visualisée au moyen d'un 
diagramme « en chenille » (« caterpillar plot ») (sur l'échelle Logit, sur l'échelle naturelle 
ou sur l’échelle des probabilité excédentaires).  
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DESCRIPTION DE LA BASE DE DONNÉES 
PROCARE  
METHODES 
La base de données PROCARE utilisée dans le cadre du présent projet couvre la 
période comprise entre 2006 et août 2010. La couverture nationale de la base de 
données a été évaluée en la comparant au Registre belge du Cancer (disponible jusqu’à 
fin 2008). Des statistiques descriptives des variables principales de la base de données 
PROCARE ont été produites.  
RÉSULTATS 
Représentativité de la base de données PROCARE  
La couverture nationale de la base de données est de 30% environ (34,6% en 2006, 
31,2% en 2007 et 26,4% en 2008). D'importantes variations en termes de couverture 
sont observées selon le stade clinique: les stades cliniques I, II et III atteignent une 
couverture supérieure à 35% (48% pour le stade clinique III) ; par contre, la couverture 
chute à 25% pour les patients en stade clinique IV.   
Description de la cohorte de l'étude 
Une population totale de 3.328 patients traités dans 79 centres était disponible pour 
analyse (nombre médian de patients inclus dans l’étude par centre = 32.5). L'âge moyen 
était de 67 ans (écart type= 12 ans) et 61% des patients étaient de sexe masculin. Il 
convient de souligner les nombreuses données manquantes dans la base de données: 
l'âge au moment du diagnostic (6%), le stade clinique (15%), le stade pathologique (14%), 
le niveau de la tumeur (10%), l'indice de masse corporelle (37%), le score ASA (21%), le 
type de chirurgie (14%), la localisation de la tumeur (25%), et la marge circonférentielle 
(36%). Le taux de suivi est en outre assez faible, car seulement 56% des patients ont au 
moins un formulaire de suivi enregistré (premier suivi planifié 6 mois après la date 
d’incidence). Le statut vital était toutefois disponible pour la presque totalité des 
patients, grâce à un lien direct avec le Registre National (de la population belge). 
ANALYSE DES INDICATEURS INDIVIDUELS DE LA 
QUALITÉ DES SOINS 
MÉTHODES 
Les 44 IQC ont été analysés individuellement. Un modèle pronostique distinct a été 
construit pour chacun d'eux, en ayant recours aux méthodes de régression pas à pas 
pour sélectionner les facteurs pronostiques. Pour traiter les données manquantes, soit 
des catégories distinctes ont été définies, soit des méthodes d'imputations multiples ont 
été utilisées.. Trois méthodes ont ensuite été testées (effet fixe, effet aléatoire et score 
de propension) pour évaluer l'effet du centre sur les IQC, en utilisant les mêmes 
facteurs de risque initiaux que ceux qui avaient été définis lors des étapes précédentes. 
Pour les indicateurs de processus, aucun ajustement n'a été effectué. Enfin, les effets des 
centres ont été présentés sous la forme d'une probabilité excédentaire de résultat (par 
rapport à un centre moyen). 
Pour préserver la confidentialité des centres, aucune statistique descriptive relative aux 
centres n'a été présentée. 
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RÉSULTATS 
Pour chacun des 44 IQC, la définition opérationnelle, le nombre de patients éligibles, le 
taux de réponse au niveau national, les facteurs pronostiques et une analyse détaillée 
par centre sont disponibles dans l'annexe 6 du rapport scientifique. 
Les résultats observés pour chacun des indicateurs étaient élevés dans la plupart des 
cas: une médiane de 90% (écart type 8%) pour les 16 indicateurs de résultat et une 
médiane de 85% (écart type 11%) pour 25 indicateurs de processus. Toutefois, 3 IQC 
de processus ont obtenu  des résultats très faibles: le pourcentage de patients en stade 
clinique I-III pour lesquels une marge de résection circonférentielle a été rapportée 
(cCRM, 26%), la correction de la stadification clinique M0 (6%) et le pourcentage de 
patients en stade I ayant reçu un traitement néoadjuvant radio(chimio)thérapie (17%).  
INDICES DE QUALITÉ AGRÉGÉS 
MÉTHODES 
Les IQC ont été agrégés en indices de qualité combinés en vue de mesurer de manière 
globale la qualité de tous les IQC de résultat (1), de tous les IQC de processus (2), par 
domaine de soins (3) et finalement un indice de qualité unique global (4). 
Les étapes suivantes ont été mises en oeuvre pour la sélection des IQC et leur 
intégration dans l'indice agrégé:  
1. Évaluation de la qualité et de la fiabilité des IQC individuels. Cette évaluation a 
été réalisée via une enquête auprès des  cliniciens du groupe PROCARE; 
2. Évaluation du nombre de dimensions requises, par le biais d’une analyse en 
composantes principales et la sélection d'IQC représentatifs via une analyse 
factorielle; 
3. Évaluation de l'importance clinique par consensus au sein du groupe PROCARE; 
4. Évaluation de la capacité de distinguer les centres (valeur p significative en termes 
de capacité prédictive par rapport à la survie globale). 
Deux méthodes d'agrégation des scores ont été comparées: la méthode tout ou rien et la 
méthode de simple moyenne. La méthode tout ou rien détermine si un patient satisfait à la 
norme de niveau patient pour tous les IQC figurant dans l'indice. La méthode de moyenne 
simple est basée sur la moyenne des probabilités excédentaires. Lorsque le suivi n'a pas 
été suffisamment long (par exemple la survie à moins de 3 ans), diverses techniques 
d'imputation ont été utilisées pour incorporer la survie de ces patients dans le calcul du 
score tout ou rien. 
Les scores agrégés impliquant des indicateurs de résultat ont été ajustés en fonction des 
caractéristiques  de risque de base des patients, en utilisant une procédure de 
régression pas à pas. Les variables suivantes ont été initialement introduites dans le 
modèle: âge, sexe, IMC, stade clinique, score ASA de comorbidité, niveau de la tumeur, 
type de chirurgie, tumeur ventrale,  cCRM, cT4, incontinence préopératoire et 
technique chirurgicale. Les centres ont été catégorisés comme ayant des résultats 
significativement inférieurs au percentile 25 (P25) ou supérieurs au percentile 75 (P75) 
lorsque les limites de leur intervalle de confiance 95% (IC 95%) autour de leur 
probabilité excédentaire étaient inférieures à P25 ou supérieures à P75. 
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RÉSULTATS 
Indice agrégé de qualité de résultat  
Sur les 16 IQC de résultat, 6 satisfaisaient aux critères de qualité des données. Trois 
d'entre eux ont été retenus pour composer l'indice de qualité de résultat: (1) survie 
globale, (2) proportion de résections R0 et (3) absence de morbidité chirurgicale 
postopératoire majeure avec réintervention sous narcose après résection chirurgicale 
radicale.  
L'approche tout ou rien s'est révélée permettre mieux distinguer les centres que la 
méthode par moyenne simple. L'indice de qualité moyen des centres était de 68%, ce 
qui signifie que, dans un centre moyen, les trois indicateurs susmentionnés étaient 
positifs pour 68% des patients. Après ajustement en fonction des caractéristiques des 
patients, un centre s'est retrouvé significativement inférieur à P25 (probabilité 
excédentaire comparée au centre moyen: -9%) et 3 centres était statistiquement 
supérieurs au P75 (probabilité excédentaire comparée au centre moyen: 8%). 
Indice agrégé de qualité de processus  
Sur les 28 IQC de processus, douze satisfaisaient aux critères de qualité. L'indice final de 
qualité de processus est fondé sur quatre IQC: (1) délai entre le premier diagnostic 
histopathologique et le premier traitement moins de 30 jours, (2) pourcentage de 
patients sans procédure APR-Hartmann ou d’exérèses totales du côlon et du rectum 
avec iléostomie définitive, (3) marge distale indemne de tumeur mentionnée dans le 
rapport de pathologie et (4) examen d’au minimum 10 ganglions lymphatiques.  
Ici aussi, l'approche tout ou rien a été préférée à la méthode par moyenne simple, en 
raison de sa plus grande capacité à distinguer les centres. Tous centres inclus, l'indice de 
qualité moyen était de 40%. Quatre et cinq centres, respectivement, ont obtenu des 
pourcentages significativement inférieurs au P25 (-11%) et significativement supérieurs 
au P75 (+17%). 
 Indice agrégé de qualité par domaine  
Un indice composite a été conçu pour 5 des 8 domaines. Le nombre de patients 
éligibles n'était pas suffisant pour les domaines 5 (traitement adjuvant), 6 (traitement 
palliatif) et 7 (suivi). Pour le domaine général, un seul IQC a été sélectionné (survie 
globale). Les résultats du processus de sélection sont présentés dans le Tableau 1.  
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Table 1: Résultats de la définition d'Indices de Qualité par domaine de soins, en utilisant la méthode tout ou rien 
Domaine de 
soins 
Nombre 
initial 
d'IQC de 
résultat 
Nombre 
initial d'IQC 
de processus  
IQC intégrés dans l'Indice de Qualité Score observé 
(médiane parmi les 
centres) 
Variabilité entre les 
centres (plage 
interquartile de 
probabilités 
excédentaires) 
1 Indicateurs de 
qualité généraux  
5 0 Survie globale  72 % 14% 
2 Diagnostic et 
stadification 
0 11 Proportion de patients possédant une distance 
documentée par rapport à la bordure anale 
Délai entre le premier diagnostic histopathologique et le 
premier traitement  
60 % 31% 
3 Traitement 
néoadjuvant  
1 6 Proportion de patients cStage II-III ayant reçu un 
traitement néoadjuvant sous la forme d’une radiothérapie 
pelvienne 
71 % 27% 
4 Chirurgie 9 1 Proportion de résections R0  
Fuite majeure après résection mésorectale + chirurgie 
d’épargne sphinctérienne + chirurgie (globale)  
Proportion de résections abdomino-périnéales – de 
procédures d’Hartmann ou d’exérèses totales du côlon et 
du rectum avec iléostomie définitive  
70 % 12% 
5 Traitement 
adjuvant 
1 4 Pas assez de patients éligibles 
6 Traitement 
palliatif  
0 1 Pas assez de patients éligibles 
7 Suivi 1 1 Pas assez de patients éligibles 
8 Examen 
histopathologique  
0 7 Pertinence de la marge distale mentionnée après une 
chirurgie d’épargne sphinctérienne ou une procédure 
d’Hartmann 
Nombre de ganglions lymphatiques examinés  
62% 25% 
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C'est dans les domaines 2, 3 et 8 que la plus grande variabilité entre centres a été 
observée. Les efforts d'harmonisation du traitement chirurgical (domaine 4) ont 
manifestement été suivis d'effet dans cette cohorte, dans la mesure où la variation qui y 
a été observée est moindre. Pour les centres outliers, le diagramme en chenille justifie 
une étude des covariables spécifiques à chaque centre qui contribuent à leur 
sous/surperformance. La Figure 1 représente le diagramme en chenille du domaine 2.  
Figure 1: Diagramme en chenille de la probabilité 'excédentaire' spécifique à 
chaque centre , pour le score 'tout ou rien' du domaine 2 (diagnostic et 
stadification)  
 
Indice de qualité composite global 
En partant de 28 IQC de processus et de 16 IQC de résultat, et après avoir appliqué de 
rigoureux critères de qualité des données, six indicateurs de résultat et douze 
indicateurs de processus ont été sélectionnés pour composer l'indice composite. Après 
application de la procédure d'agrégation statistico-clinique, deux indicateurs de résultat 
et quatre indicateurs de processus ont finalement pu être retenus.  
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DISCUSSION  
Le présent rapport documente les résultats de la conception et de la mise en œuvre de 
méthodes d'évaluation de la qualité des soins prodigués par des centres de traitement 
du cancer du rectum enregistrant de manière volontaire des informations relatives à des 
indicateurs de qualité, pour certains de leurs patients, dans le registre  PROCARE. La 
méthodologie mise au point est générique par nature et l'approche s'applique au 
monitoring des soins dans un large éventail de cancers ou d’autres domaines 
pathologiques. 
Le monitoring et l'évaluation des soins envisagés ici poursuivent essentiellement un but 
éducatif, par le biais d'un feedback confidentiel à chacun des centres de soins quant à sa 
performance par rapport aux indicateurs de qualité, le cas échéant après ajustement en 
fonction du case-mix. Ce feedback s'accompagne d'une identification des performances 
trop basses. Si cette initiative a pour but d'engendrer une amélioration des soins, aucun 
contrôle spécifique de la réponse apportée à ce feedback n'est actuellement effectué. La 
question de savoir si et dans quelle mesure le feedback induit bien la réaction souhaitée 
et une optimisation des soins, n'a pas encore été traitée spécifiquement et pourrait faire 
l'objet d'une étude ultérieure. 
Le feedback se présente sous la forme de présentations, tantôt globales, tantôt 
spécifiques au domaine, de la performance du centre exprimée sous la forme d'un 
pourcentage excédentaire: le pourcentage attendu de patients du centre, en excédent 
de celui d'un centre moyen, pour lequel tous les indicateurs de qualité pertinents 
composant l'indice composite sont satisfaits. Les centres sont classés dans un 
diagramme par ordre de probabilité excédentaire estimée (de la plus haute à la plus 
basse) et présentés avec l'intervalle de confiance à 95% autour de cette probabilité 
excédentaire. Le chevauchement des intervalles de confiance entre centres indique que 
l'ordre de représentation dans le diagramme ne doit pas être considéré comme un 
classement intrinsèque des centres. Une incertitude importante subsiste quant à la 
performance de qualité relative, en particulier pour les centres qui n'ont enregistré que 
peu de patients dans la base de données.  
Idéalement, les intervalles de confiance sur les indices de qualité devraient être 
comparés à des repères absolus de la qualité des soins. Dans la pratique, de telles 
évaluations objectives ne sont pas encore disponibles, de sorte que les intervalles sont 
simplement liés aux percentiles (quartiles) de performance pour tous les centres. Les 
évaluations relatives présentent deux inconvénients évidents: (1) des exigences plus 
fortes sont formulées dans les domaines où la performance est généralement meilleure 
(càd avec moins de variabilité entre les centres) et (2) leurs résultats fluctueront très 
probablement avec le temps et ne peuvent être utilisés à des fins de comparaison 
internationale. 
Les scores agrégés par domaine de soins permettent de comparer les centres sur des 
services spécifiques. Leur composition est conçue pour intègrer  moins d'IQC que ceux 
contenus dans la base de données, et ce sans perdre beaucoup d'informations. La 
réduction du nombre d'IQC obtenue dans ce type d'évaluation suggère donc  une 
manière plus économique de collecter les données.  
L'application des méthodes envisagées à la base de données PROCARE atteste de la 
faisabilité de l'approche choisie, mais souligne aussi ses limites, inhérentes aux lacunes 
de la base de données en termes d'exhaustivité et de qualité des données. Les résultats 
ne peuvent être utilisés sans esprit critique pour juger objectivement de la qualité du 
traitement du cancer du rectum en Belgique à l'heure actuelle. Au fur et à mesure que la 
base de données se complètera et s'enrichira, on peut espérer qu'un nombre croissant 
de variables atteindront le seuil de qualité requis pour être intégrées dans l'indice de 
qualité agrégé. On peut s'attendre en conséquence à ce que ces indices, et leurs 
modèles d'ajustement, évoluent dans un avenir proche. Une fois que la structure de la 
base de données sera stabilisée, il devrait être possible d'utiliser un modèle donné 
pendant un certain laps de temps, sans qu'il soit nécessaire de le reconstruire à chaque 
application de feedback. 
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Malgré les limites de la base de données, certaines conclusions se dessinent avec clarté. 
À titre d'exemple, les initiatives de standardisation du traitement chirurgical semblent 
avoir porté leurs fruits auprès des chirurgiens sélectionnés contribuant à la base de 
données PROCARE. Cette observation ressort de la variabilité relativement faible de la 
performance ajustée par centre dans le domaine 'chirurgie'. Cette faible variabilité 
contraste avec les résultats obtenus dans les domaines 4 (diagnostic et stadification) et 8 
(histopathologie), où les variations sont nettement plus substantielles. Dans ces deux 
domaines, respectivement cinq et deux centres ont des indicateurs dont le score est 
significativement inférieur au P25. Ces résultats donnent la mesure de la marge de 
progression potentielle dans ces domaines. Un système éducatif tel que celui mis en 
place pour la chirurgie, peut être considéré comme souhaitable pour progresser. 
QUELLE EST L'UTILITÉ DU PRÉSENT RAPPORT?  
Le traitement du cancer est un processus multidisciplinaire, qui conjugue plusieurs 
cheminements cliniques longs et complexes afin d'optimiser l'issue pour les patients. 
Des scores composites permettant d'évaluer les centres ont déjà été mis au point aux 
États-Unis dans le domaine de la chirurgie cardiaque, mais il s'agit ici d'une pathologie 
impliquant un traitement moins complexe et moins long, qui se traduit donc par des 
indicateurs de processus eux aussi moins complexes. Le présent rapport innove en 
proposant une méthodologie qui prend en compte la nature multidisciplinaire de 
l'oncologie, en s'intéressant aux domaines de soins, et qui combine des indicateurs de 
résultat et de processus en indices composites, ajustés le cas échéant en fonction des 
caractéristiques des patients.  
CONCLUSION 
En conclusion, nous tenons à répéter que le présent rapport présente essentiellement 
une approche méthodologique du problème de l'évaluation de la qualité des soins. Son 
application à l'actuelle base de données PROCARE atteste en outre de la faisabilité 
pratique des méthodes sélectionnées dans ce contexte. À ces deux égards, ni la 
méthodologie ni l'application n'apportent une 'réponse finale', mais des avancées 
significatives ont été enregistrées et une approche praticable a été présentée pour les 
travaux futurs.   
L'application à la base de données PROCARE et les résultats qui en découlent héritent 
de toutes les imperfections de la base de données actuelle. La sélectivité  des patients 
enregistrés, les données manquantes et l'inconstance dans la qualité des données sont 
autant de facteurs qui doivent inciter à la circonspection dans l'interprétation des 
résultats.  
Nous conclurons en soulignant que l'enregistrement, l'analyse et le feedback des 
indicateurs de la qualité des soins constituent autant d'instruments irremplaçables en 
vue de l'amélioration de cette qualité des soins. Ils sont essentiels pour évaluer la 
performance des centres de soins de santé en se fondant sur des données prouvées, et 
pour formuler de stratégies d'optimisation des soins. 
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RECOMMANDATIONSa 
Recommandations méthodologiques génériques, liées aux sets d’indicateurs en 
oncologie 
• Puisque les méthodes standard de régression (appelées modèles à effets 
fixes), avec adaptation  pour les faibles tailles d’échantillon, semblent être les 
meilleures dans des situations où un grand nombre de centres traite un 
faible nombre de patients, ce qui est typiquement le cas des centres 
oncologiques belges, le KCE recommande d’adopter ces méthodes 
statistiques dans les futures études visant à l’ajustement pour le risque. 
• Quand il est envisagé de construire un score composite sur base d’un set 
d’indicateurs déjà testé lors une étude pilote,  la sélection des indicateurs de 
qualité les plus appropriés devrait être basée sur les facteurs suivants :  
o qualité et fiabilité des indicateurs individuels; 
o importance clinique; 
o potentiel de distinguer les centre entre eux ; 
o capacité à prédire les résultats.  
• L’approche « tout ou rien » devrait être utilisée pour construire le score 
composite.  
• Pour visualiser la variabilité de qualité entre les centres, le KCE 
recommande d’utiliser les graphiques « en entonnoir » (funnel plot) comme 
premier outil graphique de visualisation. Les graphique « en chenille » 
(caterpillar plot) des probabilités excédentaires, ajustées si nécessaire pour 
le case-mix, devraient être utiliser pour la comparaison entre les centres.  
• Pour la comparaison entre les centres, le KCE recommande d’utiliser des 
valeurs cibles externes.  
• Pour développer un système de qualité effectif et durable, comme déjà 
recommandé dans le rapport KCE 152, l’enregistrement des données doit 
être le plus complet possible. Les data managers qui sont disponible dans les 
hôpitaux dans le cadre du Plan National Cancer devraient s’y consacrer de 
manière maximale.  
Recommandations spécifiques applicable au registre PROCARE 
• En vue de diminuer la lourdeur  actuelle de l’enregistrement dans le registre 
PROCARE, le KCE recommande une triple stratégie:  
• Dans la liste actuelle de 44 indicateurs de qualité, des indicateurs clé 
devraient être sélectionnés qui résultent de la construction du score 
composite ; 
• L’enregistrement des données dans le registre PROCARE devrait se 
limiter à l’information nécessaire pour calculer les indicateurs 
sélectionnés et à permettre l’ajustement pour le risque; 
• Quand cela est possible, les bases de données administratives (en l’espèce 
les données de l’AIM) devraient être liées aux données PROCARE. 
• Compte tenu de la faible couverture du registre PROCARE, et pour 
permettre une comparaison juste et non biaisée entre les centres 
participants, le KCE recommande qu’un centre qui participe au registre 
PROCARE doive y enregistrer tous ses patients éligibles. Le feedback vers 
les centres devrait exclure les données des centres où l’enrôlement est 
sélectif.  
                                                     
a   Le KCE reste seul responsable des recommandations faites aux autorités publiques 
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• A moins que la couverture n’augmente, les résultats de la base de données 
PROCARE ne sont pas adéquats pour permettre la comparaison avec des 
données internationales.  
• Sur base des résultats de PROCARE, un large débat d’idées incluant toutes 
les parties concernées s’impose, afin de garantir la bonne continuation du 
projet tout en s’assurant de sa qualité.  
Agenda de recherche  
• Evaluer l’effet des facteurs socio économiques sur la modélisation des 
indicateurs de résultat et sur la comparaison entre les centres. 
• Tester si la distance du domicile d’un patient à son lieu de traitement 
pourrait améliorer le modèle statistique permettant  d’ajuster les résultats 
des indicateurs au case mix des patients.  
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LIST OF ABBREVIATIONS 
5-FU   5-fluorouracil 
APR   Abdomino-Perineal Resection of the rectum 
ASA   American Association of Anesthetists score 
BCR   Foundation Belgian Cancer Registry 
BMI   Body Mass Index 
CABG   Coronary Artery Bypass Grafting 
CBSS   Crossroads Bank of Social Security  
CEA   CarcinoEmbryonic Antigen (test) 
CI   Confidence Interval 
cN   nodal status 
CRM   Circumferential Resection Margin 
cT   clinical Tumor 
ec   Excess probability of achievement 
FU   Follow-Up 
ICD   International Classification of Diseases 
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IMA   Common Sickness Funds Agency (Intermutualistisch Agentschap/L'Agence 
Intermutualiste) 
INSS  Identification Number for Social Security (IdentificatieNummer voor de Sociale 
Zekerheid/Numéro d'Identification de la Sécurité Sociale) 
IQR   InterQuartile Range 
KCE  Belgian Health Care Knowledge Centre (Federaal Kenniscentrum voor de 
Gezondheidszorg/Centre fédéral d’expertise des soins de santé) 
MRI   Magnetic Resonance Imaging 
N   number 
NA   Not Applicable 
O   Outcome (QCI) 
ORM   standard Outcome Regression Model 
p   probability 
P   Process (QCI) 
P25   1st quartile or 25th percentile 
P75   3rd quartile or 75th percentile 
PCA   Principal Components Analysis  
PME   Partial Mesorectal Excision 
PROCARE   PROject on CAncer of the REctum 
PS   Propensity Score  
QCI   Quality of Care Indicator 
QI   Quality Index 
QLI   Quality of Life Index 
QQ-plot   Quantile-Quantile plot 
R0 resection   margin negative resection 
RC   Rectal Cancer 
RT   Radiotherapy 
RX   X-ray 
SES   Socio Economic Status  
SSO   Sphincter-Sparing Surgery 
TME   Total Mesorectal Excision 
TNM   Tumor Node Metastasis  
TRUS   TRansrectal UltraSonography 
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ABBREVIATED LIST OF AVAILABLE QCIS 
To facilitate reading of this report a list of all QCIs with their abbreviation and with a 
summary description is presented here.  
QCI Abbreviations Description 
1111 OS Overall survival 
1112 DSS Disease-specific survival 
1112b RS Relative survival 
1113 LRFS Proportion of patients with local recurrence 
1113b DFS Disease-free survival 
1211 %DocDist 
Proportion of patients with a documented distance from 
the anal verge 
1212 %CT_Preop Proportion of patients in whom a CT of the abdomen and 
RX or CT thorax was performed before any treatment 
1213 %CEA_Preop 
Proportion of patients in whom a CEA was performed 
before any treatment 
1214 %Preop_Bowel_Im 
Proportion of patients undergoing elective surgery that had 
preoperative complete large bowel-imaging 
1214b %TRUS_cT12 Use of TRUS in cT1/cT2 
1214c %MR_cII/III Use of MRI in cStage II or III 
1215 %Preop_Im Proportion of patients in whom a TRUS and pelvic CT 
and/or pelvic MRI was performed before any treatment 
1216 %cCRM_rep 
Proportion of patients with cStage II-III RC that have a 
reported cCRM 
1216b cM0_Acc Accuracy of cM0 staging 
1217 Time_histo-1ther 
Time between first histopathologic diagnosis and first 
treatment 
1221 %Preop_RT 
Proportion of cStage II-III patients that received a 
neoadjuvant pelvic RT 
1221b %(C)RT_cCRM+ Proportion of patients with cCRM = 2 mm on MRI/CT that 
received long course neoadjuvant radio(chemo)therapy 
1221c %Preop_RT_cI 
Proportion of patients with cStage I that received 
neoadjuvant radio(chemo)therapy 
1224 %Preop_cont_5FU 
Proportion of cStage II-III patients treated with neoadjuvant 
5-FU based chemoradiation that received a continuous 
infusion of 5-FU 
1225 %Completed_preop_RT 
Proportion of cStage II-III patients treated with a long 
course of preoperative pelvic RT or chemoradiation that 
completed this neoadjuvant treatment within the planned 
timing 
1226 %Surg<12w_after_Preop_RT 
Proportion of cStage II-III patients treated with a long 
course of preoperative pelvic RT or chemoradiation that 
was operated 4 to 12 weeks after completion of the 
(chemo)radiation 
1227 %grade4_Tox_Preop_RT 
Rate of acute grade 4 radio(chemo)therapy-related 
complications 
1231 %R0res Proportion of R0 resections 
1232a %Defin_ostomy 
Proportion of APR- Hartmann’s procedure or total excision 
of colon and rectum with definitive ileostomy 
1232b %stoma1year 
Proportion of patients with stoma 1 year after sphincter-
sparing surgery 
1233a %Leak_PME Major leakage after PME + SSO + reconstruction 
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1233b %Leak_TME Major leakage after TME + SSO + reconstruction (global) 
1234 30d_mort Inpatient or 30-day mortality after radical surgical resection 
1234b %Major_morb 
Postoperative major surgical morbidity with reintervention 
under narcosis after radical surgical resection 
1235 %Perfor Rate of intra-operative rectal perforation 
1235b %Pos_Dist_margin 
(y)p Distal margin involved (positive) after SSO or 
Hartmann for low rectal cancer (= 5 cm) 
1235c %Pos_CRM 
Mesorectal (y)pCRM positivity after radical surgical 
resection 
1241 %Adj-Chemo<3m 
Proportion of (y)pStage III patients with R0 resection that 
received adjuvant chemotherapy within 3 months after 
surgery 
1242 %Adj_RT<3m 
Proportion of pStage II-III patients with R0 resection that 
received adjuvant radiotherapy or chemoradiotherapy 
within 3 months after surgery 
1243 %Adj_Chemo<12w 
Proportion of (y)pStage II-III patients with R0 resection that 
started adjuvant chemotherapy within 12 weeks after 
surgical resection 
1244 %Adj_5FU 
Proportion of (y)pStage II-III patients with R0 resection 
treated with adjuvant chemo(radio)therapy that received 5-
FU based chemotherapy 
1245 %grade4_Tox_Prostop_CT Rate of acute grade 4 chemotherapy-related complications 
1251 %cStage4_Chemo Rate of cStage IV patients receiving chemotherapy 
1261  
Rate of curatively treated patients that received a 
colonoscopy within 1 year after resection 
1263 %Late_Tox_RT 
Late grade 4 complications of radiotherapy or 
chemoradiation 
1271 %Path_Rep_Use Use of the pathology report sheet 
1272 %TME_Qual_Rep 
Quality of TME assessed according to Quirke and 
mentioned in the pathology report 
1273 %Dist_Margin_Pos_Rep 
Distal margin involvement mentioned after SSO or 
Hartmann 
1273b %Dist_Margin_Rep Distal tumor-free margin mentioned in the pathology report 
1274 #Nodes_Examined Number of lymph nodes examined 
1275 pCRM_mm_Rep (y)pCRM mentioned in mm in the pathology report 
1276 TRG_Rep 
Tumor regression grade mentioned in the pathology report 
(after neoadjuvant treatment) 
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1 INTRODUCTION AND RESEARCH 
QUESTIONS 
1.1 BACKGROUND 
In 2004, the Belgian Section for Colorectal Surgery, a section of the Royal Belgian 
Society for Surgery, decided to start PROCARE (PROject on CAncer of the REctum), a 
multidisciplinary, profession-driven and decentralized project with as main objective the 
reduction of diagnostic and therapeutic variability and improvement of outcome in 
patients with rectal cancer. All medical specialties involved in the care of rectal cancer 
established a multidisciplinary steering group in 2005. They agreed to approach the 
stated goal by means of treatment standardization through guidelines, implementation of 
these guidelines (workshops, meetings, training for total mesorectal excision [TME], 
pathology, radiotherapy and radiology) and quality assurance through registration and 
feedback.  
In 2007, the PROCARE guidelines were updated (PROCARE Phase I) 1. In 2008, a set of 
40 process and outcome quality of care indicators (QCI) was derived and organized in 8 
domains of care: General quality indicators (including survival), Diagnosis and staging, 
Neoadjuvant treatment, Surgery, Adjuvant treatment, Palliative treatment, Follow-up 
and Histopathologic examination. These QCIs have been pilot tested on the PROCARE 
prospective database and on an administrative (claims) database (PROCARE Phase II) 2. 
Patients who may have been registered in multiple centers (for diagnostic and treatment 
purposes) were for feedback purposes assigned to one main center by the BCR and 
registered anonymously in PROCARE with a patient ID (details in Appendix 7). Data 
submitted for the present study included a single, blinded center assignment per patient, 
in addition to basic clinical variables and eligibility status along with calculated QCI 
values per patient whenever possible. Centers have been receiving feedback from the 
PROCARE registry on these QCIs with a description of the distribution of the 
unadjusted center-averaged observed measures and the center’s position therein. To 
optimize this feedback, centers should ideally be informed of their risk adjusted 
outcomes and be given some bench marks. The PROCARE Phase III study launched by 
KCE in response to a call from the PROCARE group is devoted to developing the 
methodology to achieve the best possible feedback in this sense. 
1.2 THE CURRENT PROJECT 
The current study aims to develop a methodology to identify low and high-performing 
hospitals in the management of rectal cancer on the basis of the available set of QCIs. 
Notwithstanding its specific application, the methodology will be generic in nature and 
applicable to other cancers, and even other (chronic) diseases. Methods will be further 
deployed to examine whether and how the number of QCIs involved can be reduced 
while retaining the most important information per domain. In view of the primary goal, 
we specifically addressed the following research questions:  
1. Which patient characteristics (risk factors) should be taken into account to 
obtain a fair evaluation among centers of the set of QCIs developed for 
treatment of rectal cancer?  
2. What is the most suitable statistical methodology - taking into account practical 
feasibility - to quantify performance of centers, and to identify low and high-
performing centers?  
3. How to combine process and outcome indicators within the 8 domains of care 
(general QCI, diagnostic and staging, neoadjuvant treatment, surgery, adjuvant 
treatment, palliative treatment, follow-up, histopathologic examination)? How to 
define a composite score based on these 8 domains of care? Are there indicators 
that can be omitted, or alternatively, which indicators are essential to evaluate 
the performance of centers?  
4. How can results be presented into a feedback to individual teams?  
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The sequence of steps performed towards this goal can be consulted in online 
appendices to this report, which are listed below and cover documents produced over 
time as deliverables. These show the initial results which built on a preliminary dataset. 
We eventually arrived at the full analysis of the dataset of patients diagnosed since 2006 
and followed up until August 27th 2010, which is summarized in the present overall 
report. This final report aims to inform a more general audience of stakeholders rather 
than primarily statisticians and epidemiologists, who we refer to the more technical 
appendices for further detail. The first 2 chapters focus on methodology, while. chapters 
3, 4 and 5 cover application of the methods to the PROCARE database. In chapter 2 we 
describe the basic methodological concept and options taken in this project. In section 
2.1 we elaborate on how to adjust center effects for patient-specific factors, while 
section 2.2 reports on a literature study of known prognostic factors for outcome. In 
section 2.3 we propose an approach for the construction of aggregated scores. Section 
2.4 discusses methods for provider profiling as well as bench marking of the quality 
indicators. Section 2.5 summarizes our proposed approach. In Chapter 3 we describe 
our database and present results of patient-mix-adjusted center effects for individual 
outcome QCIs and unadjusted center effects for process QCIs. Chapter 4 summarizes 
the construction of aggregated domain scores and presents center effects on the 
corresponding quality indexes. It ends with an exploration of the explanation of center 
effects in terms of center characteristics including their general performance on process 
indicators. In chapter 5 we end with a discussion and a preliminary exploration of the 
relation between center effects on outcome and on process quality indicators.  Detailed 
figures, tables and additional results are provided in appendices. Appendices 1-6 
complement Chapter 2, Appendix 7 and 8 contain additional data for Chapter 3 and 
Chapter 4, respectively. 
• Appendix 1: Detailed discussion of the methodology with technical 
specifications and a simulation study 
• Appendix 2: Protocol, results and discussion of the literature review  
• Appendix 3: Case Record form of PROCARE 
• Appendix 4: Original definitions of the QCIs defined by PROCARE and the 
latest working definitions used in this report 
• Appendix 5: Physician survey on Clinical importance and Measurement 
Quality for the QCIs 
• Appendix 6: Descriptives of prognostic factors (section 1.1) and QCI’s 
(sections 1.2-1.8) and detailed results of analysis of individual QCIs (section 
2) 
• Appendix 7: Analysis of selectivity of the PROCARE Cohort: comparing the 
PROCARE and BCR database   
• Appendix 8: Detailed approach and results for the construction of aggregate 
quality indexes 
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2 CONCEPTUAL FRAMEWORK AND 
METHODOLOGICAL APPROACH FOR THE 
ESTIMATION AND BENCH MARKING OF 
CENTER EFFECTS ON QUALITY INDEXES 
2.1 PATIENT MIX ADJUSTMENT FOR QUALITY OF CARE 
INDICATORS. 
2.1.1 The causal inference framework for center effects  
In this section we develop a method that allows adjusting QCI for the patient mix 
treated by the center ultimately arriving at one or more global quality indexes with well 
understood bench marks. This adjustment for patient mix is anticipated to be more 
important in the outcome than process domain, since process QCIs have by definition 
been adapted to the patient type where needed. To reach the goal of identifying low 
and high-performing hospitals in the management of rectal cancer (RC) on the basis of 
the available set of QCIs, we first translated the question in a conceptual and 
operational framework. 
The framework most relevant here is that of causal inference. We wish to evaluate not 
just an association between centers and outcomes, but the effect of hospital 
characteristics, in addition to the patient characteristics, on the patient’s treatment 
quality or outcome. In other words, we aim to find out what would happen if a well-
defined group of patients was treated by provider A rather than provider B. For this 
purpose we first wish to correct for patient-specific characteristics but not for hospital 
characteristics, since these are considered part of the package the hospital provides to 
the patient. Once patient-mix-adjusted center effects have been estimated, we will 
consider hospital-specific characteristics that may help explain any variation in center 
effects and point to ways of improvement.  
To arrive at a patient-risk-adjusted measure of hospital performance, the project aimed 
to have access to data from two cohorts: the smaller but comprehensive PROCARE 
database and an administrative (claims) database. The original 40 process and outcome 
QCIs proposed earlier 2 can be derived from the combined data in those databases. 
Further information is available there on the patient’s background and general health, 
which may be prognostic for the treatment process and outcome QCIs. As the project 
got launched, however, the PROCARE steering group refused linking the PROCARE 
database to other existing databases for this goal. As a result, some of the original QCIs 
are no longer measurable and few baseline covariates remain. Nevertheless, we did have 
access to clinical baseline variables. The former aspect is largely remedied through the 
proposed updated set of QCIs given in Appendix 4. The substantially limited access to 
potential confounders of the relationship between center and outcome appears much 
more serious. It has led to some modification of the methodological development plan 
and will ultimately weaken its current application in this setting as described in the 
Section 2.1.3 
At both levels of the analysis, special attention will go to center sizes which are known 
to vary substantially. At the first level, we will need to consider that centers that 
provide data on just a few patients produce a very weak evidence base for the center’s 
general effect measurement. If these few patients were selected among more, they carry 
the additional risk of selection bias. Confidence/credibility intervals of the center-
specific QCI summary may then be so wide that they become non-informative and 
cover regions of excellent average and lower performance. Random effects models 
and/or Bayesian models are designed to overcome this in part by borrowing information 
from an assumed population distribution of center effects. 
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Center size may have an additional impact beyond the precision of our estimates. For 
instance, high-volume centers are likely to be specialized and hence perhaps subject to a 
more complicated case mix with better or worse comparative performance for that 
very reason. For the purpose of evaluating center-specific quality of care, we do not 
plan to adjust for center-specific covariates, but to consider them as part of the center 
package just as other center-specific covariates. Hence, in its potential role of 
prognostic factor, center size will only enter the analysis in a second round, i.e. to 
explain existing center effects. Equally, any interaction effects between center and 
patient-specific covariates would indicate that similar patients fare differently in different 
centers. For instance, a center specialized in geriatric medicine may care particularly 
well for older rectal cancer patients. We will not control for this in the primary analysis 
but propose to explore such mechanisms in a second round, when one wishes to 
explain differences seen in (patient-mix-adjusted) center performance.  
With the above considerations in mind we consider three main methods for risk-
adjustment:  
1. Standard outcome regression methods (ORM), adjusting for available 
confounders and possibly incorporating random center effects. 
2. Methods using the propensity score (PS), this is the estimated probability that a 
patient with a given set of risk factors was treated in each of the considered 
hospitals.  
3. Instrumental variable (IV) methods where the IV, i.e. a predictor for the hospital 
which is not further predictive of the outcome, is used as a vehicle to estimate 
the hospital effect. 
The vast majority of measured QCIs are binary measures. In addition, there are several 
important right-censored survival time measures (to be summarized in, for instance, 
overall 5-year survival probability, relative survival and disease-specific 5-year survival 
probability). Beyond this, there is a QCI describing the number of lymph nodes 
examined, which is most naturally to be approached as a continuous or count measure. 
Since treatment of continuous outcome measures tends to be the most straightforward, 
methodologically speaking, we will concentrate in this text on the development for 
binary and survival type outcomes. As a final note: since the QCI for 5-year survival is 
not mature in the current PROCARE database, which is restricted to patients diagnosed 
since 2006 and followed up until August 27th 2010, we will focus on 3-year survival for 
the database received. 
2.1.2 A motivated choice among different modeling approaches 
A detailed discussion on methods for patient mix adjustment can be found in Appendix 
1. Here, we explain our general findings and options taken, which are further supported 
by developments in the text below as well as in an extensive technical section 
(Appendix 1, Chapter 9). In terms of the statistical paradigm followed, we have elected 
the frequentist (repeated sampling based) approach rather than the Bayesian (degree of 
belief) approach. In principle, both approaches can handle similar questions under 
corresponding models and assumptions on the data. Since the BCR – who will 
eventually adopt these methods in its routine feedback practice – is familiar with the 
frequentist approach, this has been a big consideration. We recognize that in their most 
straightforward implementation, frequentist analyses tend to avoid resampling 
techniques and rely on large sample considerations which are not automatically satisfied 
in a growing data register. On the other hand, Bayesian methods tend to rely more on 
(subjective) prior information in such instances, which is not entirely satisfactory in our 
setting either. Both approaches may struggle when fitting models on centers 
contributing few patients to the register. Knowing that the small sample centers are 
recognized as providing preliminary data to be treated cautiously anyway, and that they 
should eventually mature to providing a sufficiently rich database, our choice for the 
frequentist paradigm stands.  
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We thus set out to consider three classes of methods, from the most standard to the 
most state-of-the-art, for risk adjustment in the evaluation of causal effects: outcome 
regression methods, propensity score methods and instrumental variables methods. We 
conducted our evaluation considering both the general assessment of quality of care and 
the specific context of the PROCARE database as well as the data structure made 
available to us.  
The first two approaches (ORM and PS) rely on the assumption of ‘no unmeasured 
confounders’ for estimation of the (causal) effect of center on quality outcome. In 
contrast, the instrumental variables approach allows for unmeasured confounders, but 
requires an instrumental variable instead, i.e. a variable which is associated with center 
but not otherwise with the natural outcome of the patient. Important limitations in light 
of these requirements result from the restricted access to baseline data in the 
PROCARE database. We had access to, for instance, age, gender, cStage at diagnosis 
and ASA score (on a 4 point scale), but not to variables such as  
1. socio-economic status (SES),  
2. specific co-morbidity, or  
3. patient distance from the treatment center.  
2.1.3 Limitations due to restricted variable access 
We briefly explain the limitations entailed by missing the three above-mentioned 
variables and the methodological choices resulting from that. The three variables 
mentioned are representative of different types of information not directly available in 
the PROCARE database, but potentially available through linkage with other existing 
databases such as the IMA database.  
1. SES represents a potential confounder for the center-quality relationship through 
the link with a specific natural risk profile (over and beyond what is contained in 
age-gender-cStage), while it may at the same time influence treatment quality, 
irrespective of the center, for instance because patients in a higher SES stratum 
more easily receive a more expensive or specific treatment 3 4, 5. 
2. Specific co-morbidities could definitely change the risk profile and would justify 
or may even require an adapted treatment.  
3. Distance, or a derived measure, such as distance to a given center relative to the 
nearest center distance, is likely to be a strong predictor of center choice and 
may be an instrumental variable if it does not further affect the quality outcome. 
In several studies a measure of distance, location or region was proposed in this 
sense 6-12. Alternatively, if distance affects outcome because of its association 
with region and perhaps a particular local toxin or genetic type of cancer, or if it 
moderates treatment - for instance through reduced visits with a longer distance, 
or the choice of a closer center when more frequent visits are required - it is a 
confounder or mediator and not an instrument.  
So, first, all three variables  could be confounders, that is, a common cause of center 
choice and outcome quality, for which one needs to adjust if the pure center effect is to 
be measured. Second, both SES and co-morbidity may generate a different treatment 
response for otherwise similar patients (across all centers). In an optimal quality setting 
SES should not influence treatment while co-morbidity should. In light of this, some 
scientists believe that one should not adjust for SES when analyzing treatment effects in 
view of benchmarking. We argue that in a practical setting where SES does influence 
treatment across the board (for all centers) the most relevant effect measure for the 
patient as well as the most fair comparison of quality delivered by centers is obtained 
after adjusting effect measure for SES. The arguments for this are summarized in Section 
2.1.3.1.  
Third, if distance between patient and treatment center influences the treatment 
(schedule) received and hence outcome, it affects outcome directly and can no longer 
serve as an instrumental variable. The general implications of all three points for our 
analysis approach are described following the next Subsection.  
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2.1.3.1 Arguments for adjusting for factors such as patient‘s socio economic status  
Many patient-specific characteristics (at diagnosis) influence the outcome of rectal 
cancer patients. Not all of these factors are known or can be carefully measured. 
Typically, we adjust for just a few pre-treatment patient-specific factors, including age, 
gender, cStage at diagnosis, possibly ASA score, etc... The implication is that we predict 
risks of individuals based on limited prognostic information and then evaluate how the 
observed risk in a center deviates from it. The question is, should or should we not in 
principle also adjust for factors as SES if possible (potentially obtained through a link 
with the IMA database), knowing that in practice:  
1. different SES may be treated differently across centers: e.g. patients with a higher 
SES receive a more expensive and better treatment element 3, , and  
2. different SES patients may present with different natural disease progression 
because of distinct environmental, genetic, co-morbidity conditions beyond what 
has been measured through cStage, ASA-score etc. in a necessarily limited 
prospective voluntary register. 
Without adjustment we fail to correct for a possibly associated differential natural risk 
(which is always needed) as well as for SES-related differences in treatment (which we 
may or may not wish to adjust for, if depending on SES, the treatment adaptation 
happens irrespective of the treatment center). With adjustment, we adjust for both 
different risk levels and different treatment levels associated with SES and hence do not 
penalize centers who carry a heavier load of the ‘worse treated patients’. 
In conclusion, if our perspective is the one of the patient (‘given who I am, where 
should I go to get the better treatment/outcome’), then the most relevant answer 
would be found after adjusting for SES. This is true whether or not we evaluate the 
centers for the population with their own typical patient mix or for a fixed population 
average outcome. Hence, one should adjust for SES (like) factors if possible at all, to get 
the most scientific and relevant answers as well as an honest comparison of differential 
performance between centers. 
If we would simply wish to alert the center of the fact that it has worse outcomes than 
other centers (which may be due to its different patient mix which may or may not be 
well treated), then an unadjusted analysis is in order. Since our primary goal in this 
section is on adjusting for patient mix, we will adjust for SES whenever possible, even 
though unadjusted reports have their own contribution to make. 
As we are unable to adjust the analysis for some known confounders, we must 
acknowledge that patient adjustments constructed (by regression and the propensity 
score method) will only partially correct and the residual center effects defined may 
result in part from differential representation of these factors in the center’s patient 
mix. Whether or not this is the case, can only be examined once the additional set of 
covariates becomes available for analysis. 
The propensity score approach might be weakened, as the distance, a likely strong 
predictor of center effect, cannot be included in the propensity score. This would be a 
special point of concern when the distance is also moderately associated with the 
outcome, for then it is an important confounder, although not otherwise.  
2.1.4 On the Instrumental Variables method  
For the combined set of reasons stated below, we will not use instrumental variables in 
this project.  
• Lacking the measures on the patients distance to every center considered we 
are unable to involve it in the analysis as an instrumental variable. No other 
potential instrumental variables were recovered based on the literature 
search described in Section 3.2. 
• If distance is associated with outcome or treatment (schedule), either 
because the schedule gets adapted to the distance or the other way around, 
instrumental variable property is violated and it becomes an invalid 
instrument. 
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• Preliminary results indicate that the presence of that many centers with a 
correspondingly small propensity makes that there is too little information 
about the causal effect of the centers if one wishes to allow for unmeasured 
confounders. This is translated into confidence intervals so wide they become 
unusable. 
Even though the instrumental variables approach is unworkable in the current setting, 
there may be a future role for it. While we cannot recognize the actual identity of 
specific centers and hence have no direct information on center type, it is clear that 
certain centers differ from others in important aspects. For instance, University 
hospitals tend to differ in size (larger), in equipment and staff they can draw on (more 
state of the art, costly, highly trained) and in the population they attract (more difficult 
cases). As a cluster they tend to draw on more resources which would suggest they 
have their own standard to aspire to. They are centers specifically dedicated to the 
advancement of science and its implementation in practice. It might be worth having a 
secondary analysis of center effects confined to this cluster of fewer and larger centers, 
for the development of their own benchmark. Here the argument of tiny propensity 
scores would vanish and distance could again become a workable instrument on the 
condition the instrument is rich enough to avoid multicollinearity in a two stage 
regression and no serious confounding or mediation through the distance remains.  
2.1.5 Outcome regression methods and propensity score methods 
For our goal, we now focus on the outcome regression methods and propensity score 
methods in more detail. Notwithstanding the limitations in the current setting, both 
approaches a priori have their merit here and more generally when the full scale of 
confounders and prognostic factors for center choice are included in the analysis.  
To arrive at a meaningful evaluation and the comparison of outcome regression and 
propensity score methods, several basic choices are made. Different methods 
concentrate on direct modeling of distinct target parameters. These involve patient-
specific, center-specific or population-specific risk estimation. Patient-specific 
adjustments are the more standard direct focus of modeling and will form building 
blocks of our models. Here, population-specific risks express risk of a certain event if all 
patients in one chosen common study population were treated in a given center. In 
contrast, center-specific measures compare the observed risk for patients in a given 
center with the risk that these same patients would have experienced in some ‘average’ 
center. Evidently, from the measures conditioning on more detailed information the 
more averaged measures can always be derived, but not the other way around. It was 
found that center-specific treatment effects are best evaluated on the patient mix they 
themselves currently treat. Hence this will be our primary aggregated outcome 
measure, even though this means that different centers are judged on different patient 
mixes. This reference was seen to be particularly relevant in a stable landscape where 
the patient mix tends not to change much over the years. Drastic interventions in the 
treatment landscape could of course make this stability premise untrue.  
The center-specific treatment effect will most easily be derived from outcome 
regression models (fixed or hierarchical). Current implementation of a (fixed effect) 
propensity score method naturally focuses on population averaged effects only. As 
indicated, such an effect measure has the great advantage that it constitutes a common 
reference outcome for all centers and can be derived from the results of all methods. 
Our comparisons of results of different approaches in this report will examine both 
measures before coming to a conclusion in this report. While a propensity score based 
matched analysis can in principle be developed, this is documented to be less reliable 
than what we obtain through the doubly robust propensity based methods, a version of 
the method which protects against misspecification of either the outcome regression 
model or the propensity score model for center choice, and will therefore not be 
pursued here.  
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Either approach and target parameter leaves the question: relative to which ‘specific 
center’ effect do we express our adjusted outcome measures? There are (at least) two 
basic options studied in Section 2.4.2: an external (international) reference or standard, 
and an internal (to the PROCARE database) reference. Here we briefly discuss the 
latter only – in view of the modeling choices to be made. The discussion on 
benchmarking and quality standards is left to Section 2.4.2. Standard regression models, 
involving a separate effect for each center in addition to the effects of patient-specific 
characteristics parameterize center deviations, typically on the log odds scale for binary 
data and log hazard scale for survival data, from either  
• a single chosen reference center (the first, last, largest, best, or on a 
percentile) - through ‘dummy coding’ 
• the average center effect, averaged over all centers (on the given scale) - 
through ‘unweighted effect coding’ or  
• the average center effect, averaged over all patients - through ‘weighted 
effect coding’ (= the “national” mean). 
With weighted effect coding, large centers get more weight in defining the reference 
which is not the case with unweighted effect coding. In what follows we took our 
definition of `average’ center from the unweighted effect coding above (and a 
corresponding average when a hierarchical random effects model has been 
constructed). This means that for logistic regression models, for instance, the mean 
center level was calculated on the logit (i.e. log odds) scale.  In the end, the probabilities 
generated for this `average’ center were calculated by back transformation from the log 
odds scale.   This construction has advantages and disadvantages. The variation between 
centers is typically more symmetrically or even normally distributed on the logit scale 
than on a probability scale. The probability of achieving a good quality outcome may 
indeed be close to 100% for some QCIs and hence tend to be skew.  On the normal 
scale the mean is an intuitive and efficient measure of central location. This approach 
does however become complicated when some centers have an observed proportion of 
100% and thus a logit equal to infinity which would inadvertently determine the mean. 
Because we do not involve centers with less than 5 patients in the logistic regression 
and because will use the Firth correction (as explained at the end of this section), and 
this tends to shrink results somewhat towards the mean, we do not have this problem 
with infinity. An alternative approach would consist of recalculating the average 
probabilities over all centers directly on the probability scale for each combination of 
baseline covariates whenever a center-specific reference value is chosen. The specific 
choice of reference center is not that crucial in our case since we will use relative bench 
marks (quartiles of the center specific excess probabilities).  
With those choices in mind we have developed a number of modeling options below. 
We studied in detail the fixed effect outcome regression, random effects outcome 
regression and a doubly robust propensity score method. We focused here on models 
for the most important, most common as well as most challenging outcome types which 
are binary outcomes (success) and right censored survival type outcomes (time to 
event). As prototype cases we focused on outcome QCI 1111 (overall observed 
survival) and QCI 1232a (proportion of APR and Hartman procedures among patients 
who underwent radical surgical resection). Their theoretical properties were 
considered and – more importantly - their practical potential performance in the 
PROCARE setting was evaluated through simulation based on preliminary data made 
available on August 4, 2010. The simulations were deemed necessary because the 
presence of small centers (some with just a single patient entered) precludes an 
uncritical reliance on asymptotic properties of model parameter estimators and, a 
fortiori, of estimators of center-specific effects. Through a well chosen computational 
data generating mechanism, the simulations allow one to study the accuracy of a 
particular method in a particular setting before implementing it there.  
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The precise set-up of the simulations is given in more detail in the technical part of 
Appendix 1 (Chapter 9). Basically, they mimic the available database and first generate a 
random center choice in function of baseline characteristics based on a propensity 
score. Next, from the chosen center a random outcome is generated for the patient 
based on the outcome regression model. It is thereby assumed that center effects are 
themselves randomly distributed with some variation over the various centers in the 
database. Because the propensity scores are fitted on the original data, they reflect also 
the variation in center size seen in the database.  
After fitting the various models, we display when possible both the estimated center-
specific effects and population averaged center effects for the different centers in our 
preliminary database. Based on the repeated simulations we gained insight in the 
variation of the estimators as they vary from simulated dataset to simulated dataset. We 
were concerned specifically with bias, precision and coverage of confidence intervals. 
We further considered center-specific risks and population-averaged risks estimated 
over all centers.  
In summary, for the 2 QCIs considered, with regard to the center-specific effects, which 
are not estimated by the standard propensity score methods, we saw no reason to 
distrust estimated center effects with confidence intervals for the fixed effects models, 
but could benefit for some centers substantially from the tighter confidence intervals 
around the random effects estimates when the model is correct. It was found that for 
population averaged effects, a comparison with the propensity score method results, 
which do not rely on the outcome regression model being correct, may also be prudent 
and worthwhile. In many cases the same qualitative conclusions should result from the 
different evaluations. If and when they do differ a more in depth examination will be 
required in the specific setting.  
Finally, results under a misspecified random effects model shown in the technical 
Chapter 9 of Appendix 1 were rather encouraging in this instance and largely followed 
the lines above. For right censored survival data with necessary focus on 2 year survival 
in the preliminary database, results are more tentative due to few events in a sizeable 
number of centers. When 3 year survival becomes available in an updated dataset, we 
will be able to draw more firm conclusions for that setting.  
In summary, results were encouraging for all methods on the 2 selected QCIs explored 
at this stage. We therefore carried all 3 methods forward to the next stage, where their 
performance would be judged on a much wider range of QCIs and data structures. As it 
turned out (see section 3.2.3)  for the full set of QCIs which may include some that are 
less balanced or have substantially fewer eligible patients, only fixed effects models with 
Firth bias correction 13 produced consistent results in our set-up. This correction has 
been shown to be equivalent in the case of logistic regression to maximizing a penalized 
likelihood, where the penalization follows from a noninformative prior on the 
distribution of the true center effects. Specifically, `Jeffrey’s prior’  is involved here and 
leads to some mild shrinkage towards the center since this prior is symmetrical but 
allows generously for outlying effects. Because of shrinkage towards the mean, small 
centers which achieved a particular QCI  in 100% of their registered patients,  will show 
up with a non zero estimated risk of failing the QCI. This may look unfortunate at first 
sight but is sensible as the true risk of ever failing the QCI would not be absolutely 
zero. A similar phenomenon emerges more drastically  from the more standard 
hierarchical models. It has nevertheless been accepted by the field and is used in the 
quality of care literature and  evaluation of cardiac surgeons for instance.  
Center effects estimated through the Firth corrected fixed effects method hence tended 
to show a reasonable spread over the centers, unlike hierarchical models which 
sometimes shrunk away any signal of deviations between centers. Keeping further in 
mind that 1) our goal is individual feedback for self improvement, and hence sensitivity 
rather than the specificity is for the detection of unusual center effects most important 
to protect in order not to miss centers that should be encouraged to examine their 
performance and 2) the difficulty in justifying a manageable hierarchical model, we focus 
on the Firth corrected fixed effects models in our present application.  
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We note at this point that our methods are straightforwardly adapted to a situation 
where one wishes to change the balance between sensitivity and specificity, for instance, 
if public disclosure were anticipated.  
2.1.6 Scope of analysis  
At this point it is worth stressing that before embarking on more complex modeling, 
descriptive statistics on outcomes, centers, and prognostic factors are important to help 
define the scope of analysis. Due regard is to be given to missing data at this level. 
While we are not planning to elaborate on the standard approach to this in any detail 
here, we simply point to some more important features to be examined in our setting. 
For key survival outcomes, examination of the distribution of follow-up time in the 
dataset and over the centers, together with the observed numbers of events will give an 
indication of the amount of information in the dataset and each of the centers. It will for 
instance reveal whether 5-year survival chances are estimable with any degree of 
confidence, given the extent of follow-up. If updated yearly, such measures per yearly 
epoch may also yield a helpful description of the center progress over time in response 
to the monitoring and feedback. Further for this outcome type, it is important to 
consider whether censoring is or appears to be non-informative, possibly conditional on 
certain factors, before embarking on any analysis. If censoring is related to observed 
covariates, conditioning on those factors will be necessary in (cause-specific) survival 
models to avoid censoring bias. Alternatively, marginal survival models can be fitted in 
combination with methods for dependent censoring which involve these covariates 14. 
Depending on the event (cause-specific or not) Kaplan-Meier Survival curves or the 
cause-specific cumulative incidence curves will non-parametrically describe the 
proportion of patients avoiding specific events over time.  
A similar basic description of other QCIs is warranted: tables for discrete (binary) 
variables, box plots, and summary statistics for continuous outcomes and counts. 
Regarding the centers, a first descriptive analysis should shed light on the variation in 
center size and the percentage of very small centers for which negligible information 
may be available. Secondly it will be important to recognize whether centers differ in 
amount of follow-up time (and therefore the censoring distribution) as well as more 
general completeness (missing data) over the centers. Finally, especially for sizeable 
centers, a brief inspection of covariates and correlation between covariates can help 
reveal whether some forms of center-specific characteristics, suggest special selection 
or measurement error and could be further examined. Detailed data quality control and 
a study of possibly systematic selective patient recording lies however in the hands of 
PROCARE and the Belgian Cancer Register who, unlike ourselves, have access to 
important background data in this regard (such as what percentage of its patients the 
center actually registered in the PROCARE database, and how the profile of its 
registered patients differs from that of those patients it did not register). It would 
certainly be interesting to examine the association between a center’s degree of 
participation and reported QCI levels achieved. It would further be interesting to learn 
more directly about the reasons for not participating fully.  This is beyond the scope of 
the current project and we will hence proceed with methods assuming we are dealing 
with a relevant sample of the observed patient population over the given treatment 
centers.  
Finally, we will examine the distribution of patient characteristics observed in the 
database and over the centers. Again, missing data patterns, measures of location and 
variation plus correlation between and among QCIs as well as their prognostic factors 
could vary substantially between centers. This will reveal, among other things, the 
importance of adjusting for specific characteristics in the patient mix. If there turns out 
to be little or no overlap however, the adjustment for those covariates based on a 
general model fit may no longer be meaningful 15. 
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Summary points  
• Frequentist methods have the advantage of being relatively straightforward 
to implement in routine practice, but tend to rely on large sample 
properties unless resampling techniques are used. Bayesian methods 
automatically handle small samples, but then rely on parametric 
assumptions instead. Given our goal and the setting in which the methods 
will have to be operationalized, we opted here for the frequentist approach.  
• A review of different techniques for risk-adjustment of binary and right-
censored patient-level QCI measures is presented, considering fixed effects 
outcome regression, random effects outcome regression, doubly robust 
propensity score methods and instrumental variable methods. These four 
techniques are all considered within the causal framework in which we aim 
at estimating the effect of choice of center of care on the outcome (QCI). 
• It was decided not to pursue the instrumental variables approach since the 
identified instrumental variables for this setting (distance and 
region/location) will not be available in the PROCARE database and 
preliminary results showed that the presence of many centers results in very 
imprecise estimated effects.  
• A simulation exercise emulating 2 prototype QCIs showed that no single 
technique performed uniformly better on those data. We therefore carried 
all three analyses approaches forward to the implementation stage. When 
fitted on the large set of QCIs most methods ran into problems, including 
the simple logistic regression with fixed center effects. This happened 
especially when small centers (e.g. with less than 5 patients) with few events 
entered the model. The problems were overcome by adopting fixed effects 
models with Firth’s bias correction and restricting the scope of estimation to 
centers with at least 5 patients (others may be grouped into one overlapping 
center). 
• To allow for stable results and avoid too much shrinkage of observed center 
differences in the current database, we have focused on fixed effects 
regression models with Firth correction on the sizeable centers (with at 
least 5 patients contributing to the register).  
• Issues related to the lack of access to known confounders (e.g. socio-
economic status) are discussed. The risk-adjustment analysis will necessarily 
be restricted to age and gender plus the baseline clinical patient-specific 
confounders available in the PROCARE database. 
• Missing data problems have been discussed. Methods will be implemented 
under the missing at random assumption, while acknowledging that this 
assumption may well be violated in the volunteer register. Depending on the 
setting, a separate category is assigned for missing covariate values or 
multiple imputation techniques have been used.  A limited exploration of 
the selective nature of the register has been performed through a 
comparison with data from the Belgian Cancer Register. 
• We have opted to focus on center-specific measures of performance. We 
thus evaluate each center on the type of patient mix they typically care for 
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2.2 LITERATURE SEARCH FOR PROGNOSTIC FACTORS OF 
RECTAL CANCER 
2.2.1 Methodological approach 
The aim of the PROCARE project is educational in the first place, i.e. individual centers 
receive feedback on the outcome of their rectal cancer patients as compared to all 
participating centers (the entire PROCARE database serves as the benchmark). A fair 
comparison is only possible when the center’s results are adjusted for all variables that 
may affect a patient’s outcome irrespective of the therapy or therapies administered.  
To conduct an objective search of the literature a rigorous protocol was adhered to 
and the following databases were searched: Medline through PubMed, Embase and the 
Cochrane Central Register of Controlled Trials. Details of the search strategy protocol 
are presented in Appendix 2. Details concerning these papers are summarized in 
Appendix 2B, while the global results from multivariate analyses are presented in 
Appendix 2. 
The following outcomes have been studied: 
• Overall survival 
• Local recurrence 
2.2.2 Results 
In total, 152 papers were included. The main prognostic factor for overall survival 
clearly is related to the stage at presentation. Patients with bowel obstruction, 
perforation, serosal invasion, or peritoneal metastasis fare worse. Gender does not 
seem to represent an independent prognostic factor, while the prognostic significance 
of age is variable among studies. Several studies have shown that socioeconomic 
deprivation represents an adverse prognostic factor for colorectal cancer survival 4, 5, 16. 
A wide array of pathological prognostic variables, macroscopic as well as microscopic 
and molecular, was identified. A number of recent studies have identified hospital 
volume as a prognostic factor in rectal cancer (17, 18, 19, 20, 21).  
Clinical and demographic variables with an impact on local recurrence include T stage, 
presence of liver metastasis, and gender. The impact of tumor location within the 
rectum on the risk of local recurrence is unclear at present, since some authors found a 
higher risk of local recurrence with low lying tumors (22), while others reported the 
opposite (23). Treatment-related factors influencing the risk of local recurrence include 
preoperative (chemo)radiation, performance of a TME (24), and performance of 
abdominoperineal resection (25). Among the pathological factors that may impact on 
local recurrence, the circumferential resection margin is clearly prominent (26, 27). 
Finally, anastomotic leakage was shown in some reports to be associated with a higher 
risk of local recurrence (28, 29). Several other reports, however, concluded that 
anastomotic leaks don’t have an impact on local recurrence rate (30, 31, 32, 33).  
There is very scarce literature on QCIs identified in the setting of PROCARE other 
than survival or local recurrence. Some specific factors are reported separately in 
appendix 2. Appendix 2 further tabulates relevant prognostic factors for each QCI 
based on published evidence and on expert opinion from the participating clinicians. The 
most important factors for outcome indicators such as local recurrence and (cancer 
specific) survival are patient-related (Age, Bacterial translocation to lymph nodes, BMI, 
Gender, Health and physical sub-scale of QLI, Insurance status, Marital status, Poor 
general condition/ Co-morbidity, Recurrence, Socioeconomic status, Venous 
tromboembolism), tumor-related (Bowel obstruction, Circulating tumor cells, Focal 
perforation, Local peritoneal involvement, Lymphangitis carcinomatosa, Serosal invasion, 
Surgical curability, Tumor regressing grading) or related to clinical factors (BMI, 
Distance from the anal verge, Liver metastasis, Recurrence, Stage, T-stage/ depth of 
invasion). 
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2.2.3 Discussion 
Several limitations apply to the interpretation of the present systematic literature 
search. First, most papers concern small patient numbers treated with a myriad of 
different therapeutic approaches and include colon as well as rectal cancer patients. The 
number of rectal cancer patients is usually not specified or a (small) minority of the 
overall population. This is relevant since the biological behavior of (low) rectal cancer 
and the paramount importance of surgical techniques in achieving the desired outcome 
are quite different compared to colon cancer. As we identified only 23 studies on rectal 
cancer alone, studies on colorectal cancer were nevertheless included. Second, almost 
all data were the result of retrospective studies. Studies not including some form of 
multivariate analysis were excluded. This criterion was maintained in order to guarantee 
a minimal quality of included studies. 
It is important to note that most papers study prognostic factors through joint 
regression models, which contain the patient-specific variables available. Whether a 
particular variable enters as a significant predictor into a joint model will highly depend 
on which other variables are further included in the model. Indeed, both the magnitude 
and even the indication of the true effect on outcome may change depending on which 
other factors are entered. For some sets of variables only one may need to be 
appropriately corrected for the prognostic value involved, i.e. they can act as each 
other’s surrogate in this sense. This could imply that as soon as a variable is entered, 
the other variables no longer have anything to add. Which of them actually enters may 
then be a matter of chance. This complicates the definition and role of the prognostic 
factors for reporting purposes. Beyond the magnitude of its systematic effect in the joint 
model, there is also the issue of precision. Whether a particular factor (in a joint or 
univariate model) is significant or not, not only depends on the magnitude of its 
systematic effect, but also on the precision with which it is estimated and hence on the 
sample size and covariate distribution in the studied population. In this light, and the fact 
that current and future sets of available covariates may rarely overlap exactly with what 
is reported in the literature, we will report here first on any variable found to be a 
significant prognostic factor. In the more detailed report we will indicate in what 
combination of covariates it occurred with what weight. 
Summary Points 
• The primary search identified 981 articles. From this list, 308 articles were 
selected for full-text evaluation leading to 152 articles included in the final 
assessment. From these articles, an extensive list of prognostic factors for 
overall survival was obtained as well as a less extensive list of prognostic 
factors for local recurrence, cancer-specific survival and post-operative 
complications. There is very scarce literature on prognostic factors for other 
QCIs identified in the setting of PROCARE. 
• The literature search imposed restrictions in terms of study design and 
patient population. Since a mere 23 studies considered just rectal cancer 
patients, also studies on colon cancer patients were eligible for our selection. 
• Most papers study prognostic factors through multivariate regression 
models, hence the direction and magnitude of effect of a specific prognostic 
factor on the outcome depends heavily on the other factors included in the 
model. 
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2.3 DIMENSIONS OF CARE AND THEIR AGGREGATION  
2.3.1 Goal 
In this third section on dimensions of care and their aggregation we aim at investigating 
the following research questions: 
• How to combine process and outcome indicators within the 8 domains of 
care as defined in phase 2 of the PROCARE project 2?  
• How to define a composite score based on these 8 domains of care? 
(General quality indicators, Diagnosis and staging, Neoadjuvant treatment, 
Surgery, Adjuvant treatment, Palliative treatment, Follow-up, Histopathologic 
examination) 
• Are there indicators that can be omitted, or alternatively, which indicators 
are essential to evaluate the performance of centers?  
One may examine the possibilities of developing indexes that capture the quality of care 
in the various rectal cancer centers, based on data available in the PROCARE database. 
We will construct quality indexes (QI) on three levels: QIs for evaluating respectively 
clinical outcome and process of care, one separate QI for each of the 8 domains and 
finally one global composite QI of the domain-specific QIs. 
Figure 1 and Figure 2 provide an example of the relationships among the various QCIs 
and QIs. The outcome- and process specific QIs (QIoutcome and QIprocess) and domain-
specific QIs (QI1 – QI8) are constructed from the QCIs which are provided by the 
PROCARE database (Appendix 4). A global QI may be constructed from the outcome 
and process QI, from the full set of original QIs (as was done for the outcome and 
process QI) or starting from the domain-specific QIs (as reflected in Figure 2). 
Figure 1: Schematic presentation of the construction of an outcome and 
process-specific QI 
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Figure 2: Schematic presentation of the construction of domain-specific QIs 
 
The construction of each composite quality index will be guided by the following 
principles: 
1. Involve indicators of clinical relevance/importance. For a hierarchy of clinical 
importance of the components of the composite quality index, we will rely on 
consensus in the literature and the judgment of our clinical team members and 
advisors. 
2. Involve indicators which allow for meaningful discrimination due to substantial 
variation between centers, consider dropping those who do not. 
3. Involve indicators for which we have or can obtain reliable data in the database, 
consider dropping those who do not. We seek to minimize undue influence of 
missing data and measurement error. 
4. Involve indicators that empirically show a strong association with the underlying 
constructs, different dimensions covered by the QCIs as revealed by statistical 
(‘factor’) analysis.  
As we consider building composite QIs based on subsets of the current QCIs, we will 
evaluate whether they are – or could be – close to as informative as scores built on the 
entire set. In doing so, we will acknowledge that if fewer QCIs need to be measured 
and fewer variables recorded, this may result in a lower percentage of missing data and 
more accurate measurements for the data recorded.  
2.3.2 Key approach 
In this chapter we focus on the composition of domain-specific QIs. The composition of 
an outcome and process QI as well as the global composite QI follow the same ideas.  
We plan to proceed along the lines of  previous research on composite outcomes used 
in Cardiac surgery in US 34 and will consider and compare simple or weighted averaging, 
with “all or none” scoring to combine QCIs within a domain in view of our four guiding 
principles.  
Sum score methods make use of risk-adjusted center effects as we obtained from a 
(Firth-corrected) fixed-effect (Cox, logistic or linear) regression of the QCI on the 
appropriate risk factors and a factor for the center choice as described in detail in 2.1. 
The “all-or-none” scoring method starts from the raw, unadjusted QCIs and risk-
adjustment is performed on the obtained “all or none” score.  
Domain 1
Domain 2
Domain 8
QCI11
QCI12
QCI1k
…
QCI21
QCI22
QCI2k
…
QCI81
QCI82
QCI8k
…
QI1
QI2
QI8
QI
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An alternative for the stringent “all or none” score is using the number of targets 
reached (relative to the number that should be reached in theory).  
We are well aware of the risk of data-snooping, formally or otherwise, and the 
involvement of clinicians and researchers (with a possible conflict of interest) in steering 
the choice of weights in the composite index. Before averaging or combining center 
summaries within domains, however, we suggest rescaling the QCI measures so that 
not only the directionality matches, but similar values indicate similar levels of lack of 
treatment or outcome quality. Practically, rescaling will be performed by standardization 
of the center effects with the between-center variation as estimated by a hierarchical 
regression model with at the patient-level the appropriate risk factors for the QCI in 
question. Note that this rescaling does not apply to the “all or none” scoring as this is 
one binary measure. 
We acknowledge that in the construction of any composite score there may exist great 
diversity in preferences amongst different policy makers and stakeholders [14]. 
Ultimately, one could allow for different forms of calibration and present a simple 
software tool that allows certain users to produce their own set of weights and 
examine their relative score on that basis. This could offer “local policy makers the 
freedom to set their own priorities and to seek out improvements along dimensions of 
performance where gains are most readily secured” 35. Caution is required with such 
application, however, since it opens the door to data snooping and to setting post hoc 
priorities which serve one’s own (conflict of) interest.  
2.3.3 Criteria for indexes 
2.3.3.1 Definition 
A quality index (QI) as used here is a composite indicator for a certain underlying 
construct, in this case, the quality of medical care in the various centers for rectal 
cancer. We distinguish two main types of indexes, those which are calculated as the 
linear (weighted) combination of a set of existing variables and those obtained from an 
“all or none” scoring method. 
The first type of indexes is obtained by computing a sum score, i.e. combining some or 
all QCIs within a domain by a linear combination of the following form: 
( ) ( ) ( )1 1 1 2 2 2f f fi i i i i ik k ikQI QCI QCI QCIα α α= + + +K  
where QIi is the quality index for domain i, fj(QCIij) (j = 1, ..., k) the center effects for the 
jth QCI, and αj (j = 1, …, k) the weight given to the jth QCI in the construction of the 
QI.1 
The center effects for the kth QCI are risk-adjusted center effects as obtained from one 
of the methods described in section 3.1. As we are interested in evaluating the center’s 
performance on the set of patients actually treated in that center, we will focus on 
center-specific (in contrast to population-averaged) effects for computing QIs. 
Therefore the propensity score method, which currently only allows estimation of 
population-averaged center effects, is not considered further here. Since (Firth-
corrected) fixed-effect regression models provide unbiased estimates of the center-
specific effect, this in contrast to hierarchical regression models which are subject to 
shrinkage, we will focus on the former method for estimating risk-adjusted center 
effects. The set of risk factors to correct for will be determined separately per QCI.2 
                                                     
1  Note that no assumptions are made about the relations among the center effects (fj(QCIij)’s) and that the 
weights αj (j = 1, …, k) are arbitrary in the sense that they are imposed upon the index rather than 
estimated during the construction of the index. 
2  Note that centers with less than 5 patients eligible for a QCI will be discarded from the regression as no 
reliable estimates can be obtained for them. If needed for computation of the sum score, an appropriate 
imputation technique will be used to obtain values for these centers. The fact that several QCIs may 
jointly suffer from the same low sample size will complicate this exercise.  
 Note that the center effects will typically be obtained from (Firth-corrected) fixed-effect regression 
models. From this, one can either derive the risk-adjusted center-specific effects leading to the expected 
QCI in the center for the reference group (in terms of patient characteristics for which one adjusted). To 
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The different types of sum scores have different properties and underlying ideas. An 
important difference between them lies in the weights αj (j = 1, …, k): 
• Simple averaging: all selected QCIs are considered to be equally important 
(on their original scale) for the underlying construct and hence the weights 
are all equal (to 1/k if one wishes to keep working on the same scale as the 
original center effects). 
• Weighted averaging: a different importance can be given to the different 
selected QCIs by giving each of them different weights. The weights are 
determined prior to construction and can be based on e.g. clinical importance 
of the QCIs. 
• Composite opportunity model: provides a way of accounting for the fact that 
some patients may be ineligible for some measures, the weights j (j = 1, …, 
k) are the proportion of eligible patients for the respective QCIs. For our 
goals, this opportunity-based approach is not that interesting since the 
proportion of eligible patients for the QCIs does not have a specific clinical 
importance. 
• Scaled combinations: center effects are inversely weighted by the amount of 
information captured in terms of discriminating ability (i.e. the inverse 
between-center variation as estimated from a hierarchical regression model), 
possibly in combination with a priori determined (clinical) importance of the 
QCIs used. This is a required step in domains with QCIs measured in 
different scales. 
• In latent variable models (or item response theory 36), multiple observed 
QCIs are assumed to be related to an underlying (unobserved) latent variable 
(e.g. quality of histopathological examination), the latter being the primary 
focus of interest. This type of model potentially allows quality to be estimated 
with high statistical efficiency by combining information from multiple 
observable measures into a single parameter. The relative weights for each 
observable indicator are determined iteratively from the model, obviating the 
need to make a priori weight assignments. These weights are rather abstract 
and therefore harder to interpret. 
The clinical interpretation of these five sum scores can be rather different, and depends 
on the type of information captured within the domain. In practice, a combination of 
several of these methods may be appropriate to arrive at the final QI, e.g. scaling and 
weighting. After combining the QCIs, the resulting QI may be rescaled to allow for 
easier interpretation. 
The second type of composite measure, “all or none” scoring, works differently. First, it 
is assessed for each patient whether he/she has reached all pre-specified targets for the 
QCIs within the domain. For binary QCIs the target is simply having the event (yes or 
no) while for continuous QCIs a target needs to be set by clinical experts, e.g. the time 
between first consultation and first treatment should not be longer than 30 days. 
Secondly, the “all or none” score per patient is set to 1 if the patient reached the 
targets for all the QCIs he/she is eligible for within the domain of interest and set to 0 
otherwise. Finally, this “all or none” score is risk-adjusted in the same way as binary 
QCIs in section 3.1 The (rescaled) center effects obtained from this model represent 
the final composite score. 
  
                                                                                                                                             
meaningfully combine these measures across QCIs one should refer to the same reference group for the 
different QCIs. The other option averages the predicted patient-specific outcomes over all patients within 
each center to arrive at the center effects and compares this to the predicted patient-specific outcomes 
we would observe if these patients were to be treated in the “average” center (excess outcome due to 
the center after adjusting for patient-specific confounders). This is likely more precise and can handle 
different adjustment models for different QCIs.  
26  PROCARE – phase III : benchmarking KCE Report 161 
The choice between a (weighted) sum score or “all or none” score depends on the 
interpretation we wish to give to the composite measure. If missing any one is deemed 
(almost) as unfortunate as missing several QCIsan “all or none” scoring seems 
appropriate. On the other hand, if it matters how many QCIs (irrespective of which) 
one retains, a simple average may appear as the candidate summary (the number of 
targets reached relative to the number that should in theory be achieved). When 
different QCIs are considered to differ in importance, weights in the sum may 
accommodate this. 
Compared to the simple averaging sum score measure in which all QCIs carry the same 
importance (averaging of the center effects per QCI), the “all or none” method has the 
advantage that it does not compensate when a center performs excellent on one QCI 
but poorly on another QCI (within the same domain). The fact that this “all or none” 
scoring is rather stringent can be seen as a disadvantage, but from a diagnostic 
perspective this scoring is very straightforward. An important issue that remains to be 
examined is whether the “all or none” score manages to discriminate between centers, 
which is unlikely if there are QCIs with very rare events but rather likely if all QCIs 
within a domain have a high prevalence.  
2.3.3.2 Criteria for item selection  
As the construction of QIs is more an art than a science, several decisions need to be 
made based on less scientific judgments. The choices are interrelated and will affect 
each other. 
A very important decision to make is which items (QCIs) to include in the construction 
of the QIs. This decision will be based on the guiding principles as described in Section 
0. 
Theoretical and clinical importance 
The most important criterion is whether the QCI is theoretically and/or clinically 
relevant for the underlying construct. In this case this seems unproblematic as the 
indicators in the PROCARE database were chosen for their clinical relevance 2. 
However, some QCIs might be more important than others.  
The clinical importance of each of the QCIs was assessed by performing a small survey 
among a group of clinical experts (Appendix 5). This survey helps to identify QCIs to be 
used in the construction of a valid QI. The validity of the QI refers to the extent that it 
measures what it is supposed to measure and can be evaluated in different ways: 
• Face validity: Does the QI “looks to” measure what it is supposed to? This 
can be determined by examining whether the center effects that make up the 
QI are theoretically and/or empirically related to the underlying 
characteristic, and by evaluating whether they were combined sensibly in the 
composite index. For indexes this usually is the most important type of 
validity checking. 
• Content validity: A more statistically rigorous extension of face validity, in 
which experts evaluate whether all aspects of the measured characteristic are 
represented in the measure and judge whether each item is useful for the 
underlying construct. For a proper content validity analysis a survey should 
be held among international experts in the field who should be asked to 
evaluate each of the QCIs and QIs on their validity and on the dimensions 
they cover.  
To statistically examine the clinical importance of a QCI, overall survival (ultimately 
death from rectal cancer – data permitting) will be used as the ‘gold standard’. The 
association between death from any cause (death from rectal cancer) and the QCIs will 
primarily be evaluated at the patient-level, using risk-adjusted Cox proportional hazards. 
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Ability to discriminate between centers 
Another selection criterion considers whether QCIs discriminate between excellent 
and poorly performing centers, or less informed, to what extent each of the QCIs 
captures existing differences between the centers.  
To examine whether a QCI shows at least variation between centers, caterpillar plots 
of the center-specific patient-mix-adjusted average effect of the QCI (called excess 
expectation or probability) with appropriate 95% confidence intervals (95% CI) were 
used. A descriptive table with statistical summary measures (minimum, 25%-tile, median, 
75%-tile, maximum and interquartile range) of the distribution of the center-specific 
averages facilitated the evaluation. 
To formally detect variation between centers beyond sampling variation in the QCIs, 
one may further test whether the variance of the center-level effect in the hierarchical 
regression model differs significantly from 0. To this end, a (pseudo-) likelihood ratio 
test with a mixture of 0 and 1 degrees of freedom was used. 
It is to be acknowledged that a QCI that does not discriminate between excellent and 
poorly performing centers in the dataset, may still be an important QCI. If all centers 
score excellent – or indeed poorly - on such an important quality criterion, this should 
be recognized. 
Data quality 
Data quality is another important consideration in the selection of QCIs to be included 
in the QI. A high number of missing data for a QCI or its unreliable reporting 
disqualifies the QCI from being included in the QI. The frequency of missing data should 
easily be established from the final PROCARE dataset3, the (presumed) reliability of the 
QCIs were included in the survey we wish to conduct among a group of clinical experts 
(Appendix 5). More formal measures of reliability of (the QCIs in) the PROCARE 
database (e.g. the percentage of patients actually registered per center) should be 
examined at the Belgian Cancer Registry (BCR). 
Set of eligible partners 
As seen from the denominators defined for the QCIs (Appendix 4), not all QCIs apply 
to all the patients registered in the PROCARE database. This has different 
consequences depending on the composite scoring measure that will be used. For QIs 
computed as the linear combination of center effects, it happens that for some QCIs a 
center had no eligible patients and hence no estimated center effect. In this case we 
suggest imputing a value for the missing center effect. One may for instance use a 
regression-based imputation method, allowing prediction based on the center’s available 
QCIs. For the “all or none” method, a patient will obtain an "all or none” score by 
considering only the QCIs he/she is eligible for. As long as those are all met, the score 
stays 1. 
Although the number of eligible patients per QCI is not directly visible in the QIs that 
result, QCIs applying to a very restrictive set of patients are not very interesting for 
inclusion in a QI that should be generally interpretable.  
Concurrent validity 
Concurrent validity checks can be used to select just a few QCIs that are close to as 
informative (with regard to explaining the underlying construct) as a larger set of QCIs 
within the same domain. 
Here we examine associations among the various candidates for a QI though principal 
components analysis (PCA) and an exploratory factor analysis (or adapted latent 
variables model 36). The latter was used to determine how strong each of the QCIs load 
on the underlying dimensions recognized by the PCA. High loading QCIs are prime 
candidates for inclusion in the indexes.  
                                                     
3  Based on the PROCARE database we currently have at our disposal, missingness is not very easy to 
assess. 
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To avoid issues with differential illegibility, these analyses were performed at the center 
level, using unadjusted effects for process QCIs and risk-adjusted effects for outcome 
QCIs. The number of factors to retain is based in part on the proportion of variance 
they account for and on the incremental variance accounted for between two 
subsequent factors. For the clinical interpretation of the obtained factors, clinical 
experts were consulted. 
2.3.3.3 Proposed strategy 
To finally select QCIs based on the four guiding principles described above we consider 
two item selection strategies. Decision trees describing these two approaches are 
presented in Figure 3 and Figure 4. 
Figure 3: Decision tree for the first (clinical-statistical approach) suggested 
item selection strategy 
 
 
 
Evaluate the quality  and 
reliability of all QCIs 
QCIs with 
sufficient 
quality 
Select clinically important QCIs with 
most discriminating ability 
Concurrent validity: Do the selected 
QCIs capture ‘enough’ information 
from the total domain? 
Construct the QI 
using a sum score or 
the “all or none” 
score of the 
selected QCIs 
Low quality 
QCIs 
Not eligible 
for QI 
construction 
YES  NO
Select more clinically important
QCIs with most additional 
discriminating ability above the 
already selected QCIs 
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Figure 4: Decision tree for the second (statistical -clinical approach) 
suggested item selection strategy 
 
  
 
Evaluate the quality  and 
reliability of all QCIs 
QCIs with 
sufficient 
quality 
Examine clinical importance  and discriminating ability of the selected QCIs 
per dimension 
Examine the concurrent 
validity of the selected QCIs  
Construct the QI
using a sum score or 
the “all or none” 
score  
Low quality 
QCIs 
Not eligible 
for QI 
construction 
Determine the number of 
dimensions needed to 
explain the underlying 
construct  
Expert 
feedback 
QCIs loading 
strongly on the 
first dimension 
QCIs loading 
strongly on the 
second dimension 
QCIs loading 
strongly on the 
last dimension 
… 
Select 1 
QCI for 
the first 
dimension 
Select 1 QCI 
for the 
second 
dimension 
Select 1 
QCI for 
the last 
dimension 
…
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The first step is common to both strategies. To allow for a fair and credible assessment, 
one should work with good-quality, reliable QCIs. Classification as a good-quality QCI 
follows from criteria to be imposed on the results of the second question in the survey 
to be conducted among clinical experts (Appendix 5) if in addition enough centers have 
at least 5 eligible patients for the QCI and the percentage of missing observations is 
limited. In an ideal world, this step is not needed, but in practice reliability and data 
quality must be monitored. 
After this starting point, the two selection approaches diverge in the order in which 
they invoke arguments of clinical and statistical importance for selection. 
First clinical-then-statistical selection 
The first strategy starts from QCIs deemed clinically most important. This evaluation 
can follow from the QCIs mean score on the first question of the expert clinician 
survey (Appendix 5) and its association with ‘overall' survival. Such candidate QCI will 
be selected if it further discriminates between centers, i.e. if the QCI shows important 
variation between centers beyond sampling variation and after adjusting for case mix. 
This is assessed following a likelihood ratio test for the random-effects variance, 
controlling for confounding variables.  
In the next step, one evaluates through an PCA followed by an appropriate latent-
variable technique (e.g. factor analysis for normally distributed QCIs) to what extent 
selected QCIs capture the full variation in (good quality) QCIs within their domain. The 
QCIs selected in step 2 which load high on the latent dimensions retained, will 
contribute to the QI constructed using a (weighted) sum score or an “all or none” 
score.  
First statistical-then-clinical selection 
The second approach starts from a factor analysis (or adapted latent variables 
technique) on the good quality QCIs. Based on the percentage of variation explained 
(through eigenvalues) an appropriate number of dimensions are retained per domain. 
Ideally these dimensions enjoy a clear clinical interpretation recognized by clinical 
experts.  
Per dimension, highest loading QCIs in the factor analysis are evaluated next in terms of 
their clinical importance and ability to discriminate between centers. The clinical 
importance is assessed as above, from the QCIs mean score on the first question of the 
expert clinician survey (Appendix 5) and its association with ‘overall’ survival. Similarly, 
discriminating ability is assessed following a likelihood ratio test for the random-effects 
variance, controlling for confounding variables. The QCI that scores best on these 
criteria is then selected for construction of the QI. 
Comparison of the two strategies 
The first strategy favors the clinical importance of the QCIs (evaluation by experts, 
discriminatory power, predictive validity), while the second approach gives more weight 
to QCIs’ ability to capture the variation within the domain QCI-set. The two 
approaches therefore may result in the selection of different QCIs for the final QIs. 
In the second approach the clinical importance of the QCIs is but a secondary criterion 
for QCI selection, and clinically important QCIs may not be selected as just a single 
QCI remains per dimension. The second approach may further allow for clinically less 
important QCIs to be selected when none of the most important QCIs load highly on 
one or more of the dominant dimensions. When the first approach recognizes that the 
clinically most important QCIs fail to sufficiently capture the overall variance of the set, 
this may lead to the selection of additional QCIs for the final QI. 
In the first approach, all QCIs deemed clinically important are considered for entering 
the QI (adding perhaps also a few less important ones). In the second approach the 
number of QCIs included in the QI depends on the number of dimensions that one 
distinguished in the domain since one QCI per dimension will be selected, preferably 
the clinically most important one loading high on that dimension. 
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2.3.4 Other issues in the construction of quality indicators and quality indexes 
2.3.4.1 Attribution of cases 
Clear rules need to be established for which center each of the patients in the 
PROCARE database is attributed to. As a standard, patients are attributed to the center 
in which they underwent surgery (and if no surgery was performed to the center where 
the pathology report was filled out or if this did not happen where chemo or 
radiotherapy was performed). This way of attributing patients to centers implies that 
surgical centers will be evaluated for the performance of e.g. the center where 
pathology was performed for a QI referring to the domain of histopathological 
examination. To avoid such ‘misleading’ evaluations for the domain-specific QIs, it 
should be considered attributing patients to the center where the 
therapy/surgery/follow-up/histopathology took place, depending on the domain. This 
more detailed information about what was performed where is not available in the 
PROCARE database we have currently available, but could in theory be provided. 
2.3.4.2 Relative versus absolute benchmarks 
Essential to the construction of indexes are benchmarks against which to measure the 
performance of each of the centers. There are two sources for benchmarks. One 
source derives benchmarks from the QCI distribution in the PROCARE database itself 
based on e.g. the 95% CI for the estimated (case-mix adjusted) center performance with 
the 25% and 75% percentiles of the distribution of these effects. This is suggested by the 
team of PROCARE experts for identification of poor and excellent performing centers, 
it has been our focus. The advantage of this approach is that these benchmarks are easy 
to obtain. The drawback is that for each indicator a similar prevalence of good and bad 
performers is generated by the relative QIs. These may be difficult to interpret in real 
or absolute terms and need not be comparable over time. 
The alternative approach uses external benchmarks. These may be quality standards set 
by professional organizations or an expert panel, or may be performance criteria 
derived from the literature. Although it is much more difficult to obtain such external 
benchmarks, and it might even prove impossible to obtain them for all QCIs, this 
approach is to be preferred over the former one. By evaluating the centers against 
external benchmarks one achieves absolute QIs, which could well show that, despite 
variation between centers, most centers perform well and above the international 
standard, … or reveal the opposite and hence a shared opportunity for improvement. 
The benchmarks can take various forms, depending on the nature of the QCI and the 
available information in the literature. They may involve indicators of centrality (mean, 
median,…) or dispersion (standard deviation, interpercentile range,) or of upper and/or 
lower thresholds that indicate what performance is considered excellent, good and/or 
weak. Availability of benchmarks will affect the normalization of indicators and the 
production of the QIs. 
2.3.4.3 Comparability across centers 
A good QI must allow comparing centers in terms of the quality of care provided. This 
implies 1) that centers of equal quality should obtain identical scores, 2) that centers of 
different quality should get distinguishable scores, and 3) a one-to-one relation between 
the quality of the center and its score on the QI. Given that quality of care is 
multidimensional, it is unavoidable that different combinations of the QCIs will lead to 
identical QI scores. One needs to assure that identical scores obtained this way indeed 
represent an identical overall quality as measured by the QI. The determination of the 
weights (when the QI is computed as a linear combination of center effects) for each 
QCI will be crucial to achieve this comparability. 
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2.3.4.4 Level and/or spread 
A related issue is whether the QIs should only capture the overall quality of care or 
also the distribution of quality of care over the patients. In the former, measure of 
central tendency and counts will be used in the construction of the indexes, while in the 
latter also the spread will have to be taken into account. For instance, a measure of the 
level of quality might make use of the mean, median, or mode of the pre-existing 
variables, where a spread measure would make use of the standard deviation, range, 
interquartile range, etc. Of course level and spread may be related: poorly or 
excellently performing centers may tend to have less spread among patients than 
moderately performing ones. With binary indicators spread and level are inherently 
linked, leaving only the relevant measure for non-binary QCIs. 
2.3.4.5 Comparability over time 
As the purpose of these QI includes tracking changes in the quality of care of centers 
over time, the QI should remain comparable over time. If two centers at two different 
moments in time (or even a single center) score identical on all QCIs they should score 
identical on the QI, and changes in the QCIs should be reflected in the QI. Practically, 
this means that not only the included QCIs should remain stable over time, but also 
that the method of combination and normalization of the QCIs should remain stable. 
Summary Points 
• A quality index (QI) was constructed for the outcome QCIs, for the process 
QCIs, for each domain separately as well as a global QI. 
• The QI may be a single QCI. Alternatively a set of selected QCIs was 
retained and summarized in either a (weighted) sum score (linear 
combination) or an “all or none” score for the selected set of QCIs. 
• QCIs are selected based on properties of their center-averaged excess 
probabilities, this is their expected outcome beyond what is expected for 
their patients in the “average” center. For outcome QCIs this excess 
probability was risk-adjusted for patient-specific confounders of center 
choice and QCI, for process QCIs the excess probability is not adjusted. 
• Selection of QCIs for the QI is based on four guiding principles: data quality, 
concurrent validity, clinical importance and ability to discriminate between 
centers. The order in which they are applied (order of importance) is first 
statistical, then clinical. 
• How patients are attributed to centers may depend on the type of Q(C)I and 
is an important point of discussion. 
• For labeling center performance as poor or excellent, ideally an objectively 
determined external bench mark is used on which a group of experts will 
agree. This can then – for instance - be used to judge evolutions over time. 
In practice such bench marks are not (yet) available. 
• As suggested by PROCARE, benchmarking of centers may be based on the 
internally observed 25th and 75th percentiles of estimated center 
performances. Centers with confidence limits of the QI completely below 
the 25th percentile are then flagged with lesser results and centers with 
confidence limits of the QI completely above the 75th percentile are labeled 
with relatively higher performance. Properties such as sensitivity and 
specificity of such decision rule are yet to be determined in this context. 
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2.4 REVIEW OF STATISTICAL METHODS FOR PROVIDER 
PROFILING 
2.4.1 Goals 
This section aims to review methods for provider profiling and builds on the three 
previous sections (methods for patient mix adjustment, literature review on prognostic 
variables, the construction of indexes) to arrive at a motivated proposal for 
benchmarking centers contributing to PROCARE. To this end, we take several steps 
and ultimately consider: 
1. the indexes in terms of which centers will primarily be profiled, 
2. the set of patient-specific covariates for which we will adjust the indexes (and the 
method applied), 
3. the bench-marks chosen for the different indexes, 
4. individualized feedback on these indexes. Which graphical presentations will be 
constructed? Why do we not wish to formally assign ranks to the different 
centers? 
2.4.2 Methods for provider profiling in the literature 
Provider profiling has become an active area of research. A web of science search on 
‘statistical methods for provider profiling’ yields 16 papers of which some focus on very 
specific application areas not directly relevant to the current study. Other papers are 
more general and were reviewed in more detail for our purposes here. Methods and 
results are not only published in the statistical literature 37, 38, but also in the clinical 
literature 34, 38-41, the media4 and even Consumer Reports in the US [as reflected upon in 
the New York Times, September, 2010]. The general approach of monitoring and 
profiling centers that deliver important services to the public is relatively new to the 
medical field. It has known more extensive use and experience in other areas, for 
instance education, where league tables have become popular as well as heavily 
criticized. In the clinical field, research on this topic was primarily generated and 
implemented in the domain of cardiac surgery. For an example in cancer, we can 
consider the work by the Dutch surgical colorectal audits 42, where practice is closely 
monitored and methods have been developed and applied to enable progress 43. 
We start by reviewing the approach presented in a seminal 1997 paper ‘Statistical 
Methods for Profiling Providers of Medical Care: Issues and Applications’ by Normand 
et al. in the Journal of the American Statistical Association 37. These authors recognize 
several steps in the profiling approach: 1) a risk-adjustment step, 2) the choice of an 
index and 3) benchmarking. They make a number of choices which overlap, but do not 
coincide with ours. This partial overlap is not unexpected and indeed anticipated in 
their discussion which states most relevantly: 
‘The methodologic issues confronting analysts in this area are not trivial, and simplistic 
“one-size-fits-all” approaches are not likely to work 44. Major issues include data quality, 
detail, and availability; choice of performance measures, formulation of statistical analytic 
strategies; and development of approaches to reporting and interpreting the results of 
the profiling analyses’ … ‘Because profiling methods can serve a number of purposes, 
the choice of performance measures and analytic strategy will have to be customized. 
Data availability may also play a major role. For example if a reference standard such as 
a national guideline, is available, then it is reasonable to evaluate providers using an 
absolute cut-off level of performance. Unfortunately, such reference standards are often 
not available, and comparisons of providers will need to be made using relative 
measures of performance.’ 
  
                                                     
4  In France, Le Point yearly publishes “Le palmarès des hôpitaux”, ranking all French public hospitals. 
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Results based on 37 have served to broadcast quality measures for medical (cardiac 
surgery) centers in the media and have occasionally lead to sanctions. Correspondingly, 
a quite conservative standpoint has been taken in this approach, keen to reduce the 
type I error: erroneously labeling a center as underperforming. The consequences of 
that error are indeed grave and possibly irreversible. In our setting we are working in 
view of confidential individualized feedback towards the centers with the goal to help 
centers recognize where their own weak points lie and point them in the direction of 
further improvements. In our setting, therefore, relatively more weight is given to 
avoiding type II errors, i.e. failure to diagnose an area of true underperformance. A type 
II error prevents the center from recognizing an opportunity for improvement and thus 
deprives patients from the better treatment that might result. 
In step 1, the risk adjustment step, the authors start from patient-specific data and fit 
two models: [16] 
• The first model adjusts for patient-specific (baseline) factors only. To this end, 
patient characteristics are summarized in a severity index drawn from 34 
baseline characteristics of the patients. The authors allow the effects of 
patient-specific factors to change over the hospitals. While our primary 
analysis is scheduled to adjust for patient-specific factors, interactions 
between center and patient-specific factors are not foreseen until a possibly 
tertiary analysis designed to explain any differences seen between centers in 
the primary analysis. 
• The second model additionally adjusts for hospital-specific covariates, 
specifically: for rural (vs. urban), non-academic (vs. academic) centers, and the 
number of beds (categorized as: <= 100 small, 101-299 medium, >300 large). 
This risk-adjustment is achieved here through hierarchical logistic regression. As is well 
known, and we have described and illustrated in Appendix 1 (Chapter 9, section 2.1.3) 
to section 2.1.5, such models tend to shrink estimates towards the average of all 
centers and hence produce conservative estimates for both the exceptionally weak and 
exceptionally good performers.5 
In step 2, for the choice of an index, the authors chose to focus on a single performance 
index which is easily interpreted and evaluation is based on the probability of (30 day) 
mortality/survival adjusted for patient (and ultimately also hospital) characteristics. [16] 
For step 3, benchmarking, the following specific measures are examined:  
• An indicator of whether 30-day mortality exceeds 1.5 times the median of its 
distribution over the centers. 
• The difference between the center-specific and center-averaged risk for the 
center - with its specific patient mix. This difference is compared with the 
following cut-off value: median difference plus 1.5 times the interquartile 
range of this difference. Median and quartiles are taken over the random 
effects distribution of the center effects. 1.5 times the median mortality rate 
is seen as a meaningful cut point for weak performance. Using the Bayesian 
paradigm they calculate each center’s chance of crossing the cut point. 
• The ‘more standard Z-score’, i.e. the center’s observed minus expected risk 
divided by its standard error with 1.645 as cut point for relatively poor 
performance (‘top 5 %’). The authors consider this relative measure of 
performance undesirable since a predetermined fraction of centers is 
expected to cross the cut point by design. That is true, even in the absence of 
between-center variation in true performance, purely on the basis of within-
center sampling variation.  
  
                                                     
5  Note: to avoid contamination between center effect and patient effect on the outcome in the primary 
analysis, it is important that the patient-specific characteristics for which one controls are not themselves 
influenced by the centers. For certain measures, such as P-staging, this would be an issue.  
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The authors advocate the use of several measures of performance with an inspection of 
consistency across several measures. When a particular decision rule has been identified 
to label centers as (especially) poor or excellent it becomes important to evaluate the 
sensitivity and specificity of the ensuing diagnostic tool. Such examination is developed 
in Normand et al. 38. 
In their recent reporting of ‘online CABG report cards’, Ferris and Torchiana 41 have 
labeled centers as performing significantly below (given one star) or above (three stars) 
the mean center performance based on 99% confidence intervals (99% CI). This 
resulted in 23 to 27% of the programs to be identified as outliers over the past 3 years. 
In the Dutch 2009 report 45 one calculates percentiles of performance over the center 
distribution and compares the expected percentile based on the observed case mix with 
the observed percentile. One thus evaluates unusual performance aided by QQ-like 
plots.  
Based on a survey, the team of PROCARE experts suggests to produce 95% CI for the 
estimated (case mix adjusted) center performance and to compare this with the 25% 
and 75% percentiles of the distribution of these effects over the centers for the 
confident identification of poor and excellent performance.  
2.4.3 Visualizing variation between centers  
2.4.3.1 Variation in case-mix 
In the Dutch 2009 report 45, one depicts variation over the centers in case-mix through 
simple scatter plots of expected values of important prognostic factors. They produce, 
for instance, one plot of average ages over the centers, one plot for the percentage of 
ASA scores exceeding a threshold, … and one ‘summary plot’ showing how the 
expected 30-day mortality rate based on case-mix alone varies over the centers.  
2.4.3.2 Variation in quality indexes 
Revealing the variation in true quality index across the centers poses a special challenge. 
Since this true quality index is estimated with varying precision, one needs to ‘subtract’ 
sampling error from observed variation between estimated center effects. Indeed, 
variation in observed outcome is expected based on sampling variation alone, and tends 
to be larger for small centers than for larger centers. One therefore wishes to establish 
any evidence for variation in true center effects over and beyond the random sampling 
variation. The technique of hierarchical (random effects) models outlined in section 2.1 
comes with a natural estimator of the variation in true center effects. A test can be 
derived to establish whether this variation is significantly different from zero as in van 
Houwelingen et al. 2002 46. If not, one lacks evidence of any systematic variation 
between centers and the profiling may end there. Once significant variation is 
established, however, it becomes important to engage in the evaluation of (relative) 
performance of the distinct centers. The final column in Table 30 and Table 31 refers to 
the significance (p-value) of such variation in the hierarchical model fit. If so desired one 
may add a measure of variation explained by centers along the lines of Efron 47 and van 
Houwelingen et al. 46  
Inspired by techniques developed for meta analysis, Spiegelhalter 48 developed the funnel 
plot which shows to what extent observed variation in estimated (possibly risk-
adjusted) center effects lies within the boundaries of sampling variation - or not. To 
achieve this, the funnel plot starts from an estimated average effect. Assuming this effect 
is common to all centers, hence in the absence of variation in true effects between 
centers, one can calculate the sampling variation of the estimated center effect, and 
derive corresponding 95% and 99% confidence intervals in function of the center size. 
One may then test whether more than the expected number of estimated center 
effects lie beyond those boundaries. The typical plot shows estimated center effects 
either  against  the sample size or more directly against the information (1/variance) 
represented by each center. Plots in function of center size may not sufficiently protect 
center confidentiality. In some instances one may chose to present this type of graph 
also for feedback to centers, rather than the catterpillar plots.  
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Unlike caterpillar plots, they avoid a suggestion of implied ranking between the centers. 
Such suggestion is easily perceived from the order in which the estimated effects are 
shown in the caterpillar plots, even though confidence intervals emphasize substantial 
uncertainty on such ranks. The disadvantage of the funnel plot for our purpose is 
however that it does not focus on the relative bench marks that were chosen for our 
evaluation.  
By way of example, Figure 5 shows a funnel plot for the all-or-none score indicating 
whether all selected quality indices in the process domain were achieved or not (more 
detail on this score is given in section 4.4). The central red line gives the percentage of 
all eligible patients who achieved this score, If all centers experience the same chance of 
achieving the score, this percentage produces an accurate measure of this probability of 
success. The dots on the plot show per center (of size 5 or larger) the percentage of 
patients for which this all-or-none score was actually achieved. The inverse of the 
variance of these estimates is the information measure on the x-axis. If all centers have 
indeed the same chance of achieving this score, then 5% (1%) of centers are expected 
to fall beyond the green (blue) inner (outer) lines. This amounts to respectively 3.4 and 
.68 expected centers of the 68 centers shown. In reality, respectively  26 and 18 centers 
were found beyond these bounds. The chance of this occurring if the probabilities of 
achieving the score were indeed identical are negligeable. Substantial evidence thus 
emerges of systematic variation between centers in achievement on the aggregate 
process score,  
Figure 5 Funnel plot for the aggregate index of the process indicators.  
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2.4.4 Graphical presentation of center results 
Visualization of the estimated center effects with their precision using caterpillar plots 
was shown by Spiegelhalter 48, 49. Caterpillar plots order centers by estimated effect size 
and plot them with their credibility/confidence intervals as illustrated for QCI 1271 (Use 
of the pathology report sheet) in Figure 6 below. Figure 6 shows an overview of case-
mix adjusted center performances. Here, the adjustment was done for age, gender and 
cStage based on the preliminary PROCARE database. The expected center-specific 
outcome for the average aged male in C-stage III is shown. The red lines show the first 
and third quartile of the estimated excess probabilities as well as the median of these 
values over the center distribution. This helps evaluate centers in line with the 
boundaries identified as useful benchmarks by the PROCARE steering group who chose 
to label centers as performing poorly when the upper boundary of their 95% confidence 
interval stays below the 25% percentile. 6  A similar plot on the logit scale has the 
advantage that the 95% CI around the estimated center effects are symmetrical. This 
facilitates an understanding of their genesis and the estimation procedure. On the other 
hand, the plot on the original probability scale allows for an intuitive (clinical) 
interpretation of the center effects along with a subjective evaluation of their distance 
from the P25 and P75 boundaries. It was therefore preferred. Whether or not these 
P25 and P75 percentiles represent meaningful boundaries for poor and weak 
performance in absolute terms is indeed a question more easily judged by experts on 
this original probability scale. When performing this analysis for a whole range of QCIs, 
we chose to move to a relative measure, which we called excess expectation or excess 
probability: the difference between a center’s expected outcome on his patient mix and 
the expected outcome for the same patient mix for the (logit based) average center 
(see Figure 6 below).  We then also decided to focus on unadjusted measures for 
process quality indicators and adjusted measures for outcome indicators. 
                                                     
6  Note how the empirical quantiles are simple and transparent estimates of the corresponding quantiles of 
the true expected center effects. They are not necessarily optimal however. Since the estimated center 
effects suffer some imprecision their observed variation may generally be larger than that of the true 
center effect variation. This will be compensated to some degree in our case by the mild shrinkage 
achieved by the Firth correction. For a more comprehensive discussion on (Bayesian) optimal estimation 
of percentiles, see the work of Paddock and Louis, 2011  and Carlin and Louis, 2000, 
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 Figure 6: Caterpillar plot for QCI 1271 [%Path_Rep_Use] on the natural 
scale.  
 
The x-axis shows the estimated probability of use of the pathology report sheet after 
adjustment for the three baseline covariates gender, age and cStage. The probability is 
given for males, aged 67 in cStage III. Red lines show P25 and P75 of the estimated 
values. 
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Figure 7: Caterpillar plot of excess chances for QCI 1271 [%Path_Rep_Use]. 
The x-axis shows the estimated “excess” probability (beyond what is expected on the 
average center) of use of the pathology report sheet. Red lines show P25 and P75 of the 
estimated values. 
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2.5 PROPOSED APPROACH FOR PROCARE 
2.5.1 Choice of index 
This follows from the statistical-clinical approach outlined section 2.3 and we anticipate 
profiling in terms of each of the indexes developed there: one index for each of the 8 
domains, one global index, one index for outcome and finally one for process. 
2.5.2 Adjusting for patient specific factors 
As argued in section 2.1 and established through the results of the literature review 
summarized in 2.2, one ideally adjusts for a whole range of patient-specific factors to 
account for case-mix. The list of prognostic factors may vary with the QCI considered. 
Especially for outcome QCIs (e.g. survival) several evidence-based prognostic variables 
have been identified, including some important ones which are either not present in the 
existing databases relevant to PROCARE or subject to denied permission for linking.  
For the primary analysis we are therefore left with the more limited set of baseline 
covariates available in the PROCARE database. We note in this regard the also rather 
limited set of covariates adjusted for in the Dutch report 45. These were age, gender, 
body mass index, Charlson score and ASA score for co-morbidity, history of abdominal 
problems, distance tumor anal verge, tumor complications, clinical stage. 
In the PROCARE database we specifically have access to age, gender, height and weight 
(hence body mass index) and ASA score for co-morbidity (not the Charlson score). 
From the pre-operative data entry form we further consider: BMI with an indicator of 
its missingness, and the 9 categorical variables including a category for missingness: 
cSTAGE, ASA co-morbidity score, level of the tumor, mode of surgery, ventral tumor, 
cCRM, cT4, pre-operative incontinence and surgical technique. 
2.5.3 Bench marking 
We follow the suggestion of the PROCARE team and provide 95% CI for estimated 
case-mix-adjusted center effects and compare them with the relative P25 and P75 
measures. Whether or not these relative measures also represent a meaningful 
delineation of areas of poor or excellent performance in absolute terms remains to be 
established. An expert consensus on this should allow complementing relative measures 
with more absolute markers of high and low performance. That clinically meaningful 
distances are captured in absolute terms is more generally one of the arguments 
pleading against formally ranking center performance. This was raised in the context of 
comparisons between institutions in the areas of health and education already in 1996 
49, and followed in our seminal reference 37. We agree with this and for that reason do 
not pursue this avenue here. A well-known added complication is the difficulty in 
assessing uncertainty associated with ranks 50. 
2.5.4 Visualization  
We plan to use in sequence 1) funnel plots to indicate whether variation is present 
between centers beyond sampling variation: if this is the case, then 2) caterpillar plots 
will allow centers to position themselves at a glance in the distribution of observed 
center effects. The confidence intervals should caution against over-interpretation of 
ranks, while the vertical lines give relative and possibly also absolute markers of weak 
and good performance.  
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Summary points for the methods chapter  
• A more technical description of different techniques for risk-adjustment of 
binary and right-censored QCIs is presented, considering fixed effects 
outcome regression, random effects outcome regression, doubly robust 
propensity score methods and instrumental variable methods. These four 
techniques are all considered within the causal framework in which we aim 
at estimating the effect of choice of center of care on the outcome (QCI). 
• It was decided not to pursue the instrumental variables approach since the 
identified instrumental variables for this setting (distance and 
region/location) were not made available from the PROCARE database and 
preliminary results showed that the presence of many centers results in very 
imprecise estimated effects. 
• An extensive simulation exercise has shown that there is no single   
technique that performs uniformly better than another. We therefore 
performed all three analyses, and evaluated the combined results in light of 
their described strengths and limitations. 
• Convergence problems when fitting simple models with center choice as 
fixed predictor have been identified. These problems were most prominent 
when small centers (with e.g. less than 5 patients) with few events were 
entered in the model. To allow for reliable results, we restricted estimation 
of center effects to centers with at least 5 patients (other centers may be 
grouped into one overlapping center). 
• Issues related to the lack of access to known confounders (e.g. socio-
economic status) are discussed. The risk-adjustment analysis was necessarily 
restricted to age and gender plus the baseline clinical patient-specific 
confounders available in the PROCARE database. 
• Missing data problems have been discussed and we suggest multiple 
imputation techniques for reconstruction of the database under the missing 
at random assumption, while acknowledging that this assumption may well 
be violated. 
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3 APPLICATION AND RESULTS ON THE 
PROCARE DATABASE  
3.1 INTRODUCTION 
In this chapter, we apply the first set of methods described in Chapter 0 to the data 
available in the PROCARE register up to August 27th, 2010. After summarizing basic 
descriptive statistics on centers, prognostic variables and QCIs, we embarked on a 
multivariate risk adjustment of outcome QCIs and univariate risk adjustment for 
process QCIs in all 8 domains. Results per center are shown in caterpillar plots and 
outlying centers on either side of the spectrum are noted. 
Since these data originated from a voluntary register which is in constant development 
and not yet fully matured, results should be interpreted with caution. First, one should 
examine to the extent possible the patient inclusion rates as well as any selectivity in the 
choice of patients who enter the data register. Secondly, certain variables show more 
missing data than one would normally expect, others still show some inconsistencies 
and for specific survival outcomes, few events could result in a weak information base 
and instability of the statistical methods used. Correspondingly, the implementation 
developed below serves first and foremost as an illustration of the application of the 
methods in this setting, for now adapted to the current version of the database (follow 
up until August 27, 2010). Limitations of the data become evident in the patient-mix-
adjusted QCIs, and especially in the build-up of the QI, which explicitly foresees to 
eliminate variables with excess missing data or limited information content. In other 
words, as the database becomes subject to more quality control and events accumulate 
over time, the composition of these indexes may change drastically under the same 
index building process. This being said, a lot has been learned from this pioneering 
effort. 
Before starting with the approach and the descriptive analysis of our observed cohort, 
we elaborate briefly on the selective nature of our cohort. More on this can be found in 
Appendix 7 on the representativeness of the observed cohort. As explained early on, 
participation in PROCARE is on a voluntary basis. This means that the PROCARE 
database has no full coverage of rectal cancer patients in Belgium, because: 
• Some centers do not participate 
• Within participating centers, not every specialist involved in the treatment of 
rectal cancer, participates 
• A participating specialist may not include all rectal cancer cases in PROCARE 
To get a better insight into the participation rate (completeness) and the degree of 
randomness in participation, the PROCARE database has been linked with and 
compared to the BCR database. The BCR database has full coverage of all new primary 
cancers in Belgium from 2004 onwards and in addition, this database provides 
information on topography, morphology, stage, and the center that delivered the data. 
Therefore, the BCR database is the most suitable source to investigate the 
completeness of the PROCARE database. The link is, however, not without problems as 
explained first.   
First, the rules for patients to be included in PROCARE are the following: 
1. The lower limit of the tumor must be situated between 0 and 15 cm above the 
margo ani, 
2. Only adenocarcinoma are included, 
3. Only invasive tumors are included, 
4. Multiple synchronous tumors are left out in PROCARE if it is indicated on the 
PROCARE data entry form. Note that before January 2010, this was not 
mentioned on the data entry form. Therefore, this exclusion criterion will not be 
considered for the present study, 
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5. Patients for whom the INSS is not indicated cannot be included in the PROCARE 
database system. People not residing in Belgium are not included in the 
PROCARE database.  
For the present analysis, only PROCARE patients with year of incidence between 2005 
and 2008 were selected, because the BCR data after 2008 are not yet available. As a 
rule, the PROCARE database was linked to the BCR selection of only those patients 
who fulfill the PROCARE criteria in the more strict sense. A second complication for 
linking both databases results from the way patients are attributed to centers. In 
PROCARE, the decision rule to assign a patient to a center is based on the medical 
specialism that delivered the data. In case a patient has been operated, the center of 
surgery is chosen. If this is missing, the center in which the pathological examination is 
performed is chosen. If this still yields no center, the center of chemotherapy is chosen. 
If no surgery is performed, then the center of chemotherapy is chosen. In the BCR 
database, it is less clear which speciality has delivered data. BCR data comes from 
multiple sources. More detail on this is given in Appendix 7. 
To examine the completeness of the PROCARE database, a final selection was made of 
those patients with ICD code C20-C21 and an adenocarcinoma in the BCR database 
(PROCARE inclusion criteria). 
The completeness of the PROCARE database per year of incidence is presented in 
Table 1. When 2005 is ignored (the prospective registration has started in 2006, only 
few centers have retrospectively registered patients of 2005), the completeness of the 
PROCARE database is around 30%. Also note that up until now, cases of 2008 are still 
being registered, so the actual proportion of 2008 might be underestimated. 
Table 1: Proportion of PROCARE patients in BCR database. 
Incidence year N in PROCARE N in BCR database % coverage 
2005 239 2091 11.4 
2006 792 2287 34.6 
2007 717 2298 31.2 
2008 618 2340 26.4 
Total 2366 9016 26.2 
Next, it was investigated which stages, as registered in the BCR were best represented 
in the PROCARE database (Tables 2-3). The cases from the incidence year 2005 as well 
as stage 0 cases were not included for the analyses per stage. 
For cStage I and II the proportion present in PROCARE is little less than 40%, whereas 
for stage III, this increases to nearly 48%. From the stage IV patients, only 25% were 
present in the PROCARE database. This was expected given that PROCARE has a firm 
surgical background and many stage IV patients did not undergo surgery. Twenty 
percent of patients with an unknown cStage in the BCR database were registered in 
PROCARE.  
For pStage, the picture is similar, although the distribution between stage I, II and III is 
more equal.7 
Table 2: Proportion of PROCARE patients in BCR database – per cStage 
(2005 not included) 
cStage N in PROCARE N in BCR database % coverage 
I 212 563 37.7 
II 313 813 38.5 
III 810 1690 47.9 
IV 194 781 24.8 
NA 8 54 14.8 
X 588 3021 19.5 
TOTAL 2125 6922 30.7 
 
                                                     
7  Patients who have ypStage 0 in the PROCARE database, are registered in the BCR database with pStage 
X (88.7%), pStage I (6.7%), pStage II (2.1%) and pStage III (2.6%) respectively. 
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Table 3: Proportion of PROCARE patients in BCR database – per pStage 
(2005 not included) 
pStage N in PROCARE N in BCR database % coverage 
I 501 1327 37.8 
II 472 1322 35.8 
III 576 1605 35.9 
IV 97 388 25 
NA 8 54 14.8 
X 471 2226 21.2 
TOTAL 2125 6922 30.7 
Next, both databases were compared on age and sex. The mean age of the patients in 
the PROCARE database (67.0 years) was lower than the mean age of the patients who 
were only in the BCR database and not in the PROCARE database (69.9 years). This 
difference was significant t(9013)=10.14 (p<.001). 
Furthermore, there were 61.9% male patients included in the PROCARE database. For 
the patients who were not included in this database, the percentage of men was 58.5%. 
This difference was also significant ² (1) =8.74 (p<.01). 
In conclusion, in the PROCARE database, the coverage of stage IV patients is lower, 
patients are on average younger, and the percentage of male patients is higher. In 
Appendix 7 (see Table 7) one finds more detail on this investigation as well as a table 
with coverage rates per center. Ideally we would also need to compare survival curves 
per center between the BCR and PROCARE database to get a more outcome directed 
measure of selectivity. Unfortunately the BCR could not provide this under the current 
database constraints. 
3.2 METHODS 
3.2.1 Descriptive statistics 
As announced in section 2.1.7, descriptive statistics were computed for center, baseline 
patient-level characteristics (potential prognostic factors) and QCIs before embarking 
on more complex modeling. Special attention was paid to missing data.  
We first describe the distribution of patients over the centers and the pace at which 
new patients are registered in PROCARE. To be informative while protecting 
confidentiality, centers will be (sample) size-grouped based on the number of patients 
registered in PROCARE (grouping levels: [1-10[, [10-20[, [20-40[, [40-60[, [60-80[, [80-
100[ and 100+ patients registered in PROCARE). 
We then describe the study sample in terms of baseline characteristics, first univariately, 
then bivariately, followed by an examination of joint missingness patterns and some 
information on the follow-up information that is available in the PROCARE database. 
For discrete variables (e.g. gender, cStage, …) tables show the overall frequency 
distribution, as well as for the size-grouped centers. For binary variables a caterpillar 
plot (see section 2.4.4 for more details) shows for individual (and one merged with less 
than 5 eligible patients) centers c unadjusted proportions ( ݌̂௖ ) with corresponding 
asymptotic confidence intervals: 
቎݌̂௖ െ 1.96ඨ
݌̂௖ሺ1 െ ݌̂௖ሻ
݊௖
, ݌̂௖ ൅ 1.96ඨ
݌̂௖ሺ1 െ ݌̂௖ሻ
݊௖
቏ 
Currently, for centers with proportions equal to 0% or 100%, no confidence intervals 
are provided, while lower or upper confidence limits below 0% or above 100% are 
truncated at 0% or 100%, respectively. For small centers the confidence intervals are 
hence approximate and merely give an indication of the level of uncertainty in this 
exploratory analysis. Where needed, exact confidence intervals may be given instead. 
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Continuous variables (e.g. age, BMI, …) are described using the five-number summary 
(i.e. minimum, P25, median, P75 and maximum), mean and standard deviation, overall 
and per size-grouped centers. Additionally, a box plot per center illustrates how 
distributions differ between centers. 
For all QCIs there is – overall and for the size-grouped centers – a descriptive table 
with the total number of patients, the number of patients with missing information for 
the QCI, the number (%) of eligible patients, and 
• for binary QCIs the number (%) of eligible patients meeting the QCI,8 
• for survival QCIs the five-number summary of follow-up times, total person 
years, number of events and event rates are listed as well as Kaplan-Meier 
curves shown. 
• for continuous QCIs the five-number summary of observed values. 
Additionally, we plot for binary QCIs an unadjusted caterpillar plot (as described 
above), for survival QCIs (cStage-stratified) Kaplan-Meier curves and for continuous 
QCIs a box plot per center.9 
3.2.2 Identification of relevant prognostic factors 
Three sources are considered for identifying possibly relevant baseline characteristics as 
prognostic factors for outcome QCIs: 
1. prognostic factors identified in the literature review of Appendix 2; 
2. prognostic factors identified in the PROCARE consensus on risk/confounding 
factors per QCI of January 5th, 2011 (Appendix 2), 
3. empirical associations between the QCI and a fixed set of prognostic factors 
occurring in the literature review and/or the PROCARE consensus: gender, age, 
BMI, ASA co-morbidity score, cStage, level of the tumor (high, mid or low), 
mode of surgery (elective or scheduled versus urgent or emergency), ventral 
tumor, cCRM positivity, cT4, preoperative incontinence and surgical technique 
used (PME versus TME). 
For both outcome and process QCIs, statistically significant (p-value < 0.10) univariate 
associations with abovementioned baseline variables are reported.  
To obtain an appropriate risk-adjustment model for the outcome QCIs, in a first step a 
backward modeling strategy (p-value for exclusion > 0.05) is applied to obtain a 
(multivariate) risk-adjustment model with only main effects. Next, in a forward modeling 
strategy (p-value for inclusion < 0.10), we consider all possible two-way interactions 
between main effects that were retained after the first step.10 
                                                     
8  In PROCARE II, this % was called a weighted mean, it corresponds to the QCI results for the cohort as a 
whole. At some point we will also talk about unweighted means, being the average of the center-specific 
proportions for that QCI. 
9  Note In the caterpillar plot and box plot as described above, centers with less than 5 available patients 
have been grouped into one overlapping center. 
 For the binary QCIs funnel plots are produced, but not shown in this report to protect confidentiality of 
the centers.   
10  Note The modeling strategy as described above is performed in a fixed effects outcome regression 
model with Firth’s correction. 
 All risk-adjustment models for outcome QCIs will adjust for the prognostic factors gender and age, even 
if they are not significantly associated with the QCI. 
 When building these models, centers with less than 5 available patients for the QCI of interest are 
grouped into one overlapping center. 
 Handling of missing data 
 For categorical variables a separate level is created for the missing value. 
 For continuous variables, an interaction between the original variable and a dummy variable indicating 
missingness will enter the model. With very few (less than 5) missing values, we will discard these 
patients from the analysis. 
 Caution, using a missingness indicator to allow all patients in the model has some drawbacks; by 
conditioning on the missingness indicator one does not avoid the selection bias among the available data 
and adjusts only partially for confounding, it avoids deleting observations by making some assumptions on 
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3.2.3 Estimation of unadjusted and case mix adjusted center effects 
As discussed in section 2.1, three methods have been explored for estimating the 
center effects for the outcome QCIs: fixed effects outcome regression and random 
effects (hierarchical) outcome regression for center effects related to the center’s own 
patient population, and a doubly robust propensity score method for center effects 
related to a common reference population (i.e. the patients registered in the PROCARE 
database). The same (multivariate) risk-adjustment model, as obtained from the 
modeling strategy described in Section 3.2.2, is used in all three methods. 
For ease of presentation on the larger scale, center effects are expressed as an ‘excess’ 
(relative to the average center) probability or outcome value, i.e. the obtained center-
specific mean will be ‘standardized’ by subtracting from it the probability or mean 
outcome value one would expect to observe if all patients of that specific center have 
been treated in the average center. Results for the ‘average center’ are implicitly 
obtained by taking the unweighted (case-mix adjusted) mean of all centers considered 
for a QCI. In other words, this ‘excess’ probability or outcome value can be seen as the 
probability or outcome value associated with the specific center a patient was treated 
in. We refer to Appendix 1 (Chapter 10, section 1) for more detail on these ‘excess’ 
center effects. 
For process QCIs, the center effects primarily remain unadjusted for prognostic factors, 
but statistically significant associations with prognostic factors are reported.  
To visualize results, for outcome QCIs, unadjusted as well as adjusted center effects are 
estimated and compared in scatter plots. In addition, a caterpillar plot (see section 2.4.4 
for more details) with the unadjusted center effects and a caterpillar plot with adjusted 
(from the fixed-effects model) center effects are produced. Equally, caterpillar plots with 
unadjusted center effects are reported for all process QCIs. Appendix 1 (Chapter 10, 
section 1) gives more detail on the computation of the error bars in these caterpillar 
plots. 
3.2.3.1 Technical notes 
While the propensity score analysis has desirable properties in large samples, we have 
found that the small size of various centers in this setting does not enable accurate 
assessment of the propensity score, i.e., the probability to attend a given center in 
function of patient characteristics. It must therefore at present be viewed as a more 
experimental analysis that is only included for illustrative purposes (in a more detailed 
analysis for QCI 1227 [%grade4_Tox_Preop_RT]). In particular, if we were to adhere 
to the heuristic ‘rule of 10' according to which 10 events are needed per covariate in a 
logistic regression model to prevent important finite-sample bias, then each covariate 
that is included into the propensity score model for a given center would require at 
least 10 patients in that center. This imposes severe limitations on the number of 
covariates that we can realistically deal with in the propensity score model, or indeed 
any non-penalized regression model. 
Future research will examine more closely a number of strategies that may help 
improve the performance of propensity score methods when the number of patients 
per center is relatively small. Some approaches are suggested in the Appendix 1. 
Similarly, the hierarchical regression approach encounters problems in estimating 
(adjusted) center effects with standard pseudo-likelihood estimation techniques, often 
when there is a very low or very high event rate, for instance QCIs 1231 [%R0res], 
1233a [%Leak_PME], 1234 [30d_mort], 1235 [%Perfor], 1235b [%Pos_Dist_margin], 
1245 [%grade4_Tox_Prostop_CT].  Of course, there is little information to support or 
refute the shape of the random effects distribution assumed in those instances. The 
hierarchical regression model was then fitted using a maximum likelihood procedure 
with a Laplace approximation, which resolved the problematic model fit for all 
abovementioned QCIs except for 1235b and 1245.  
                                                                                                                                             
the missing data. A multiple imputation strategy might be a more solid strategy for handling missing data, 
but this method then requires strong distributional assumptions. 
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For QCI 1235b the event rate is extremely low (2%) and for QCI 1245 there are only 
128 patients eligible, hence few information is available for fitting the model. For these 
latter two QCIs no center effects from a hierarchical regression are reported. 
Taking these estimation issues with the hierarchical regression approach and the 
propensity score method into account, we have decided to rely on the risk-adjusted 
center effects as obtained from the Firth-corrected fixed-effects regression approach 
for evaluating center performance and aggregating QCIs into quality indices (QIs). 
To be consistent, unadjusted center effects for both process and outcome QCIs have 
also been obtained from a Firth-corrected fixed-effects outcome regression with ‘center 
choice’ then as the only predictor. 
3.3 DESCRIPTION OF THE STUDY COHORT 
The PROCARE database contains data on rectal cancer patients registered on a 
voluntary basis by the multidisciplinary clinical team, including surgeons, radiotherapists, 
oncologists and pathologists. The following exclusion criteria for registered patients 
from the database are applied by the Belgian Cancer Registry (BCR): 
• patients in which the rectal cancer type is not an adenocarcinoma (e.g. 
carcinoid), 
• patients in which the lower limit of an invasive adenocarcinoma is above 15 
cm from the anal verge, 
• patients with pStage 0 (i.e. pTis and pT0),11 
• patients with synchronous primary tumors outside of the rectum, 
• patients who do not reside in Belgium. 
For the present study, patient inclusion was stopped on August 27th, 2010. 
3.3.1 Centers 
At the time of database closure, 3328 patients were included, involving 79 centers and 3 
patients for whom the center of treatment is not known (even though the data must 
have been submitted in some way by ‘a’ center). These three patients are grouped into 
one ‘artificial’ center. The number of patients registered in the PROCARE database 
ranges from 1 patient in 5 centers up to 254 patients in 1 center. The median and 
average center sizes are respectively 32.5 and 41.6 patients. The distribution of the 
center sizes is shown in the histogram in Figure 8. 
                                                     
11  Note that an ypStage 0 (ypTis and ypT0) is possible when the tumor is totally regressed after 
neoadjuvant radiochemotherapy and if the cT stage was cT1 or more and/or a biopsy or endoscopic 
resection confirmed the presence of an invasive cancer; these records are included in the database used 
for feedback. 
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Figure 8: Distribution of center sizes, i.e. number of patients registered in 
the PROCARE database. 
 
As seen in Table 4, there are 12 centers with less than 5 patients registered in the 
PROCARE database. Note that one of these centers is the ‘artificial’ center 
representing the 3 patients for whom the center choice is not known. 
Table 4: Frequency, cumulative frequency and cumulative percentage of the 
center sizes in the PROCARE database, up to centers with 10 patients. 
Number  
of patients 
Center  
frequency 
Cumulative 
frequency 
Cumulative 
percent 
1 5 5 6.25 
2 4 9 11.25 
3 2 11 13.75 
4 1 12 15.00 
5 2 14 17.50 
8 1 15 18.75 
9 3 18 22.50 
10 1 19 23.75 
… …  … 
254 1 80 100 
We found 20 centers with no patients registered in the PROCARE database after 
January 1st, 2008 (i.e. 2.5 years prior to the database closure). Eight of these centers 
have registered altogether less than 10 patients in the PROCARE database. This raises 
the following questions about centers that did not report any new patients ‘recently’: 
• Are they still participating in PROCARE, and do they still expect feedback on 
their (or the overall) performance? 
• Can these be centers that used to work independently but merged at a 
certain moment with another center? In this case, would it not be better to 
also include the patients from before the fusion into the merged center? 
To protect confidentiality of centers with patients registered in the PROCARE database, 
no center-level descriptive statistics are provided, but instead descriptive statistics per 
grouping level as in Table 5, where grouping was based on the center sizes, e.g. grouping 
level [1-10[ contains 68 patients from the 18 centers who registered less than 10 
patients so far in the PROCARE database. 
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Table 5: Distribution of the number of patients and number of centers over 
the different grouping levels based on center size. 
Grouping  
level 
Number  
of patients 
Number  
of centers 
[1-10[ 68 18 
[10-20[ 219 15 
[20-40[ 424 14 
[40-60[ 663 14 
[60-80[ 399 6 
[80-100[ 527 6 
[100-] 1028 7 
3.3.2 Prognostic factors 
3.3.2.1 Gender and age 
Of all patients in the PROCARE database, 61% are male, and the average age at 
incidence is 67 years with a standard deviation of 12 years. Forty-six percent of the 
patients in the database are older than 70 years. The age at diagnosis is not available for 
198 (6%) of the patients in the database, due to a missing incidence date. This 
missingness occurs rather center-specifically: 165 (or 83%) of all missing incidence dates 
occur in 10 of the 80 centers, with more than 5 missing observations in each of these 
centers (details not shown to protect center confidentiality). 
Appendix 6 (section 1.1, Tables 1-2) tabulates how age and gender are distributed in the 
size-grouped centers. Figures there show the percentage of male patients per center 
(A6-section 1.1, Figure 2) and a box plot of the age distribution per center (A6-section 
1.1, Figure 3).  
3.3.2.2 cStage 
From Table 6 we can see how 46%, of the patients in the PROCARE database has 
cStage III, 13% has cStage IV, 15% has cStage II and 12% cStage I. There are 10 patients 
with cStage 0, but these are allowed in the database because they have a (y)pStage that 
is non-zero. However, for the statistical analyses per QCI the 10 patients with cStage 0 
will be discarded. 
For the remaining 392 (12%) patients, cStage is missing or could not be determined (X). 
The missingness (or X) of cStage is less center-specific than for age: there are 31 
centers with a higher percentage missingness (or X) than the overall percentage of 
14.9% (details not shown to protect center confidentiality). 
Table 6: Distribution of cStage in the PROCARE database 
cStage Frequency Percent 
0 10 0.30 
I 392 11.78 
II 492 14.78 
III 1520 45.67 
IV 419 12.59 
X 103 3.09 
missing 392 11.78 
In Table 7 the relation between the cStage and the (y)pStage is presented. It shows e.g. 
the number of (y)pStage I-II patients that had clinical stage III, and that the patients with 
cStage 0 do not have (y)pStage 0 (although missing for 2 patients). Beside this we 
observe substantial clinical over- and under-staging of patients. Note that for 
determining the (y)pStage with regard to metastases, the clinical M stage is used since 
there is no uniform determination of the pathological M stage. This explains the exact 
match of cStage IV and (y)pStage IV patients. 
The distribution of the different cStages and (y)pStage over size-grouped centers is 
explored in Appendix 6 (Section 1.1, Tables 3-4). 
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Table 7: Relation between cStage and (y)pStage in the PROCARE database. 
cStage 
(y)pStage 
Total 
0 I II III IV X missing 
0 0 6 2 0 0 0 2 10 
I 12 169 62 84 1 13 51 392 
II 41 120 178 110 4 1 38 492 
III 192 338 379 479 27 2 103 1520 
IV 0 0 0 0 419 0 0 419 
X 3 18 29 23 1 4 25 103 
missing 6 46 59 49 9 158 65 392 
Total 254 697 709 745 461 178 284 3328 
The accuracy of cStaging relative to (y)pStaging is summarized in Table 8, overall and 
separately for patients who are known to have received neoadjuvant treatment and for 
patients for whom this is not known. From this we learn that 1245 of the 3328 patients 
are consistently staged, while 1082 have higher clinical stage (which might be related to 
rectal cancer regression after neoadjuvant treatment) and 296 lower clinical stage. For 
705 patients the staging accuracy cannot be determined because either their cStage or 
(y)pStage is missing. 
Note that for patients who are known to have received neoadjuvant treatment cStage 
and (y)pStage need not coincide due to the downstaging effects of neoadjuvant therapy. 
This is reflected in the high proportion (48%) of clinically over-staged patients in that 
group. In the group of patients with missing valid information on neoadjuvant treatment 
there is an overrepresentation of patients with missing cStage and/or (y)pStage. Hence, 
missingness of staging is associated with missingness of neoadjuvant treatment. 
Table 8: Staging accuracy for all patients in the PROCARE database, overall 
and separately for patients that underwent neoadjuvant treatment or not. 
The (y)pStage is taken as the reference stage to assess under- or over-
staging.  
Clinical staging 
relative to (y)p-
staging 
Overall 
Neoadjuvant 
treatment 
No / missing 
neoadjuvant 
treatment 
Frequency Percent Frequency Percent Frequency Percent 
Under-staging 296 8.89 92 4.88 204 14.15 
Correct 1245 37.41 682 36.16+ 563 39.04 
Over-staging 1082 32.51 898 47.61 184 12.76 
Missing c- or 
(y)pStage 
705 21.18 214 11.35 491 34.05 
Total 3328 100 1886 100 1442 100 
3.3.2.3 Lower limit and tumor level 
The lower limit of a tumor is – in order of priority - determined by 1) pretreatment 
rectoscopy, 2) pretreatment colonoscopy or 3) rectoscopy or colonoscopy at surgery 
and classified depending on the distance from the margo ani as shown in Table 9. 
The distribution of the three tumor levels in the PROCARE database is presented in 
Table 9. 
Table 9: Frequency and percentage of the level of the primary tumor in 
patients for whom the lower limit of the tumor is known 
Lower limit tumor (cm) Tumor level Frequency Percent 
≤ 5 cm Low 1292 42.94 
>5 - ≤ 10 cm Mid 1198 39.81 
>10 cm High 519 17.25 
Available  3009 100 
Missing  319 9.58 
Overall total  3328  
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The missingness of the lower limit of the tumor is quite center-specific: almost 80% of 
missings occur in 17 of the 80 centers, all with at least 10 patients registered in the 
PROCARE database (details not shown to protect center confidentiality).  
Appendix 6 (section 1.1, Table 5) tabulates the more detailed distribution of tumor 
levels per size-grouped center. 
3.3.2.4 BMI 
BMI is known for 2084 (63%) of the 3328 patients in the PROCARE database. It ranges 
from 13 to almost 60 kg/m². The average and median BMI are respectively 25.7 and 25.2 
kg/m².  
BMI is categorized in four groups: underweight (BMI<18.5), normal (BMI < 30), obese 
(30 <= BMI < 35) and morbidly obese (BMI >= 35). The frequency distribution is given 
in Table 10. Eighty-one percent of the patients have a normal BMI, 12% is classified as 
obese, 70 patients (3.4%) as underweight and 74 patients (3.6%) as morbidly obese. 
Table 10: Frequency and percentage of the categorized BMI levels for the 
patients in the PROCARE database for whom BMI is known (63%). 
Categorized BMI Frequency Percent 
Underweight 70 3.36 
Normal 1691 81.14 
Obese 249 11.95 
Morbid_obese 74 3.55 
Available 2084 100 
Missing 1244 37.38 
Overall total 3328  
Missingness of BMI occurs in all centers, and does not seem to be very much center-
specific (details not shown to protect center confidentiality). 
Appendix 6 (Section 1.1, Table 6 and Figure 4) provides a more detailed view of the 
distribution of BMI and frequency distribution of categorized BMI per (size-grouped) 
center. 
3.3.2.5 ASA co-morbidity score 
The ASA co-morbidity score can range from 1 to 5 with a higher value corresponding 
to worse general health, Table 11, 51. 
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Table 11: ASA classification  
 
Source: Reference [50] 
The ASA score is known for 2637 (79%) of the 3328 patients in the PROCARE 
database. From Table 12 we learn that 28% of the patients have no co-morbidity, half of 
the patients experience moderate to severe systemic disease, 20% suffers from severe 
systemic disease that limits activity but is not incapacitating. Over 1% of the patients 
suffer from an incapacitating disease that is a constant threat to life and just 4 patients 
entered in a moribund state and did not expect to survive 24 hours, regardless of 
treatment. 
Given the few patients with score 4 and 5, we have merged scores 3, 4 and 5 into one 
score. Missingness tends to be center-specific: over 80% of all missing ASA scores occur 
in 26 of the 80 centers, all with at least 10 patients registered in PROCARE (details not 
shown to protect center confidentiality).  
More detail on the distribution of the ASA score over the size-grouped centers is 
provided in Appendix 6 (Section 1.1, Table 7). 
Table 12: Frequency, percentage and cumulative distribution of the ASA co-
morbidity score among patients for whom the ASA score is known.  
ASA score Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
1 742 28.14 742 28.14 
2 1325 50.25 2067 78.38 
3 534 20.25 2601 98.63 
4 32 1.21 2633 99.85 
5 4 0.15 2637 100.00 
Available 2637 100   
Missing 691 20.76   
Overall total 3328    
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3.3.2.6 Tumor complications 
Preoperative tumor complications 
Among the 2948 patients in the PROCARE database for whom information on tumor 
complications is available, 38 patients had tumor complications detected during pre-
treatment coloscopy. No further detail about the type of complications is available in 
the database. The distribution of tumor complications over the size-grouped centers is 
provided in Appendix 6 (Section 1.1, Table 8). 
Because of the very small proportion of reported tumor complications this prognostic 
factor is unlikely to be useful for risk-adjusting the outcome QCIs. 
Operative tumor complications 
In the operative part of the surgical PROCARE form, surgeons can report tumor 
complications before any mobilization. These complications are reported in four 
categories for 207 patients. There is no further indication on the status for the other 
patients (no complications or not reported), see Table 13. 
Table 13: Distribution of the types of reported tumor complications during 
surgery among patients registered in the PROCARE database. 
Operative tumor complications Frequency Percent 
Free perforation 7 3.38 
Peri-rectal abscess 31 14.98 
Stenosis or obstruction 103 49.76 
Other 66 31.88 
Available 2948 100 
Missing 380 11.42 
Overall total 3328  
Because this is not a preoperative characteristic of the patients and it does not allow 
distinguishing between patients without a tumor complication and patients for whom 
the information on tumor complications is missing, it will not be used for risk-adjusting 
outcome QCIs. 
3.3.2.7 CEA performed 
The CEA serum before treatment is reported in the pre-treatment part of the surgical 
PROCARE form. Based on the reported value an indicator variable for CEA performed 
(yes or no) was constructed. For 2706 (81%) of the 3328 patients a CEA-level was 
reported. For the other 622 patients it is not sure whether CEA was either not 
performed or not reported.  
The frequency distribution of CEA reported per size-grouped center is given in 
Appendix 6 (Section 1.1, Table 9). Because we are not able to distinguish between 
patients without CEA performed and patients for whom it is not known whether CEA 
was performed, this variable is not deemed reliable as prognostic factor. 
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3.3.2.8 Mode of surgery 
The mode of surgery is known for 2872 (86.3%) of the patients in the PROCARE 
database and is either elective, scheduled, urgent or an emergency. Because the 
difference between elective and scheduled surgery and urgent and emergency surgery is 
not always very clear we merged these categories two-by-two. The frequency 
distribution of the resulting groups is presented in Table 14. 
Table 14: Frequency and percentage of the mode of surgery for the 86.3% 
patients with a known mode of surgery in the PROCARE database.  
Mode of surgery Frequency Percent 
Elective-Scheduled 2820 98.19 
Urgent-Emergency 52 1.81 
Available 2872 100 
Missing 456 13.70 
Overall total 3328  
There appear to have been 52 urgent or emergency operations. Missingness of the 
mode of surgery occurs mainly in a selection of the centers: 75% of the missings occur 
in 16 of the 80 centers, all with at least 10 patients in the PROCARE database (details 
not shown to protect center confidentiality). 
The distribution over the size-grouped centers is given in Table 10 in Appendix 6 
(section 1.1). 
3.3.2.9 Ventral tumor 
Of the 2494 (75%) patients for whom the location of tumor is known in the database, 
779 (31%) has a ventral tumor. The frequency distribution is shown in Table 15. 
Table 15: Frequency and percentage of the distribution of ventral tumors for 
the 75% patients with a known tumor location in the PROCARE database. 
Ventral tumor Frequency Percent 
No 1715 68.77 
Yes 779 31.23 
Available 2494 100 
Missing 834 25.06 
Overall total 3328  
Missingness of tumor location does not appear to be strongly related to specific centers 
much (details not shown to protect center confidentiality). 
The distribution of the percentage of ventral tumors over the size-grouped centers is 
given in Table 11 in Appendix 6 (Section 1.1). 
3.3.2.10 Circumferential margin 
The clinical circumferential margin (cCRM) is available for 612 (18%) of the 3328 
patients in the PROCARE database. When defining cCRM positivity as having a 
circumferential margin < 5mm, 448 (73%) of the patients with known cCRM have a 
positive cCRM, Table 16. 
Table 16: Frequency and percentage of the distribution of cCRM positivity 
for the 18% patients with a cCRM in the PROCARE database. 
cCRM positive Frequency Percent 
No 164 26.80 
Yes 448 73.20 
Available 612 100 
Missing 2716 81.62 
Overall total 3328  
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The pathological circumferential margin, (y)pCRM, is available in the PROCARE 
database for 2144 (64%) of the 3328 patients. When defining (y)pCRM positivity as 
having a circumferential margin < 1mm, 387 (18%) of the patients with known (y)pCRM 
have a positive (y)pCRM, Table 17. 
Table 17: Frequency and percentage of the distribution of (y)pCRM positivity 
for the 64% patients with a (y)pCRM in the PROCARE database. 
(y)pCRM positive Frequency Percent 
No 1757 81.95 
Yes 387 18.05 
Available 2144 100 
Missing 1184 35.58 
Overall total 3328  
Missingness of cCRM and (y)pCRM occurs in almost all centers and is as such not 
center-specific (details not shown to protect center confidentiality). 
The distribution over the size-grouped centers is given in Table 12 and Table 13 in 
Appendix 6 (Section 1.1). 
3.3.3 Associations between prognostic factors 
To examine associations between some of the above-described prognostic factors, we 
provide cross-tabulation of key prognostic factors in the PROCARE database. 
Table 18 shows the distribution of the kind of neoadjuvant treatment given versus 
cStage. Remarkably, for 1442 (43%) of the 3328 patients in the PROCARE database it 
was not reported whether or which treatment they received. This is problematic since 
we cannot distinguish between patients who did not receive treatment and patients for 
whom the kind of treatment they received was missing. A recommendation for 
improving the quality of the PROCARE database is to link it to the administrative 
database to correct these kinds of gaps. 
Other rather unexpected observations relate to the substantial number of cStage 0-I-II 
patients receiving long-course neoadjuvant treatment. Further investigation of these 
patients reveals that 63% of the cStage 0-I-II patients receiving long-course neoadjuvant 
radiochemotherapy have tumor located in the lower third of the rectum. This is 
substantially more than the overall percentage of patients with a tumor in the lower 
third of the rectum (Table 9). 
Table 19 shows the frequency table of the mode of surgery versus cStage. Here we 
observe that for 86 (21%) of the 419 cStage IV patients, the mode of surgery is missing. 
This is proportionally higher than for lower-staged patients and might be an indication 
that these patients in fact did not undergo any surgery. It would be interesting if the 
database would allow distinguishing between missing mode of surgery and no surgery 
performed, which is currently not possible.  
Table 20 cross-tabulates cStage and tumor level among patients with a recorded tumor 
level. A significant association is found between cStage and tumor level (p-value < 
0.0001) with lower cStages 0/I/II overrepresented among high tumors (10 – 15 cm from 
the anal verge) and cStage III underrepresented among high tumors. 
Table 21 cross-tabulates ASA score versus BMI level among patients with recorded ASA 
score and BMI level. There is no significant association between ASA score and BMI 
level (p-value = 0.11). 
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Table 18: Cross-tabulation of neoadjuvant treatment versus cStage. 
cStage 
Neoadjuvant treatment 
Total 
Long 
course 
RT + 
chemo 
Long course 
RT + 
no/unknown 
chemo 
Short 
course 
RT + 
chemo 
Short course 
RT + 
no/unknown 
chemo 
Missing 
RT 
course + 
chemo 
Missing RT 
course + 
no/unknown 
chemo 
Other 
RT 
course + 
chemo 
Other RT 
course + 
no/unknown 
chemo 
No/unknown 
RT + chemo 
No/unknown 
treatment 
0/I 40 2 0 21 2 4 0 0 0 333 392 
II 180 23 4 68 23 6 0 1 0 187 492 
III 954 68 6 87 81 10 0 0 1 313 1520 
IV 114 10 2 28 14 3 1 0 9 238 419 
X/miss 70 14 0 12 22 5 0 0 1 371 103 
Total 1358 117 12 216 142 28 1 1 11 1442 3328 
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Table 19: Cross-tabulation of mode of surgery versus cStage among all 
patients in the PROCARE database 
cStage 
Mode of surgery 
Total 
Elective / Scheduled Urgent / Emergency Missing 
0/I 356 3 43 402 
II 455 11 26 492 
III 1436 9 75 1520 
IV 317 16 86 419 
X/miss 256 13 226 495 
Total 2820 52 456 3328 
Table 20: Cross-tabulation of cStage versus tumor level among patients in 
the PROCARE database with valid tumor level information. 
Tumor level 
cStage 
Total 
0/I II III IV X/miss 
Low 154 211 682 152 93 1292 
Mid 148 165 613 161 111 1198 
High 86 100 181 70 82 519 
Total 388 476 1476 383 286 3328 
Table 21: Cross-tabulation of ASA score versus BMI among patients with 
valid information for both BMI and ASA score in the PROCARE database. 
BMI 
ASA score 
Total 
I II III 
Underweight 17 35 14 66 
Normal 447 823 333 1603 
Obese 66 129 45 240 
Morbidly obese 10 45 17 72 
Total 540 1032 409 1981 
Table 22 cross-tabulates ASA score versus age categories among patients with recorded 
ASA score and age. A significant association is found between ASA score and age (p-
value < 0.0001), with more frequent ASA score II or III in the older age categories. 
Table 22: Cross-tabulation of ASA score versus age categories among the 
patients with valid information for both age and ASA score in the PROCARE 
database. 
Age category 
ASA score 
Total 
I II III 
[20-40[ 27 20 2 49 
[40-50[ 100 69 4 173 
[50-60[ 199 233 36 468 
[60-70[ 233 416 115 764 
[70-80[ 150 431 230 811 
[80-[ 31 156 183 370 
Total 740 1325 570 2635 
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3.3.4 Joint missingness patterns of prognostic factors 
The joint missingness of the prognostic factors is examined in Table 14 in Appendix 6 
(section 1.1). This table can be read in different directions: 
• Row-wise, e.g. 
o From the first row we learn that only 1632 (49%) of the 3328 patients in 
the PROCARE database has non-missing information for the basic 
prognostic factors (age, gender, BMI, ASA co-morbidity score, cStage, 
(y)pStage and tumor level), 
o the third row tells us that 126 patients (first column) had a missing value 
for just one prognostic factor (1 in last column): cStage (and 0 in column 
‘cStage’), 
o the second last row shows 170 patients (first column) with a missing value 
for 6 prognostic factors (6 in last column): age, (y)pStage, tumor level, 
cStage, ASA score and BMI, 
o the last row informs us about the total number of missing values per 
prognostic factor. 
• Column-wise, e.g. from the ‘age’-column we learn that there is one patient 
with just missing age and BMI, there are 2 patients with missing age, ASA 
score and BMI and that there is one patient with missing age, tumor level and 
BMI, but otherwise all values available. For all other patients with missing age, 
there are at least 3 other prognostic factors that are also missing. 
3.3.5 Follow-up information 
The quality of the general quality indicators (overall survival, disease-specific survival, 
local recurrence and disease-free survival) heavily relies on 1) the quality of the link with 
the Crossroads Bank of Social Security (CBSS) for the dead/alive status of all patients in 
the PROCARE database and 2) the follow-up information as (should be) provided by 
the clinical teams on a 6 monthly basis. 
First note that for 198 of the 3328 patients in the PROCARE database no incidence 
date is available and no other information can be used to approximate the incidence of 
rectal cancer in these patients. As all survival QCIs start counting time from the 
incidence date, these 198 are automatically excluded from the analysis. 
The dead/alive status is known for 3315 (99.6%) of the 3328 patients in the PROCARE 
database. The other 13 patients were not found in the CBSS and hence no information 
on their dead/alive status is available. For the patients who are known to have died, the 
corresponding date of death is available.  
Follow-up information in the PROCARE database, on the other hand, is far from 
complete for most patients. Overall, there are 1878 (56%) patients in the PROCARE 
database who have at least one follow-up form recorded besides the incidence date. 
Table 23 provides more detailed information on the frequency distribution of recorded 
follow-up forms. Only these patients can be considered for survival QCIs related to 
recurrence of the disease (local recurrence or distant metastasis). We lack an indicator 
of whether the last available follow-up corresponds to the last follow-up as expected 
based on the incidence date. 
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Table 23: Number of patients in the PROCARE database for whom follow-up 
information is available (per follow-up period) and the distribution of timing 
of the last available follow-up. 
Follow-up  
(months) 
# patients 
# patients  
with last FU 
Cum. # patients  
with last FU 
6 953 388 388 
12 777 319 707 
18 522 216 923 
24 422 218 1141 
30 287 165 1306 
36 231 158 1464 
42 148 125 1589 
48 69 69 1658 
54 0 0 1658 
60 0 0 1658 
Missing 220 220 1878 
For 220 of these 1878 patients with some available follow-up information, it is not 
known to which follow-up time (6 or 12 or 18 or … months after incidence date) this 
information pertains. Among these patients are 137 patients with a reported local 
recurrence or distant metastasis and 83 patients without a recurrence. For 131 of the 
137 patients with a reported local recurrence or distant metastasis, the length of their 
follow-up can in principle be computed from the reported date of local recurrence or 
distant metastasis, while for the other 6 no such date is available. For the 83 patients 
without a reported recurrence, the length of follow-up cannot be obtained from 
available information.  
Hence, another 89 patients lack the follow-up information for recurrence-related 
survival QCIs. Additionally discarding 8 patients with missing dead/alive status, we arrive 
at 1781 (54%) patients in the PROCARE database who can be used for recurrence-
related survival QCIs. Note that the missing subset is likely selective in terms of local 
recurrence.  
For 34 of the 1878 patients with available follow-up information and with a reported 
local recurrence and/or distant metastasis, the date of this event is not available in the 
database, but can be recomputed based on the last follow-up (6, 12, 18, … months) as: 
incidence date + (last follow-up)*30.4. 
If we compare this recomputed date of recurrence with the reported date of 
recurrence (for patients for whom this date is reported), we notice that it is not a very 
accurate surrogate, with differences ranging between 720 days (2 years) in one direction 
and 827.8 days (2¼ years), see also Figure 9. 
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Figure 9: Distribution of the difference in recomputed event date and 
reported event date in the PROCARE database based on the formula above.  
 
3.4 DESCRIPTION AND ANALYSIS OF INDIVIDUAL QUALITY 
OF CARE INDICATORS  
Appendix 6 (Section 2) shows the full results for the list of about 40 QCIs as presented 
in the PROCARE consensus of July 24th, 2010. By way of example, we run here through 
the analysis of arguably the most important outcome measure: `overall survival’.  
3.4.1 The worked out case of Overall Survival QCI 1111 
In principle, QCI definitions as provided in the PROCARE documents are clear, but for 
good practice these QCIs need to be translated into technically correct working 
definitions containing the observed time and endpoint, which may be either the event of 
interest, a competing event or censoring. 
Censoring happens for patients for whom no event of interest was observed before 
closure of the database. The current PROCARE database was closed at the end of 
October 2010 and was linked with the death records of the version of the Cross Banks 
Social Security database of August 2010. All deaths up to July 31st, 2010 are registered in 
the database we have at our disposal. Therefore, July 31st, 2010 will be used as the 
administrative censoring date for the current PROCARE database. 
PROCARE definition 
N: Number of patients in denominator that survived 1-5 years. 
D: Number of patients for whom the national registry number is known and have a 
follow-up of 1-5 years, respectively. Survival status was obtained through cross-link with 
the Crossroads Bank for Social Security (CBSS). 
Working definition 
Kaplan-Meier based probability of surviving at least 5 years after rectal cancer diagnosis. 
This involves follow-up time since incidence date (in years) and as endpoint the event 
(death) or censoring.  
D: Number of patients for whom the national registry number is known and the 
incidence date is known to be before the administrative censoring date (July 31, 2010). 
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3.4.1.1 Description 
All together, 3103 (94%) of the 3318 patients meet the requirements for the 
denominator of this QCI. Of the 215 patients who are not eligible, 13 have an unknown 
social security number, 198 had a missing incidence date and 4 had an incidence date 
after July 31st, 2010. 
Of the 3103 selected patients, 697 (22%) patients have died since their incidence date 
over a median follow-up time of 2.5 years. More detail per size-grouped center on the 
follow-up time, person years and event rate can be found in Section 1.2 (Table 15) of 
Appendix 6. After merging centers with less than 5 eligible patients into one overlapping 
center, 69 centers remain to evaluate performance with regard to overall survival. The 
estimated survival curve for the study population is given as the green line among the 
cStage-stratified Kaplan-Meier curves presented in Figure 10, corresponding (y)pStage-
stratified Kaplan-Meier curves can be found in Appendix 6 (Figure 5). Table 24 presents 
the number of patients, number of events and censored patients and the percentage of 
censored patients per cStage level. 
From Table 15 in Appendix 6 (section 1.2) and Figure 10 we learn that the maximum 
follow-up time is less than 5 years for all cStage levels. This will be resolved in time 
when the PROCARE database matures. Given the currently available data, in this report 
we calculate 3-year survival probabilities instead of 5-year survival probabilities for all 
survival-related QCIs. When x-year survival is calculated based on modeled survival 
data, one may introduce administrative censoring at x-years to avoid unnecessary 
reliance on modeling assumptions beyond that time. 
Figure 10: Kaplan-Meier curves per cStage stratum, estimating the 
(unadjusted) probability of surviving t years after the incidence of rectal 
cancer. The unstratified curve is shown in green. Numbers at risk for that 
curve are shown on the x-axis. 
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Table 24: The number of patients, events and censored patients, per level of 
cStage. 
cStage # patients # Events # Censored % Censored 
I 383 45 338 88.25 
II 488 104 384 78.69 
III 1505 247 1258 83.59 
IV 412 217 195 47.33 
X/Missing 315 84 231 73.33 
Total 3103 697 2406 77.54 
Unexpectedly, estimates in Figure 10 (and percentage censored in Table 24) show 
cStage II patients having lower survival probabilities than cStage III patients. This 
observation is borderline significant (hazard ratio [ ref. = III ] = 1.23 [0.98, 1.55], p-value 
= 0.08). Possible explanations could be a consistent clinical over-staging of actual stage II 
patients (see also Table 7) or that cStage III gets the better treatment. 
As there is no significant difference in overall survival between patients with missing 
cStage and cStage X (hazard ratio [ref. = Missing] = 0.77 [0.47, 1.28], p-value = 0.31), 
we collapse these two categories into one overlapping category. To examine possible 
non-randomness of the collapsed X/missing category, the expected survival probability 
for a random patient with available cStage information in the PROCARE database is 
computed at each event time (as a weighted average of survival probabilities for cStage 
I, II, III and IV patients), and shown in Figure 11. 
Figure 11: cStage-stratified Kaplan-Meier survival curves with an extra 
survival curve (red dotted line) showing the probability of surviving t years 
for a random patient (with available cStage information) in the PROCARE 
database. The green line presents the survival probability after t years for 
patients with X/missing cStage. 
 
Figure 11 shows how the survival probabilities of patients with cStage X/missing are 
very similar to the weighted average of survival probabilities for cStage I, II, III, IV 
patients, the data is hence consistent with missingness at random at this level. This 
would leave a set of patients with available cStage information that is representative of 
the total PROCARE population. Whether this is actually the case, we do not know. 
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3.4.1.2 Identification of relevant prognostic factors 
Prognostic factors identified in the literature review of Appendix 2 
Appendix 2 contains an extensive list of prognostic factors that were found to be 
significantly associated with overall survival. Given our goals and methods as explained 
in section 2.1, we only consider pre-treatment prognostic factors of which BMI, co-
morbidity status, age, tumor location and TNM-stage are available in the PROCARE 
database. 
Prognostic factors identified in the PROCARE consensus on 
risk/confounding factors per QCI  
Results from the PROCARE consensus survey in Appendix 3 suggest the following 
factors are to be used for adjustment: age > 70 years, gender, extraperitoneal location 
(i.e. tumor level), (y)pN+, no tumor response to long course radio(chemo)therapy. 
Of these, the former 3 will be considered when building the risk-adjustment model for 
this QCI. The latter 2 are post-treatment factors, which can already be influenced by 
the quality of care provided by a certain center, and would hence ‘cover’ part of the 
center effect. Note that the (clinical) nodal status is partly considered through 
stratification by cStage. We will hence not adjust for it. 
Empirical associations 
Significant univariate associations between available prognostic factors and cStage-
stratified overall survival are presented in Table 25. 
Table 25: Hazard ratio [95% Wald confidence interval] estimate and 
corresponding p-value from univariate cStage-stratified Cox regression 
models for QCI 1111 [OS]. For categorical variables, ‘ref.’ indicates the 
reference level. 
Prognostic factor Level 
Hazard ratio  
[95% CI] 
p-value 
Joint  
p-value 
Age (years) (continuous) 1.05 [1.04, 1.06] < 0.0001  
BMI (kg/m²) (continuous) 0.99 [0.97, 1.01] 0.33 
< 0.0001 Missing BMI  
[ ref. = Not missing ] 
Missing 1.28 [0.73, 2.26] 0.39 
Gender 
[ ref. = Male ] 
Female 0.86 [0.74, 1.01] 0.06 
 
ASA score 
[ ref. = I ] 
II 1.19 [0.94, 1.50] 
< 0.0001 
 
III-V 3.39 [2.68, 4.29] 
Missing 2.67 [2.10, 3.41] 
Level 
[ ref. = Low ] 
Mid 1.07 [0.91, 1.27] 
0.01 
 
High 1.01 [0.81, 1.26] 
Missing 1.71 [1.25, 2.33] 
Mode of surgery  
[ ref. = Elective/Sch. ] 
Urgent / Emergency 3.38 [2.33, 4.89] 
< 0.0001 
 
Missing 2.41 [1.95, 2.98] 
Ventral tumor  
[ ref. = No ] 
Yes 0.78 [0.64, 0.95] 
< 0.0001 
 
Missing 1.54 [1.29, 1.83] 
cCRM positive 
[ ref. = No ] 
Yes 0.96 [0.59, 1.54] 
0.02 
 
Missing 1.36 [0.90, 2.07] 
cT4 
[ ref. = No ] 
Yes 1.52 [1.23, 1.87] 
0.0003 
 
Missing 1.24 [0.91, 1.68] 
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Preoper. incontinence  
[ ref. = No ] 
Yes 1.43 [1.17, 1.75] 
0.0006 
 
Missing 1.42 [0.99, 2;03] 
Surgical technique  
[ ref. = PME ] 
TME 0.83 [0.68, 1.00] 
< 0.0001 
 
Missing 1.94 [1.52, 2.49] 
interpretation of the hazard ratios obtained from univariate Cox regression models, 
illustrated using the results of Table 25. 
Interpretation of the hazard ratio for continuous covariates: 
• For each BMI increase of 1 unit (kg/m2) in the group of patients with a valid BMI, 
the hazard (of dying) is estimated to ‘decrease’ with a factor 0.99; the 95% 
confidence interval [0.97, 1.01] accounts for finite-sample imprecision. This effect 
should be considered together with the missingness indicator for BMI: for the 
group of patients with missing BMI the hazard is estimated to be 1.28 times higher 
than for the patient group with a valid BMI. 
• A similar interpretation holds for age; per age increase of 1 year in the group of 
patients with a valid age, the hazard (of dying) is estimated to increase with a factor 
1.05 (95% CI [1.04, 1.06]). Note that all patients with missing age are automatically 
excluded from the denominator since they also have a missing incidence date. 
Interpretation of the hazard ratios for a categorical covariate: 
• E.g. for the ASA score: for the group of patients with ASA score III, IV or V the 
hazard (of dying) is estimated to be 3.39 times higher than for patients with ASA 
score I (95% CI [2.68, 4.29]). 
3.4.1.3 Estimation of unadjusted and case-mix-adjusted center effects 
The unadjusted center effects are estimated from a (Firth-corrected) fixed effects Cox 
regression model and expressed as ‘excess’ probabilities of surviving 3 years after the 
incidence of rectal cancer. This ‘excess’ probability (relative to the average center) can 
be seen as the center-specific deviation in probability of surviving 3 years after the 
incidence of rectal cancer associated with the population specific to the center under 
evaluation. 
Unadjusted center effects range between -25% and 19% ‘excess’ probability of surviving 
3 years after the incidence of rectal cancer. The P25 and P75 are located at -9% 
respectively 5%, hence the interquartile range is 14%. 
A model building procedure was performed to identify joint associations between 
prognostic factors and overall survival, stratified by cStage. In this, the prognostic factors 
BMI, ASA co-morbidity score and level of the tumor (high, mid or low) were 
considered, while the adjustment for age and gender was always made. 
A model with main effects for age (with a different slope before and after the 
breakpoint of 70 years), gender, ASA score and BMI was retained. A significant 
interaction between gender and BMI was found (p-value = 0.002), indicating that survival 
rates differ for different levels of BMI depending on the gender. In other words, in the 
PROCARE database BMI was missing for a subset of patients with increased hazard, to a 
different degree for men and women. 
The hazard ratios (with corresponding 95% confidence interval and p-value) for the 
prognostic factors in the multivariate risk-adjustment model are presented in Table 26. 
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Table 26: Hazard ratio [95% Wald confidence interval] estimate and 
corresponding p-value from the final multivariate cStage-stratified Cox 
regression model for QCI 1111 [OS]. For categorical variables, ‘ref.’ 
indicates the reference level. 
Prognostic factor Level 
Hazard ratio  
[95% CI] 
p-value 
Joint  
p-value 
Age (continuous) 1.00 [0.99, 1.02] 0.69 
< 0.0001 
Age (+ 70 years) (continuous) 1.08 [1.06, 1.11] < 0.0001 
BMI (for males) (continuous) 0.96 [0.93, 0.99] 0.007 
0.01 Missing BMI  
[ ref. = Not missing ] 
Missing 0.41 [0.18, 0.91] 0.03 
Gender 
[ ref. = Male ] 
Female 0.12 [0.04, 0.39] 0.0004 
 
Gender – BMI interaction 
[ ref. = Male, (cont.) ] 
Female, (continuous) 1.07 [1.02, 1.12] 0.001 
0.002 Gender - Missing BMI 
interaction 
[ ref. = Male, Not missing ] 
Female, Missing 
7.44 [2.23, 
24.80] 
0.03 
ASA score 
[ ref. = I ] 
II 1.07 [0.82, 1.39] 
< 0.0001 
 
III-V 2.74 [2.06, 3.64] 
Missing 1.98 [1.46, 2.69] 
Interpretation of the hazard ratios obtained from multivariate Cox 
regression models, illustrated using the results of Table 26 
Interpretation of the hazard ratio for continuous covariates: 
• Per age increase of 1 year in the group of patients younger than 70 years with 
otherwise the same characteristics in terms of BMI, gender and ASA score, the hazard (of 
dying) is estimated to ‘increase’ with a factor 1.00 (95% CI [0.99, 1.02]).  
Per age increase of 1 year in patients older than 70 years with otherwise the same 
characteristics in terms of BMI, gender and ASA score, the hazard (of dying) is 
estimated to additionally increase with a factor 1.08 (given 95% increase CI [1.06, 
1.11]). 
• For a BMI, there is a separate effect for male and female patients. 
o For males, per increase of 1 unit (kg/m2) in patients with a valid BMI and 
otherwise the same characteristics with regard to age and ASA score, the 
hazard (of dying) is estimated to decrease with a factor 0.96; the 95% 
confidence interval [0.93, 0.99] accounts for finite-sample imprecision.  
o For females, per increase of 1 unit (kg/m2) in patients with a valid BMI and 
otherwise the same characteristics in terms of age and ASA score, the hazard 
(of dying) is estimated to increase with a factor 1.07; the 95% confidence 
interval [1.02, 1.12] accounts for finite-sample imprecision. 
Note that these effects should be considered together with the missingness 
indicator for BMI. Also, the goal here is prediction correction and not causal effect 
estimation for baseline characteristics. 
Interpretation of the hazard ratios for a categorical covariate: 
• E.g. for the ASA score: for the group of patients with ASA score III, IV or V, the 
hazard (of dying) is estimated to be 2.74 times higher than for patients with ASA 
score I with otherwise the same available or availability characteristics in terms of age, 
BMI and gender (95% CI [2.06, 3.64]). 
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From Table 26 it appears that the association between missing BMI and overall survival 
is very pronounced in the multivariate risk-adjustment model. There is no immediate 
explanation for this observation, but it cannot be ignored. The fact that this selectivity is 
different for male and female patients makes it extra complex. From Table 27 we 
estimate that for women with missing BMI in most cStage levels, the event rate is twice 
that in women with valid BMI, while for men this ratio of event rates is much smaller. 
Table 28 shows how the stage distribution among patients with missing BMI is different 
for men and women. For male patients with missing BMI, cStage IV patients are 
overrepresented, while for female patients with missing BMI cStage I patients are 
overrepresented. 
These two observations shed extra light on the selective missingness, but do not 
completely explain this difference between men and women. 
Table 27: Number of patients, person years, number of events and event 
rate for each cStage-Gender-BMI missingness combination among patients 
eligible for QCI 1111 [OS] with a non-missing/X cStage. 
cStage-Gender-
Missing BMI 
Total N 
(missing) 
N (%) 
eligible 
Person 
years 
N (%) 
events 
Event 
rate 
Ratio 
I-Female-Missing 79 (   3) 76 (96%) 191.28 10 (13%) 0.05228 
2.7 
I-Female-Not Missing 90 (   0) 90 (100%) 259.67 5 (6%) 0.01926 
I-Male-Missing 80 (   4) 76 (95%) 183.50 13 (17%) 0.07084 
1.4 
I-Male-Not Missing 143 (   1) 141 (99%) 347.96 17 (12%) 0.04886 
II-Female-Missing 68 (   2) 65 (96%) 159.17 18 (28%) 0.11309 
1.9 
II-Female-Not Missing 130 (   0) 130 (100%) 376.92 22 (17%) 0.05837 
II-Male-Missing 89 (   0) 89 (100%) 231.99 28 (31%) 0.12070 
1.9 
II-Male-Not Missing 205 (   1) 204 (100%) 562.29 36 (18%) 0.06402 
III-Female-Missing 160 (   5) 155 (97%) 357.33 40 (26%) 0.11194 
2.4 
III-Female-Not Missing 399 (   3) 396 (99%) 1064.55 50 (13%) 0.04697 
III-Male-Missing 255 (   3) 252 (99%) 662.70 48 (19%) 0.07243 
1.2 
III-Male-Not Missing 706 (   3) 702 (99%) 1832.79 109 (16%) 0.05947 
IV-Female-Missing 63 (   3) 60 (95%) 100.57 38 (63%) 0.37786 
2.5 
IV-Female-Not Missing 92 (   0) 92 (100%) 203.81 31 (34%) 0.15210 
IV-Male-Missing 113 (   3) 110 (97%) 195.40 69 (63%) 0.35313 
1.4 
IV-Male-Not Missing 151 (   1) 150 (99%) 315.70 79 (53%) 0.25024 
Table 28: Row percentages of the cross-tabulation of cStage versus BMI 
missingness for patients with non-missing/X cStage in the PROCARE 
database, separately for male and female patients. 
Row Percent 
Male Female 
I II III IV Total I II III IV Total 
BMI Not Missing 11.87 17.01 58.59 12.53 69.17 12.66 18.28 56.12 12.94 65.7 
BMI Missing 14.90 16.57 47.49 21.04 30.83 21.35 18.38 43.24 17.03 34.23 
Total 12.80 16.88 55.17 15.15 100.00 15.63 18.32 51.71 14.34 100.00 
Adjusted center effects are estimated from both a fixed effects outcome regression (i.e. 
a Firth-corrected Cox regression model) and a hierarchical outcome regression (i.e. 
frailty Cox regression model). As described before, center effects are expressed as the 
‘excess’ probability of 3-year survival relative to the ‘average’ center. 
A basic summary of the distribution of center effects as estimated from the unadjusted 
analysis and the two adjusted analyses is presented in Table 29.  
Table 29: Minimum, P25, P75, maximum and interquartile range of the 
center effects (%) for QCI 1111 [OS] as estimated by different methods. 
Method Min P25 P75 Max IQR 
Unadjusted -25 -9 5 19 14 
Fixed-effects regression -30 -9 5 23 14 
Hierarchical regression -8 -3 3 11 6 
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Figure 12 shows the relation between adjusted and unadjusted center effects. From this 
we learn how the center effects obtained from the fixed-effects adjustment model (blue 
circles) stay generally close to the unadjusted center effects, and that the center effects 
obtained from the random effects adjustment model (red squares) are – compared to 
the unadjusted and fixed-effects adjusted center effects - shrunken towards zero (as 
anticipated in section 2.1). 
Figure 12: Scatter plot of adjusted center effects (from both fixed- and 
random effects outcome regression) versus unadjusted center effects for 
QCI 1111 [OS]. 
 
Center effects measured as adjusted excess probabilities range between 31% and 22%. 
Note that these excess chances are automatically constrained between -78% and 22% 
(since the average center has achieved this QCI in 78% of their patients). The P25 and 
P75 are located at -9.4% resp. 4.8%, hence the interquartile range is 14%. In the 
caterpillar plot, we observe no centers performing significantly below P25, i.e. with 
upper bounds of their confidence intervals below P25. We do observe 2 centers 
performing significantly above P75, i.e. the lower bound of their confidence interval is 
higher than P75. 
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Figure 13: Adjusted excess chance (%) of 3-year overall survival 
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3.4.2 Tabulated results for the QCIs 
In Table 30 and Table 31:   
Survey results are median scores over all responses 
PROCARE consensus results are: 1: highly relevant, 2, secondary order, 3: not relevant 
Visual discriminating ability is scored as: 1: good, 2. some, 3. None  
N is the number of eligible patients and %events refers to the percentage of eligible patients with a recorded event of  the given type in the database;  
• for DSS the first number refers to deaths with local recurrence and/or distant metastasis while the second refers to deaths without reported 
recurrence. 
•  for LRFS the first number refers to recorded local recurrences as first events and the  second to deaths without reported local recurrences.  
Both the DSS and LRFS measure suffer from the fact that follow-up information was quite incomplete. Absence of a reported recurrence might therefore 
either indicate absence of recurrence or simply missing data. Because of this lack of reliability, DSS and LRFS have not been analyzed in any depth here. For 
their summary in the table below. deaths recorded without any indication of follow-up have been discarded and are not listed as either cause-specific death 
for the DSS summary, Specialized competing risks methods allowing for missing cause of death could be applied in this case provided every death is registered 
and the missing cause is either missing at random or there is some information on how much more likely deaths with than deaths without recurrence are to 
generate missing follow-up records (and hence missing cause-specific information) 52. To be eligible for the LRFS variable required that at  least one follow-up 
record was filed.  
The final column gives the p-value for testing for between center variation in a mixed effects model with normal random effects. 
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Table 30: Criteria considered in constructing a QI for outcome of rectal cancer, split by data quality, clinical importance and 
discriminating ability. 
 Data quality Clinical importance Discriminating ability 
QCI Short name 
N 
patients 
% 
events 
N 
centers 
N 
only 
0/1 
N 
≥ 5 Survey 
% 
patients 
% 
≥ 5 Survey 
Predictive 
ability 
PROCARE 
consensus 
% 
only 
0/1 
IQR 
Random 
effect 
variance – 
p 
1111 OS 3103 22 79 5 67 5 88 84 5  1 7 14%  
1112 DSS 2807 7/7 79 1 66 4 85 83 5  1 1   
1113 LRFS 1186 2/8 63 7 49 4 36 61 5  1 14   
1113b DFS 1234 18 64 3 49 4 37 61 5  1 6 10%  
1227 %grade4_Tox_Preop_RT 544 11 51 9 30 2 16 38 4 0.295 1 29 12% 0.2492 
1231 %R0res 2914 87 78 11 67 5 88 84 5 0.0001 1 16 11% 0.0001 
1232b %stoma1year 123 27 37 3 9 4 4 11 3 0.003 2 30 32% 0.0987 
1233a %Leak_PME 556 6 59 27 42 4.5 17 53 4.5 0.0284 1 63 16% 0.0444 
1233b %Leak_TME 1592 6 74 16 54 4 48 68 4 0.0003 1 29 7%  
1234 30d_mort 2919 2 78 35 67 5 88 84 5 0.0001 1 51 4% 0.0019 
1234b %Major_morb 2913 6 78 18 67 4 88 84 3 0.0001 2 26 6% 0.0319 
1235 %Perfor 2900 8 78 14 67 4.5 87 84 4 0.0001 2 21 8% 0.0003 
1235b %Pos_Dist_margin 516 2 64 21 27 5 16 34 5 0.5033 1 75 6% 0.2716 
1235c %Pos_CRM 1932 19 73 6 60 5 58 75 5 0.0001 1 10 16% 0.0045 
1245 %grade4_Tox_Prostop_CT 128 8 37 6 10 2 4 13 4 0.8356 1 55 5%  
1263 %Late_Tox_RT 1890 0 74 58 61 2 57 76 3 0.9681 2 94 3%  
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Table 31: Criteria considered in constructing a QI for process QCIs related to quality of care of rectal cancer, split by data quality, clinical 
importance and discriminating ability. 
 Data quality Clinical importance Discriminating ability 
QCI Short name 
N 
patients 
% 
events 
N 
centers 
N 
only 
0/1 
N 
≥ 5 Survey 
% 
patients 
% 
≥ 5 Survey 
Predictive 
ability 
PROCARE 
consensus 
% 
only 
0/1 
IQR 
Random 
effect 
variance - 
p 
1211 %DocDist 3318 91 80 29 68 4 100 85 4 0.0001 1 42 12% 0.0001 
1212 %CT_Preop 322 79 41 13 22 4 10 28 3 0.7458 1.5 57 22% 0.0001 
1213 %CEA_Preop 3318 81 80 7 68 4 100 85 2.5 0.0499  10 18% 0.0001 
1214 %CEA_Preop_Bowel_lm 2811 98 77 48 67 4 85 84 3 0.4557 2 71 4% 0.0001 
1214b %TRUS_cT12 74 82 29 2 4 4 2 5 3.5 0.4604 2 40 24% 0.094 
1214c %MR_cII/III 103 91 25 4 9 4 3 11 4 0.0853 1 40 19% 0.0967 
1215 %Preop_lm 435 61 49 5 25 4 13 31 5 0.3780 1 19 50% 0.0001 
1216 %cCRM_rep 1950 26 74 21 62 3 59 78 4 0.0095 1 33 29% 0.0001 
1216b cM0_Acc 634 6 55 18 34 4 19 43 3.5 0.8077 2 51 5% 0.0009 
1217 Time_histo-1ther 2687  76  65 4 81 81 2.5 0.9467 2   0.0001 
1221 %Preop_RT 1830 74 74 4 60 5 55 75 5 0.0001 1 7 27% 0.0001 
1221b %(C)RT_cRM+ 286 81 37 1 14 4 9 18 5 0.0325 1 7 27% 0.0001 
1221c %Preop_RT_cl 344 17 56 12 27 4 10 34 2 0.3072 2 43 18% 0.0002 
1224 %Preop_cont_5FU 469 91 49 21 30 4 14 38 2 0.6439 2 68 7% 0.0001 
1225 %Completed_preop_RT 1196 97 70 34 51 3 36 64 3 0.7915 2 65 5% 0.0001 
1226 %Surg<12w_after_Preop_RT 1123 97 69 33 49 5 34 61 2.5 0.0683 2 66 5%  
1232a %Defin_ostomy 2945 24 78 2 67  89 84  0.0001 1 3 19% 0.0001 
1241 %Adj_Chemo<3m 28 86 14  1 4 1 1 4  1    
1242 %Adj_RT<3m 46 98 23  3 5 1 4 5  1    
1243 %Adj_Chemo<12w 58 93 23  4 4 2 5 3  2    
1244 %Adj_5FU 57 95 23  4 4 2 5 2.5  2    
1271 %Path_Rep_Use 1980 98 69 42 56 5 60 70 1.5 0.3454 3 74 4% 0.0001 
1272 %TME_Qual_Rep 1572 68 67 6 55 4 47 69 5 0.0053 1 11 38%  
1273 %Dist_Margin_Rep 2051 86 75 15 63 5 62 79 4.5 0.0012  23 17% 0.0001 
1273b %Dist_Margin_Pos_Rep 2034 91 74 20 63 5 61 79 4 0.0548 3 31 14% 0.0001 
1274 #Nodes_Examined 2714  77  64 5 82 80 5 0.0027 1   0.0001 
1275 pCRM_mm_Rep 2615 74 77 6 66 5 79 83 5 0.6578 1 9 23% 0.0001 
1276 TRG_Rep 1427 75 71 7 53 3 43 66 4 0.3149 1.5 13 39% 0.0001 
There is a big diversity in eligibility rate in the PROCARE database among both process and outcome QCI’s. For outcome QCI’s we found 5 QCI’s having eligibility rates 
below 30%, 5 between 30%-60% and 5 between 60% and 90% respectively. 1 QCI (QCI 1111) scored higher than 90%. For process QCI’s we found eligibility rate to be very 
low (<30%) in about half of the QCI’s (n=12), moderately low rates (between 30%-60%) were found in 7 QCI’s, fairly high rates (between 60% and 90%) in 7 QCI’s. 2 QCI’s 
(QCI 1211 and 1213) score very high eligibility rates (>90%).  
The achievement rate was uniformly high for all 16 outcome QCI’s (mean: 90% +/- sd-dev.:8%) and 25 process QCI’s (mean: 85% +/- sd-dev.:11%). As an exception there are 
3 process QCI’s with very low achievement rate, i.c. QCI’s 1216, 1216b and 1221c (with 26%, 6% and 17% achievement rate respectively). 
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Table 32: Center effect for general (outcome) quality indicators: inter quartile range, number of centers significantly below P25 or above 
P75 and multivariate prognostic factors retained at the 5% level. [NA: not applicable; Center effects for these QCI’s were not calculated] 
QCI Short name IQR # below P25 # above P75 Prognostic factors 
*1111 OS 14% 0 2 *Age, Age (+ 70 years), BMI, Missing BMI, Gender, 
Gender – BMI interaction, Gender - Missing BMI 
interaction, ASA score and cStage (the latter as 
stratification variable) 
1112 DSS NA NA NA Age, Age (+ 70 years), Gender, ASA score, BMI, 
Missing BMI and cStage (the latter as stratification 
variable) 
1113 LRFS NA NA NA Ventral tumor 
1113b DFS 10% NA NA Age, Age (+ 70 years), BMI, Missing BMI, Gender, 
Gender – BMI interaction, Gender - Missing BMI 
interaction, ASA score 
The clinical importance of all these indicators was rated very high (highest scores) but data quality was only deemed sufficient for QCI 1111 and QCI 1112.  
QCI 1112 is not included since it reflects a component of survival which is already part of QCI 1111 while - due to generally limited follow-up information on local recurrence 
and distant metastasis in the PROCARE database - its quality is judged to be weak with at present little hope for an improved signal in that QCI. The general quality indicators 
all have a high achievement rate (>78%). 
QCI 1112b was added later and not considered in this report. 
Table 33: Center effect for (process) quality indicators related to diagnosis and staging: inter quartile range, number of centers 
significantly below P25 or above P75 and univariate prognostic factors retained at the 5% level.  
QCI Short name IQR # below P25 # above P75 Prognostic factors 
1211 %DocDist 12% 7 0 Age, Missing Age, BMI, Missing BMI, ASA score, 
cStage, Mode of surgery, Ventral tumor, cCRM 
positive, cT4, Preoper. Incontinence, Surgical 
technique 
1212 %CT_Preop 22% 3 0 cT4, Preoper. Incontinence, Surgical technique 
1213 %CEA_Preop 18% 8 3 Age, Missing Age, BMI, Missing BMI, Tumor level, 
ASA score, cStage, Mode of surgery, Ventral tumor, 
cCRM positive, cT4n Preoper. Incontinence, 
Surgical technique 
1214 %CEA_Preop_Bowel_lm 4% 0 0 Age, Missing Age, BMI, Missing BMI, Tumor level, 
ASA score, cStage, Ventral tumor, cT4, Preoper. 
incontinence 
1214b %TRUS_cT12 25% 0 0 Missing BMI 
1214c %MR_cII/III 19% 0 0 cStage 
1215 %Preop_Im 50% 3 1 BMI, Missing BMI, Tumor level, ASA score, cStage, 
Mode of surgery, Ventral tumor, cCRM positive, 
cT4, Preoper. Incontinence, Surgical technique 
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QCI Short name IQR # below P25 # above P75 Prognostic factors 
1216 %cCRM_rep 29% 0 5 Age, Missing Age, BMI, Missing BMI, Gender, Tumor 
level, cStage, Ventral tumor, Preoper. Incontinence, 
Surgical technique 
1216b cM0_Acc 6% 0 1 Age, Missing BMI, ASA score, cStage, Ventral 
tumor, Surgical technique 
1217 Time_histo-1ther 14% 1 3 Age, BMI, Missing BMI, Tumor level, cStage, Surgical 
technique 
QCI 1215 was most discriminating between centers (IQR of 50%). Clinical importance was rated highest for this QCI (1215) on both the survey and the PROCARE consensus 
score. QCI1217 was considered the least important clinical parameter. Only 4 out of 10 QCI’s (1211, 1213, 1214 and 1217) reached sufficient data quality in terms of 
percentage of eligible patients (mean: 91%) and having at least 5 patients/center (mean: 84% of centers). The diagnosis and staging QCI’s have a fair achievement rate (>60%) 
except for 1216 and 1216b (<30%). 
Table 34: Center effect for (process) quality indicators related to neoadjuvant treatment: inter quartile range, number of centers 
significantly below P25 or above P75 and univariate prognostic factors retained at the 5% level. 
The QCI indicated by a * is an outcome QCI and has multivariate prognostic factors listed. 
QCI Short name IQR # below P25 # above P75 Prognostic factors 
1221 %Preop_RT 27% 5 1 Age, Missing Age, BMI, Missing BMI, Gender, Tumor 
level, ASA score, cStage, Mode of surgery, Ventral 
tumor, cCRM positive, Preoper. Incontinence, 
Surgical technique 
1221b %(C)RT_cCRM+ 27% 0 0 Age, Gender, ASA score, cStage, Preoper. 
Incontinence 
1221c %Preop_RT_cl 18 0 0 BMI, Missing BMI, Surgical technique 
1224 %Preop_cont_5FU 7 3 0 BMI, Missing BMI, ASA score, cStage 
1225 %Completed_preop_RT 5 1 0 Age, Tumor level, Mode of surgery, Ventral tumor, 
Preoper. Incontinence, Surgical technique 
1226 %Surg<12w_after_Preop_RT 5% 0 0 none 
*1227 %grade4_Tox_Preop_RT 12% 0 0 *Age, Gender 
Discriminating ability was highest for 1221/1221b (27%). QCI 1221 and 1221b were rated with highest clinical importance for this domain. 
Except for QCI 1221c (17%) and 1227 (11%) achievement rate was fairly high (on average: 88%). 
Data quality was quite low (on average 20% eligible patients and 42% of centers with at least 5 patients) except for QCI 1221 (with 55% eligible patients 75% of centers having 
at least 5 eligible patients) 
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Table 35: Center effect for (outcome) quality indicators related to surgery: inter quartile range, number of centers significantly below P25 
or above P75 and multivariate prognostic factors retained at the 5% level.  
QCI Short name IQR # below P25 # above P75 Prognostic factors 
1231 %R0res 11% 0 2 Age, Gender, cStage, Tumor level, cT4, Mode of surgery 
1232a %Defin_ostomy 19% 1 1 Age, Missing Age, BMI, Missing BMI, Tumor level, ASA 
score, cStage, Mode of surgery, Ventral tumor, cCRM 
positive, cT4, Preoper. Incontinence, Surgical technique 
1232b %stoma1year 32% 0 0 Age, Gender 
1233a %Leak_PME 7% - 0 Age, Gender, Tumor level, ASA score, cStage, Gender – 
ASA interaction 
1233b %Leak_TME 8% 1 0 Age, Gender, ASA score, Age – ASA interaction 
1234 30d_mort 4% 0 0 Age, Missing Age, Gender, ASA score, Mode of surgery, 
Age – Gender interaction, Missing Age – Gender 
interaction 
1234b %Major_morb 5% 2 0 Age, Gender, Level, ASA score, Age – ASA score 
interaction, Gender – ASA score interaction 
1235 %Perfor 8% 0 0 Age, Missing Age, Gender, Level, ASA score, cStage 
1235b %Pos_Dist_margin 6% 0 0 Age, Gender, ASA 
1235c %Pos_CRM 16%   Age, Missing Age, Gender, cT4 
Discriminating ability for these QCI’s was considered very low in the surgery domain except for QCI 1232a. The mean IQR is a low 13%, reflecting a fair degree of 
homogeneity in surgical practice. 
Half of the QCI’s (1231, 1232a, 1234, 1234b, 1235) have very good data quality parameters (>84% eligible patients with at least 5 eligible patients/center ) 
At this stage it should be noted that some ambiguity surrounded QCI 1232a. First, not everybody had realized that the current definition implies brackets around the two final 
statements, so it should read: `Proportion of APR- Hartmann’s procedure or (total excision of colon and rectum with definitive ileostomy)’.  As a result the definition can refer 
to colostomy rather than ileostomy in some cases and the achievement rate is no longer unusual.  Second, whether or not the colostomy/ileostomy is a sign of good quality 
treatment according to guidelines, depends on the underlying condition of the patient. In some conditions (e.g. sphincter invasive tumor) this is the outcome per guideline and 
hence this would become a process indicator. In other instances, this is not the result of targeted therapeutic efforts, but rather an unfortunate outcome of the disease 
process. We recommend that two different versions would be defined of this QCI, conditional on the tumor level. Conditional on a sphincter invasive tumor this would then 
become a process indicators and under the complement condition it would be an outcome indicator. Given the current ambiguity in interpretation, this QCI has been 
eliminated for further use at present.  
Table 36: Center effect for (process) quality indicators related to adjuvant treatment: inter quartile range, number of centers significantly 
below P25 or above P75 and multivariate prognostic factors retained at the 5% level.  
QCI Short name IQR # below P25 # above P75 Prognostic factors 
1241 %Adj_Chemo<3m  - - Not estimable 
1242 %Adj_RT<3m  - - Not estimable 
1243 %Adj_Chemo<12w  - - Not estimable 
1244 %Adj_5FU  - - Not estimable 
1245 %grade4_Tox_Prostop_CT 5% 0 0 Age, Gender 
Lack of data quality (on average 2% of patients are eligible and 6% of centers have at least 5 eligible patients) does not allow further analysis of center effects in the “adjuvant 
treatment” domain. 
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Table 37: Center effect for (process) quality indicators related to histopathological examination: inter quartile range, number of centers 
significantly below P25 or above P75 and multivariate prognostic factors retained at the 5% level.  
QCI Short name IQR # below P25 # above P75 Prognostic factors 
1271 %Path_Rep_Use 4% 2 0 cStage, cT4 
1272 %TME_Qual_Rep 38% 3 2 BMI, Missing BMI, ASA score, cStage, Mode of 
surgery, cCRM positive, cT4 
1273 %Dist_Margin_Rep 17% 4 0 BMI, Missing BMI, Tumor level, ASA score, cStage, 
Mode of surgery, Ventral tumor, cCRM positive, 
cT4, Preoper. Incontinence, Surgical technique 
1273b %Dist_Margin_Pos_Rep 14% 2 0 BMI, Missing BMI, Tumor level, ASA score, cStage, 
Ventral tumor, Preoper. Incontinence, Surgical 
technique 
1274 #Nodes_Examined  3 4 Missing BMI, Tumor level, cStage, Surgical technique 
1275 pCRM_mm_Rep 23% 4 1 BMI, Missing BMI, Gender, Tumor level, ASA score, 
cStage, Mode of surgery, Ventral tumor, cCRM 
positive, Surgical technique 
1276 TRG_Rep 39% 6 0 Age, BMI, Missing BMI, cStage, cCRM positive, 
Surgical technique 
Together with domain 2, diagnosis and staging, (average IQR of 20%), and domain 8, histopathologic examination, is most discriminatory between centers (IQR is 23% on 
average). Achievement rates were uniformly fair to high (68% and higher) for the QCIs in domain 8. QCIs 1272, 1274 and 1275 were rated with the highest clinical importance 
score in the survey and PROCARE consensus. Data quality was excellent for 1274 and 1275 (>79% patients eligible and >80% of centers have at least 5 eligible patients).  
76  PROCARE – phase III : benchmarking KCE Report 161 
3.5 SUMMARY POINTS 
On the methodology 
• Of the different methods, fixed effects outcome regression, random effects 
outcome regression and doubly robust propensity score methods, only the 
former – with Firth correction – fitted consistently well with the data.   
• Hierarchical methods often shrink results dramatically to the point of 
eliminating any substantial differences. They work especially well in settings 
with exchangeable center effects and when protecting the null hypothesis of 
no center effect is of prime importance. In our setting of feedback aimed at 
learning for self improvement protecting against false negative results is 
most important since this would overlook substantial room for 
improvement.  
• In light of both arguments above we opt for the fixed effects model with 
Firth correction as our primary patient-mix-adjustment approach.  
On the current database 
• Limited availability of prognostic factors for center choice and for outcome 
result in suboptimal adjustments for patient mix. Results shown are 
therefore likely still confounded to some degree. 
General remarks on the QCI’s:  
• There is generally weak evidence of any differences between centers in  
performance except for the domains 2, diagnosis and staging, and 8, 
histopathologic examination, where substantial variation is seen, and the 
domain of surgery where fair homogeneity is found. The discriminating 
ability is expected to grow with more patient data and narrower confidence 
intervals. This effect may be counterbalanced by increasing homogeneity in 
practice. 
• QCI’s were not always defined reliably (ileostomy procedure in QCI 1232a, 
consistent definitions of denominators (e.g. QCI’s 1263 vs.QCI 1245).  
• There is a big diversity in eligibility rate in the PROCARE database among 
both process and outcome QCI’s. 
• The achievement rate was generally fair to high for 16 outcome QCI’s and 
25 process QCI’s. 3 process QCI did not reach 30% achievement. 
Domain-specific summary points 
• GENERAL QUALITY INDICATORS 
o The general quality indicators all have a high achievement rate (>78%). 
Only QCI 1111 was found to have high enough data quality but relatively 
few events were seen and the discriminating ability between centers was 
low.  
• DIAGNOSIS AND STAGING 
o Only 4 out of 10 QCI’s (1211, 1213, 1214 and 1217) reached sufficient 
data quality in terms of percentage of eligible patients (mean: 91%) with 
at least 5 patients per center in 84% of centers. QCI 1215 was most 
discriminating between centers (IQR of 50%).- 
• NEOADJUVANT TREATMENT 
o Data quality was very low (on average 20% of eligible patients with 42% of 
centers having at least 5 patients) except for QCI 1221 (with 55% eligible 
patients and 75% of centers having at least 5 eligible patients) 
• SURGERY 
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o Half of the QCI’s (1231, 1232a, 1234, 1234b, 1235) have high data quality 
parameters; QCI 1232a was found to have been interpreted ambiguously 
with respect to the ileostomy procedure. The IQR is quite narrow, only 
13%, reflecting fair homogeneity in surgical practice 
• ADJUVANT TREATMENT  
o Lack of data quality precludes further analysis.  
• PALLIATIVE TREATMENT 
o There are no data available yet for evaluation.  
• QUALITY INDICATORS RELATED TO FOLLOW-UP 
o The condition ‘patients treated with neoadjuvant or adjuvant 
radio(chemo)therapy’ cannot currently be assessed reliably in the 
PROCARE database because of the low quality of treatment data. 
• HISTOPATHOLOGIC EXAMINATION 
o Together with domain 2, diagnosis and staging, (IQR of 20%), this domain 
8 shows most variation between centers (with an IQR of 23%).  
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4 AGGREGATED QUALITY INDEXES 
4.1 INTRODUCTION 
As described in Section 0, we will aggregate well defined sets of QCIs into a combined 
quality index (QI) as a summary measure of quality which may pertain to a specific 
domain. In this way, outcome and process QCIs will first be combined into an ‘outcome 
quality index’ and a ‘process quality index’, respectively. In the next section we will also 
construct aggregated quality indexes per domain of care and eventually an overall global 
quality Index. In line with our treatment of the original QCIs, our primary measure for 
evaluation will adjust the quality index for baseline patient characteristics when it 
involves an outcome QCI, but not otherwise. 
4.2 METHODS 
4.2.1 Evaluation of quality and reliability of the QCIs 
Data Quality is first judged, using the following criteria: 
• Median score should be at least 3.5 on the data quality survey. 
• At least 80% of all patients in the PROCARE database should be eligible. 
• At least 75% of all centers should have 5 eligible patients or more. 
4.2.2 Number of dimensions needed  
To determine the number of dimensions needed per domain we conduct a principal 
components analysis on the center-specific excess probabilities. Factor analysis is 
subsequently applied to find a (set of) high loading QCI(s) per selected dimension. In 
line with deliverable 6 excess probabilities for process QCIs remained unadjusted while 
for outcome QCIs excess probabilities were adjusted for baseline patient 
characteristics.  
4.2.3 Clinical importance and discriminating ability of selected QCIs per 
dimension 
For each principal component dimension we now chose the most ‘clinically important’ 
and ‘discriminating’ QCI among the sets suggested by factor analysis, based on the 
following criteria: 
• Median score of at least 4 on the clinical importance survey. 
• Significant p-value for the predictive ability with regard to overall survival. 
• Score 1 (= highly relevant) in the PROCARE consensus. 
4.2.4 Construction of the Quality Index 
4.2.4.1 All-or-none-score 
We have used the all-or-none-score here as the preferred aggregated quality index. The 
sum score was not calculated as it was shown in deliverable 6 to yield similar or less 
discrimination between centers. 
4.2.4.2 Aggregated scores for domains with few reliable and/ or quality-proof QCIs 
When there is at most 1 quality-proof QCI available for a domain, excess probabilities 
have been derived directly from the representative QCI. Appendix 8 gives more detail 
for the construction of binary indexes involving survival data for use in an all-or-none-
score 
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4.2.5 Risk adjustment 
Below we will adjust aggregated all-or-none scores for baseline patient characteristics 
when needed. To this end a stepwise procedure has been performed whereby we 
always adjust for main effects of age (continuous, with breakpoint after 70 years) and 
gender and then build a main effects model, allowing the following variables to enter: 
BMI with an indicator of its missingness, and the 9 categorical variables including a 
category for missingness: cStage, ASA co-morbidity score, level of the tumor, mode of 
surgery, ventral tumor, cCRM, cT4, pre-operative incontinence, surgical technique. 
After adding significant main effects in a stepwise forward manner (with significance 
level 0.05 for entering the model and 0.1 for leaving the model), significant interactions 
from among the main effects are added, again in a stepwise forward manner (with 
significance level 0.05 for entering the model and 0.1 for leaving the model). 
For the construction of the aggregate score, we follow the method and different steps 
outlined in Section 0 and depicted in the decision tree of Figure 4. For further detail on 
the build-up we refer to Appendix 8.  
4.3 AN AGGREGATED OUTCOME QUALITY INDEX 
4.3.1 Quality and reliability of the QCIs 
From Table 39, we first judge the data quality of all outcome QCIs. Based on the 
minimal quality requirements established in 2.3.3 we take QCIs 1111 [OS], 1231 
[%R0res], 1234 [30d_mort], 1234b [%Major_morb], 1235 [%Perfor] and 1235c 
[%Pos_CRM] to the next step. For QCI 1235c, we have been slightly less stringent, 
based on 75% of the centers with at least 5 eligible patients we also included this QCI. 
QCI 1112 is not included since it reflects a component of survival which is already part 
of QCI 1111 while - due to generally limited follow-up information on local recurrence 
and distant metastasis in the PROCARE database (see Section 3.3.5) - its quality is 
judged to be weak with at present little hope for an improved signal in that QCI. 
4.3.2 Concurrent validity of the selected QCIs 
To examine the concurrent validity we performed a principal component analysis on the 
risk-adjusted ‘excess’ probabilities (from the fixed-effects regression model) for QCIs 
1111, 1231, 1234, 1234b, 1235 and 1235c. 
The PCA confirms that there is not one single dimension underlying the six indicators. 
The main dimension (factor 1) accounts for only 41% of the overall variance for the six 
indicators. The second factor accounts for an additional 20%. Based on the default 
statistical selection criterion of eigenvalues greater than 1, 3 dimensions are retained 
which account for almost 80% of the information available among these QCIs.  
From a factor analysis we learn that the first dimension is mainly related to survival with 
a natural different direction for QCI 1111 (overall survival) and QCI 1234 (30-day 
mortality). Dimension 2 appears to summarize the technical aspects of surgery, and 
dimension 3 consists mainly of QCI 1234b (major morbidities after surgery), i.e. the 
immediate patient outcome after surgery. 
4.3.3 Clinical importance and discriminating ability of the selected QCIs per 
dimension 
For each dimension we then chose the most ‘clinically important’ and ‘discriminating’ 
QCI, based on the criteria of section 2.3.3 and listed properties in Table 39.  
For the first dimension, QCIs 1111 and 1234 both score very well on clinical 
importance, but QCI 1111 is much more discriminative between centers and is 
therefore selected for use in the outcome QI. 
For the second dimension, both QCI 1231 and 1235b score very well on clinical 
importance and on discriminating ability, but since there are more centers with at least 
5 eligible patients for QCI 1231, this QCI is selected for use in the outcome QI. 
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In the third dimension there is only one QCI (1234b) which does not score very well 
on clinical importance, but is selected anyway for use in the outcome QI. 
4.3.4 Constructing the quality index (QI) 
The outcome QI will hence be constructed using the following QCIs: 
• QCI 1111: Overall survival 
• QCI 1231: Proportion of R0 resections 
• QCI 1234b: Postoperative major surgical morbidity with reintervention under 
narcosis after radical surgical resection. 
4.3.4.1 “All-or-none” score 
The “all-or-none” score for a patient indicates whether this patient reaches patient-level 
benchmarks for all QCIs for which it is eligible, in this case: 
• whether he/she survived 3-years since incidence of rectal cancer, 
For patients with a follow-up of less than 3 years, a model-based multiple 
imputation technique is used to construct the “all or none” score and 
corresponding confidence limits. For more detail, see Appendix 8. 
• whether he/she had an R0 resection, and 
• whether he/she did not have postoperative major surgical morbidity with 
reintervention under narcosis after radical surgical resection. 
A first assessment of the discriminating ability between centers of this “all-or-none” 
score is made by looking at the caterpillar plot of the excess probability in Figure 14 and 
considering the statistical summary measures in Table 38. In this caterpillar plot we find 
one center performing ‘significantly’ below P25 and four centers performing significantly 
above P75.  
4.3.4.2 Simple averaging 
We computed the simple average of risk-adjusted center-specific excess probabilities of 
having QCI 1111, 1231 and 1234b into one global QI, statistical summary measures are 
provided in Table 38. 
This amounts to averaging the excess chance of achieving each QCI over its eligible 
patients. 
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Figure 14: Caterpillar plot of the unadjusted center-specific ‘excess’ 
proportion of patients for whom the “all-or-none” outcome score was met. 
 
4.3.4.3 Decision 
From Table 38, the all-or-none score appears more discriminating between centers than 
the simple average. Since it is also easier to interpret, we chose this as our quality index. 
Table 38: Statistical summary measures for the “all or none” QI and simple 
averaged QI, both based on QCIs 1111 [OS], 1231 [%R0res] and 1234b 
[%Major_morb]. 
QI Min  P25 Median P75 Max IQR 
“All or none” (%) -55 -10 -1 7 28 17 
Simple average (%) -25 -4 -1 2 10 7 
Both QIs further show a relatively strong correlation in Figure 15, with a Pearson 
correlation coefficient = 0.78, suggesting that both may ultimately express a similar 
quality measure. 
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Figure 15: Scatter plot comparing the “all-or-none” score to the simple 
averaged QI for QCIs 1111 [OS], 1231 [%R0res] and 1234b [%Major_morb]. 
 
We decide to use the all-or-none score of QCIs 1111, 1231 and 1234b as outcome QI. 
The funnel plot for the outcome QI reveals systematic variation between centers in this 
(unadjusted) score.  
4.3.5 Adjusting the outcome QI for patient characteristics 
Forward stepwise model building leads to a model adjusting for main effects of age (with 
a different slope before and after the breakpoint of 70 years), gender, cStage, ASA 
score, cT4, mode of surgery and interactions between age and ASA as well  as  cStage 
and Mode-of-Surgery’.  
The caterpillar plot of adjusted excess probabilities for the outcome “all or none” score 
is shown Figure 16. In this caterpillar plot we see 1 center performing ‘significantly’ 
below P25 (-9%) and 3 above P75 (8%). 
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Figure 16: Caterpillar plot of the adjusted excess probabilities for the 
outcome “all or none” score. 
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Table 39: Criteria considered in constructing a QI for outcome of rectal cancer, split by data quality, concurrent validity (PCA), clinical 
importance and discriminating ability 
 
QCI Short name N patients % events N centers N only 0/1 N >= 5 Survey % 
patients
% >= 5 Include Dimension Loading Survey Predicitiv
e ability
PROCARE 
consensus
Include Visually % only 0/1 IQR Random effects 
variance
Include
1111 OS 3103 22% 79 5 67 5 88 84 x 1 -0.74 5 1 x 7 14% x
1112 DSS 2807 7%/7% 79 1 66 4 85 83 5 1 1
1113 LRFS 1186 2%/8% 63 7 49 4 36 61 5 1 14
1113b DFS 1234 18% 64 3 49 4 37 61 5 1 6 10%
1227 %grade4_Tox_Preop_RT 544 11% 51 9 30 2 16 38 4 0.295 1 2 29 12% 0.2492
1231 %R0res 2914 87% 78 11 67 5 88 84 x 2 0.94 5 0.0001 1 x 2 16 11% 0.0001 x
1232b %stoma1year 123 27% 37 3 9 4 4 11 3 0.003 2 3 30 32% 0.0987
1233a %Leak_PME 556 6% 59 27 42 4.5 17 53 4.5 0.0284 1 2 63 16% 0.0444
1233b %Leak_TME 1592 6% 74 16 54 4 48 68 4 0.0003 1 3 29 7%
1234 30d_mort 2919 2% 78 35 67 5 88 84 x 1 0.83 5 0.0001 1 x 3 51 4% 0.0019
1234b %Major_morb 2913 6% 78 18 67 4 88 84 x 3 0.99 3 0.0001 2 x 3 26 6% 0.0319 x
1235 %Perfor 2900 8% 78 14 67 4.5 87 84 x 1 0.75 4 0.0001 2 3 21 8% 0.0003
1235b %Pos_Dist_margin 516 2% 64 21 27 5 16 34 5 0.5033 1 3 75 6% 0.2716
1235c %Pos_CRM 1932 19% 73 6 60 5 58 75 x 2 -0.92 5 0.0001 1 x 2 10 16% 0.0045
1245 %grade4_Tox_Prostop_CT 128 8% 37 6 10 2 4 13 4 0.8356 1 3 55 5%
1263 %Late_Tox_RT 1890 0% 74 58 61 2 57 76 3 0.9681 2 3 94 3%
Data quality PCA Clinical importance Discriminating ability
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4.4 AN AGGREGATED PROCESS QUALITY INDEX 
4.4.1 Quality and reliability of the QCIs 
From Table 39, we first judge the data quality of all QCIs. Based on the criteria 
established in 2.3.3 we decide to take QCIs 1211, 1213, 1214, 1217, 1221, 1232a, 1271, 
1272, 1273, 1273b, 1274 and 1275 to the next step, being less stringent for QCIs 1221, 
1271, 1272, 1273 and 1273b with regard to one or more of the proposed criteria. 
4.4.2 Concurrent validity of selected QCIs 
A principal component analysis is preformed on the unadjusted ‘excess’ probabilities for 
QCIs 1211, 1213, 1214, 1217, 1221, 1232a, 1271, 1272, 1273, 1273b, 1274 and 1275. 
The PCA confirms that there is not one single dimension underlying the twelve 
indicators. The main dimension accounts for only 20% of the overall variance for the 
twelve indicators. The second factor accounts for an additional 19%. Based on the 
default statistical selection criterion of eigenvalues greater than 1, 4 dimensions are 
retained and account for 63% of the information available among these QCIs.  
4.4.3 Clinical importance and discriminating ability of selected QCIs per 
dimension 
For each dimension we now chose the most ‘clinically important’ and ‘discriminating’ 
QCI, based on the criteria established in 2.2.3: 
For the first dimension, QCIs 1273 and 1275 both score very well on clinical 
importance and discriminating behavior between centers. Since QCI 1273 loads 
stronger on the first dimension, this QCI is selected as the first component of the 
process QI. 
For the second dimension, both QCI 1211, 1221 and 1232a score very well on clinical 
importance. QCI 1211 is discarded because of the high percentage of centers with 100% 
documented distance from the anal verge, which does not allow discriminating between 
these centers easily. Finally, QCI 1232a is selected as the second component in the 
process QI, because of perceived problems with QCI 1221: one could not always 
distinguish between a missing value for RT and the actual absence of the RT treatment. 
In the third dimension, only QCI 1274 scores very well on clinical importance, and is 
therefore selected as third component for the process QI. 
Finally, the fourth dimension is dominated by QCI 1272, but since only 47% of the 
patients are eligible for this QCI it is not considered for the QI. Since on the other hand 
QCI 1217 scores well on both data quality and discriminating ability, it is selected as 
fourth component for the process QCI. 
4.4.4 Construction of the quality index (QI) 
The process QI will be constructed using the following QCIs: 
• QCI 1217: Time between first histopathological diagnosis and first treatment. 
• QCI 1232a: Proportion of APR- Hartmann’s procedure or total excision of 
colon and rectum with definitive ileostomy. 
• QCI 1273: Distal tumor-free margin mentioned in the pathology report. 
• QCI 1274: Number of lymph nodes examined. 
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4.4.4.1 “All or none” score 
The “all or none” score for a patient is an indicator expressing whether the patient 
reaches patient-level benchmarks, in this case: 
• whether the time between first histopathologic diagnosis and first treatment 
was no more than 30 days, 
• whether he/she did not have APR- Hartmann’s procedure or total excision of 
colon and rectum with definitive ileostomy, 
• whether he/she had the distal tumor-free margin mentioned in the pathology 
report, and 
• whether there were at least 10 lymph nodesl examined. 
A first assessment of the discriminating ability between centers of this “all or none” 
score is done by inspecting the caterpillar plot of unadjusted excess probabilities in 
Figure 18 and considering the statistical summary measures in Table 40. In this 
caterpillar plot we find four centers performing ‘significantly’ below P25 and five centers 
performing significantly above P75. 
4.4.4.2 Simple averaging 
We compute the simple average of unadjusted center-specific excess probabilities of 
having QCIs 1232a, 1273, for QCI 1217 the unadjusted excess number of days between 
first histopathological diagnosis and first treatment (scaled between -1 and 1 by dividing 
by 50) and for QCI 1274 the unadjusted excess number of lymph nodes examined 
(scaled between -1 and 1 by dividing by 10) into one global QI, statistical summary 
measures are provided in Table 40. 
Table 40: Statistical summary measures for the “all or none” QI and simple 
averaged QI, both based on QCIs 1217 [Time_histo-1ther], 1232a 
[%Defin_osotmy], 1273 [%Dist_Margin_Pos_Rep] and 1274 
[#Nodes_Examined]. 
QI Min  P25 Media
n 
P75 Max IQR 
“All or none” 
(%) 
-29 -11 -1 17 64 28 
Simple average -21 -5 -2 7 22 12 
4.4.4.3 Decision 
When comparing the two methods for combining QCIs 1217, 1232a, 1273 and 1274, 
we consider especially the discriminating ability which can be examined in Table 40. 
Since the simple average is on a different scale (as one of its components is on a 
different scale) it is not possible to directly compare it with the “all or none” score 
based on this Table. The Pearson correlation between the two QIs is now 0.61 (Figure 
17).  
                                                     
l  We have chosen cutpoint 10 rather than 12 (used in the PROCARE II report) as a conservative 
compromise between common cutpoints available in the literature. This avoids a greater dominance in 
failures in the all-or-none score.  
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Figure 17: Scatter plot comparing the “all or none” score to the simple 
averaged QI for QCIs 1217 [Time_histo-1ther], 1232a [%Defin_ostomy], 
1273 [%Dist_Margin_Pos_Rep] and 1274 [#Nodes_Examined]. 
 
The choice between the two measures is a matter of judgment, and preference is 
eventually given to the QI that is best interpretable, i.e. the “all or none” score which 
will lead to an unadjusted excess probability in this instance.  
DECISION: Use the “all or none” score of QCIs 1217 [Time_histo_1ther] (with no 
more than 30 days between diagnosis and first treatment as threshold), 1232a 
[%Defin_ostomy], 1273 [%Dist_Margin_Rep] and 1274 [#Nodes_Examined] (with at 
least 10 lymph nodes to be examined as threshold) as process QI. 
Over the centers this score is on average obtained in 40% of the patients. As for the 
other QI’s (data not shown), the funnel plot reflected systematic variation between 
centers. This is also seen on the caterpillar plot: four centers fall significantly below the 
P25 (-11%) and 5 above the P75 (+17%) excess probability.  
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Figure 18: Caterpillar plot of the unadjusted center-specific ‘excess’ 
proportion of patients for whom the “all or none” process score was met. 
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Table 41 (next page): Criteria considered in constructing a QI for process QCIs related to quality of care of rectal cancer, split by data 
quality, concurrent validity (PCA), clinical importance and discriminating ability 
 
QCI Short name N patients
% 
events
N 
centers
N only 
0/1 N >= 5 Survey % patients % >= 5 Include Dimension Loading Survey Predicitive ability PROCARE consensus Include Visually % only 0/1 IQR Random effects variance Include
1211 %DocDist 3318 91% 80 29 68 4 100 85 x 2 0.7 4 0.0001 1 x 1 42 12% 0.0001
1212 %CT_Preop 322 79% 41 13 22 4 10 28 3 0.7458 1.5 2 57 22% 0.0001
1213 %CEA_Preop 3318 81% 80 7 68 4 100 85 x 2 0.84 2.5 0.0499 1 10 18% 0.0001
1214 %Preop_Bowel_Im 2811 98% 77 48 67 4 85 84 x 3 0.49 3 0.4557 2 2 71 4% 0.0001
1214b %TRUS_cT12 74 82% 29 2 4 4 2 5 3.5 0.4604 2 2 40 24% 0.094
1214c %MR_cII/III 103 91% 25 4 9 4 3 11 4 0.0853 1 2 40 19% 0.0967
1215 %Preop_Im 435 61% 49 5 25 4 13 31 5 0.378 1 1 19 50% 0.0001
1216 %cCRM_rep 1950 26% 74 21 62 3 59 78 4 0.0095 1 1 33 29% 0.0001
1216b cM0_Acc 634 6% 55 18 34 4 19 43 3.5 0.8077 2 2 51 5% 0.0009
1217 Time_histo-1ther 2687 76 65 4 81 81 x 1 / 4 -0.48 / 0.5 2.5 0.9467 2 0.0001 x
1221 %Preop_RT 1830 74% 74 4 60 5 55 75 x 2 0.73 5 0.0001 1 x 1 7 27% 0.0001
1221b %(C)RT_cCRM+ 286 81% 37 1 14 4 9 18 5 0.0325 1 2 7 27% 0.0001
1221c %Preop_RT_cI 344 17% 56 12 27 4 10 34 2 0.3072 2 2 43 18% 0.0002
1224 %Preop_cont_5FU 469 91% 49 21 30 4 14 38 2 0.6439 2 2 68 7% 0.0001
1225 %Completed_preop_RT 1196 97% 70 34 51 3 36 64 3 0.7915 2 2 65 5% 0.0001
1226 %Surg<12w_after_Preop_RT 1123 97% 69 33 49 5 34 61 2.5 0.0683 2 3 66 5%
1232a %Defin_ostomy 2945 24% 78 2 67 89 84 x 2 0.53 0.0001 1 x 1 3 19% 0.0001 x
1241 %Adj-Chemo<3m 28 86% 14 1 4 1 1 4 1
1242 %Adj_RT<3m 46 98% 23 3 5 1 4 5 1
1243 %Adj_Chemo<12w 58 93% 23 4 4 2 5 3 2
1244 %Adj_5FU 57 95% 23 4 4 2 5 2.5 2
1271 %Path_Rep_Use 1980 98% 69 42 56 5 60 70 x 3 0.62 1.5 0.3454 3 2 74 4% 0.0001
1272 %TME_Qual_Rep 1572 68% 67 6 55 4 47 69 x 4 0.85 5 0.0053 1 1 11 38%
1273 %Dist_Margin_Rep 2051 86% 75 15 63 5 62 79 x 1 0.88 4.5 0.0012 x 1 23 17% 0.0001 x
1273b %Dist_Margin_Pos_Rep 2034 91% 74 20 63 5 61 79 x 1 0.84 4 0.0548 3 2 31 14% 0.0001
1274 #Nodes_Examined 2714 77 64 5 82 80 x 3 0.77 5 0.0027 1 x 0.0001 x
1275 pCRM_mm_Rep 2615 74% 77 6 66 5 79 83 x 1 0.59 5 0.6578 1 x 1 9 23% 0.0001
1276 TRG_Rep 1427 75% 71 7 53 3 43 66 4 0.3149 1.5 1 13 39% 0.0001
Data quality PCA Clinical importance Discriminating ability
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4.5 AGGREGATED QUALITY INDEXES PER DOMAIN 
4.5.1 Overview of results 
We now construct a quality index for each of 8 separate domains of care from their 
available QCIs as indicated in the table below. For the construction, we return to the 
statistical-clinical decision tree described in section 2.3.3.3. The resulting all-or-none 
scores are briefly described inTable 42. Outcome QCIs retained there are in bold and 
imply the primary QI measure will be a center-specific excess probability which has 
been adjusted for baseline patient characteristics. NAs show up as we could not assess 
performance of the centers for domains 5 (not enough eligible patients), 6 and 7 
(insufficient data to date). 
Table 42: Summary of QCIs per domain, incl. the domain name, the number 
of outcome (#O) and process (#P) indicators available and the QCIs retained 
per domain.13 The last column shows the average achievement rate over the 
centers for the derived quality index which is an “all or none” score.  
Domain #O #P QCIs in QI achieved 
1 General quality 
indicators 
4(+1) 0 1111 (OS) 72 %14 
2 Diagnosis and staging 0 10(+1) 1211(%DocDist), 
1217 (Time_histo-1ther) 
60 % 
3 Neoadjuvant 
treatment 
1 6 1221 (%Preop_RT) 71 % 
4 Surgery 9 1 1231 (%R0res), 
1233b (%Leak_TME),  
1232a (%Defin_ostomy) 
70 % 
5 Adjuvant treatment 1 4 NA NA 
6 Palliative treatment 0 0(+1) NA NA 
7 Follow-up 1 0(+1) NA NA 
8 Histopathologic 
examination 
0 7 1273 (%Dist_Margin_Pos_Rep), 1274 
(#Nodes_Examined) 
62% 
Total number of QCIs: 16 
(+1) 
28 
(+3) 
  
For each of the obtained scores we show caterpillar plots of adjusted center-specific 
excess probabilities as soon as the quality index contains an outcome QCI and 
unadjusted excess probabilities otherwise. In the former case we also list the variables 
adjusted for in the model. We end with a table summarizing primary results over the 
different domains. Further detail can be found in Appendix 8. 
4.5.1.1 DOMAIN 1`General quality indicators’ 
Since the single QCI 1111 is retained for this domain QI corresponding excess 
probabilities for surviving at least 3 years have been derived previously and are shown in 
section 3.4.1.3.  
4.5.1.2 DOMAIN 2 `Diagnosis and staging’ 
Since this index aggregates process QCIs, we show the unadjusted results. On average 
over the centers, it is achieved in 59.7% of the patients. In the caterpillar plot, we 
observe that four centers perform significantly below P25 (-15%) and six perform 
significantly above P75 (+16%). A multivariate regression model found significant  main 
effects of age (with a different slope before and after the breakpoint of 70 years), 
gender, Tumor Level, cT4 and cStage with the 2 interaction effects “Age by Gender” 
and “Gender by cStage”.  
                                                     
13  Notation: Y(+n): The number of indicators Y is given together with the number of recently defined new 
indicators n 
14  Based on imputed score will be replaced by direct Cox model based value 
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Figure 19: Caterpillar plot of the unadjusted center-specific ‘excess’ 
probability for the “all-or-none” score for domain 2 ’Diagnosis and staging’ 
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4.5.1.3 DOMAIN 3 `Neoadjuvant treatment’  
A single process QCI has been retained here: QCI 1221 `Proportion of cStage II - III 
patients that received neoadjuvant pelvic RT’. On average over the centers, it is 
achieved in 74% of the patients. In the caterpillar plot, we observe that five centers 
perform significantly below P25 (-14%) and one that performs significantly above P75 
(+13%). 
KCE Report 161 PROCARE – phase III : benchmarking 93 
Figure 20: Caterpillar plot of the unadjusted center-specific ‘excess’ 
probabilities of QCI 1221 (as an index for domain 3 `Neoadjuvant 
treatment’) 
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4.5.1.4 DOMAIN 4 `SURGERY’  
On average over the centers, this “all or none” score has been obtained in 70% of 
patients. The model has adjusted for main effects of age (with a different slope before 
and after the breakpoint of 70 years), gender, Tumor level, surgery, mode of surgery, 
cT4, cCRM, cStage, Ventral Tumor, ASA score and 2 interactions “ASA score by Mode 
of surgery” and ”cStage by ventral Tumor”.  
In the caterpillar plot of adjusted excess probabilities, we find one center performing 
‘significantly’ below P25 (-6%) and two centers significantly above P75 (6%).  
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Figure 21: Caterpillar plot of the adjusted center-specific ‘excess’ probability 
for the “all-or-none” score for domain 4 ‘Surgery’  
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4.5.1.5 DOMAIN 8 `Histopathologic examination’  
On average over the centers, this “all or none” score has been obtained in 61.7% of 
patients.  Unadjusted center effects are shown in the caterpillar plot (Figure 22), where 
we find 5 centers performing ‘significantly’ below P25 (-15%) and 8 above P75 (+ 10%).  
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Figure 22: Caterpillar plot of the unadjusted center-specific ‘excess’ 
probability for the “all-or-none” score for domain 8 ’Histopathological 
examination’. 
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4.5.2 Overview of variation per domain  
Table 43 summarizes variation between centers expressed as the Inter Quartile Range 
of relevant excess probabilities as well as the number of centers with significant excess 
probabilities on domain quality indexes, i.e. the number of centers scoring significantly 
below P25 and above P75.  
Table 43: Overview of quality index results per domain. Inter quartile range 
and number of centers significantly performing below P25 and above P75 in 
caterpillar plots of (un-)adjusted excess probability.  
Domain Description unadjusted adjusted 
IQR (%) <P25 >P75 IQR (%) <P25 >P75 
1 General quality indicators    14 0 2 
2 Diagnosis and staging 31 4 6 25 5 5 
3 Neoadjuvant treatment 27 5  1  - - - 
4 Surgery 15 1 3 12 1 2 
5 Adjuvant treatment - NA NA  NA NA 
6 Palliative treatment - NA NA  NA NA 
7 Follow-up - NA NA  NA NA 
8 
Histopathologic 
examination 
25 5 8 24 2 5 
NA: not assessed due to data availability or data quality; primary analysis is in bold (adjusted if outcome 
QCI is involved); italic: domains 1 and 3 are represented by single QCIs, analyzed as described in section 
4.5  
One concludes that domain 2 and 8 show most variation between centers. The efforts 
to harmonize surgical treatment appear to have paid off in this cohort, since less 
variation is seen in this domain (and quality achievement rates were quite high). For 
more extreme centers, the caterpillar plots warrant an investigation of the centre-
specific covariates that contribute to their under/outperformance.  
It is anticipated that fewer missing data will yield better discrimination in the future (i.e. 
there will be more significant outliers due to more narrow confidence intervals).  
4.6 AN OVERALL COMPOSITE QUALITY INDEX 
Here we report on the construct of a composite index for outcome and process QCIs 
combined. We appreciate this is a complex measure to interpret and produce it in 
response to the request to arrive at a single global quality index. The relative weight of 
outcome and process QCIs in this construction is to some degree a matter of choice. In 
an attempt to give similar chances to outcome and process QCIs to enter, a first 
approach started from the previously selected QCIs for respectively outcome and 
process aggregated scores. A second approach started instead from all available QCIs 
with sufficient data quality. For a number of reasons pertaining to data quality of 
measures involved and the discriminating ability of the resulting score, we opted for the 
second quality index and report on it below. Further detail can be found in Appendix 8.  
Starting from 28 process and 16 outcome QCIs, and after imposing stringent data 
quality criteria (see Methodology section 2.1), we were left with 6 outcome QCIs 
(1111, 1231, 1234, 1234b, 1235 and 1235c) and 12 process QCIs (i.e. QCIs 1211, 1213, 
1214, 1217, 1221, 1232a, 1271, 1272, 1273, 1273b, 1274 and 1275) to construct a 
composite index.  
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A principal component analysis confirmed that there is not one single dimension 
underlying the 18 indicators. The main dimension (factor 1) accounts for only 18% of 
the overall variance for the 18 indicators. Based on the default statistical selection of 
eigenvalues greater than 1, 6 dimensions were retained. These six factors account for 
69% of the information available among the QCIs. Following a factor analysis and our 
criteria for inclusion, the composite QI is constructed using the following 2 outcome 
(O) and 4 process (P) QCIs: 
• QCI 1111 (O): Overall survival 
• QCI 1231 (O): Proportion of R0 resections 
• QCI 1211 (P): Documented distance from anal verge 
• QCI 1273 (P): Distal tumor-free margin mentioned in the pathology report. 
• QCI 1274 (P): Number of lymph nodes examined 
• QCI 1272 (P): Quality of TME assessed according to Quirke and mentioned 
in the pathology report 
Over the centers, the resulting “all or none” score is on average obtained in 29% of the 
patients. Since outcome QCIs are involved in this quality index, a model is built that 
adjusts for main effects of age (with a different slope before and after the breakpoint of 
70 years), gender, ASA score, Tumor level, cStage, cT4, surgery and “cStage by 
Surgery”.  In terms of adjusted excess probabilities 2 centers are found to perform 
significantly below P25 (-9%) and one above P75 (8%).  
Summary points 
• The methodology described in section 2 for aggregating quality indexes for 
the outcome domain, the process domain, for each of the 8 specific domains, 
and finally the overall composite index was applied to the available 
PROCARE dataset. In a first step principle components and factor analysis 
conducted on the center-specific excess chances lead to a selected set of 
QCIs to be included in the aggregated index. Because of limited data quality 
the most clinically relevant QCIs could not always be included in this 
construction. This was particularly apparent in the domain `Diagnosis and 
staging'. 
• After considering discriminating ability and interpretation, the all-or-none 
scoring method was chosen to yield the aggregate quality index measure 
from the retained QCIs. 
• Aggregated all-or-none scores which involved outcome QCIs were adjusted 
for baseline characteristics of the patients to yield center-specific excess 
probabilities. When only process QCIs were involved the all-or-none score 
was left unadjusted. The same method was used to calculate excess 
probabilities as for the original QCIs. 
• Substantially more variation was seen in the achievement levels of the 
domains `Diagnosis and staging'  and `Histopathological Examination' than in 
the `Surgery' domain suggesting there is still room for improvement in these  
former domains. 
• A few centers were found to lie significantly below the P25 level for one or 
more of the aggregated outcomes. Given the present limitations of the 
database, especially the limited data quality and selectivity of registration, 
these results can not be seen as conclusive. 
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Figure 23: Caterpillar plot of the adjusted center-specific ‘excess’ probability 
for the “all-or-none” composite score. 
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5 MODEL BUILDING TO EXPLAIN EXCESS 
PROBABILITIES 
5.1 INTRODUCTION 
As suggested by Normand et al.37 centers were evaluated based on a comparison 
between the average expected outcome over the patient set they treated and the 
expected outcome these patients would have experienced had they been treated at the 
’average’ center. We called this measure the center-averaged excess outcome and 
denoted it with ce for center c. For binary outcomes it was obtained through logistic 
regression and for survival outcome through the proportional hazards model (both with 
Firth correction, see Appendix 1, Chapter 10). In this section we propose a first 
explanatory analysis of these excess probabilities in terms of center-specific 
characteristics including excess probabilities on process QCIs as well as size. Specifically, 
we 1) regress excess probabilities for overall survival on the said predictors and 2) list 
average unadjusted excess probabilities on process QCIs for the 5 centers with the 
highest and lowest estimated adjusted excess probability for the 3 year survival 
outcome QCI. Given the current reservations on the data quality and derived excess 
probabilities this merely presents an illustration of such an approach referring to a 
limited set of possible center-specific explanatory variables and has no ambition of being 
a full-fledged explanatory analysis. 
5.2 METHODOLOGY: FORWARD STEPWISE REGRESSION 
Excess probabilities of achievement, ceˆ  were calculated per center for both outcome 
and process quality control indexes (see additional figures in Appendix 6, sections 1.2-
1.8). We regressed them on selected center-specific characteristics through a weighted 
least squares linear model. The centers were inversely weighted with their estimated 
variance on outcome ceˆ . This is a first approximation to such explanatory regression. 
If one believes that there remains residual between center variation in this regression 
model, then this would contribute to the variance around the line and can be modelled 
to improve the weights and efficiency in the weighted least squares regression model as 
in van Houwelingen et al. 2002 46. If one furthermore believes that the true expected 
center effects on the process QCI determine the effect on outcome, one may recognize 
that the current predictors measure this with imprecision which would lead to an 
attenuated slope in the regression. With estimated variances of the excess probabilities 
on the process QCI, one can correct for this measurement error on the predictor. As 
our outcomes take both positive and negative values (which are constrained by -1 and 
+1) we start off with simple linear regression. If the data show substantial deviation 
from the model, we propose to transform outcomes into the 0-1 range and then fit a 
generalized linear model with logit link on the mean. Such transformation could consist 
of dividing ceˆ  first by two and then adding 0.5 to that result. 
We specifically entered the following centre-specific predictors in a forward stepwise 
fashion, including: 
• Excess probabilities on process QCIs (unadjusted, provided sufficient data 
quality). 
• Center size (derived from the BCR database) 
For confidentiality reasons we lacked substantial detail on the center characteristics, 
which could be of interest at this stage and point to reasons for differential 
achievement.  
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5.3 EXPLANATORY DESCRIPTIVES FOR EXTREME CENTER 
PERFORMANCE 
The list of predictors considered for explaining the adjusted excess probability of 3 year survival 
is given in Table 44. For 5 centers with the highest (see Table 45) and lowest (see Colour code 
outcome QCI: orange: mean excess prob is not significantly below P25; red: significantly below P25; -Colour code 
process QCI: dark red: negative mean excess prob; dark green: positive mean excess prob; BCR: Belgian Cancer 
registry; PRO:PROCARE database 
Table 46) estimated value of the latter, the mean center-specific unadjusted excess 
probabilities on 12 process indicators (with sufficient data quality) are given in Table 47.
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Table 44: List of selected process QCIs with sufficient data quality 
QCI Abbreviations Description Domain 
1211 %DocDist Proportion of patients with a documented distance from the anal verge 2 
1213 %CEA_Preop Proportion of patients in whom a CEA was performed before any treatment 2 
1214 %Preop_Bowel_Im Proportion of patients undergoing elective surgery that had preoperative complete large bowel-imaging 2 
1217 Time_histo-1ther Time between first histopathologic diagnosis and first treatment 2 
1221 %Preop_RT Proportion of cStage II-III patients that received a neoadjuvant pelvic RT 3 
1232a %Defin_ostomy Proportion of APR- Hartmann’s procedure or total excision of colon and rectum with definitive 
ileostomy 
4 
1271 %Path_Rep_Use Use of the pathology report sheet 8 
1272 %TME_Qual_Rep Quality of TME assessed according to Quirke and mentioned in the pathology report 8 
1273 %Dist_Margin_Pos_Rep Distal margin involvement mentioned after SSO or Hartmann 8 
1273b %Dist_Margin_Rep Distal tumor-free margin mentioned in the pathology report 8 
1274 #Nodes_Examined Number of lymph nodes examined 8 
1275 pCRM_mm_Rep (y)pCRM mentioned in mm in the pathology report 8 
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Table 45: Excess probabilities (%) for process QCIs for centers with lowest adjusted excess probability for 3 year survival  
#patients15 S(3) 
QCI1111 1211 1213 1214 1217 1221 1232a 1271 1272 1273 1273b 1274 1275 
BCR PRO 
23 5 -30.3 -1.4 8.1 -5.6 4.5 19.7 -0.3 -5.5 24.8 5.6 0.7 -4.8 1.5 
34 13 -29.5 3.3 -1.4 -1.1 -13.7 -26.9 -0.3   -17.9 -31.8 -2.8 -34.2 
81 12 -22.6 3.1 4.9 -8.8 -0.1 13.1 1.6 -1.0 -21.9 8.9 4.1 -2.7 7.3 
8 9 -22.1 1.9 11.4 -2.8 12.1  24.7     0.9 20.2 
36 17 -17.3 -1.4 2.5 -6.1 14.7 -15.3 13.0 -2.7 -59.8 10.1 5.2 6.7 -5.9 
Colour code outcome QCI: orange: mean excess prob is not significantly below P25; red: significantly below P25; -Colour code process QCI: dark red: negative mean excess prob; dark green: positive mean excess 
prob; BCR: Belgian Cancer registry; PRO:PROCARE database 
Table 46: Excess probabilities (%) for process QCIs for centers with highest adjusted excess probability for 3 year survival  
#patients14 S(3) 
QCI1111 1211 1213 1214 1217 1221 1232a 1271 1272 1273 1273b 1274 1275 
BCR PRO 
14 16 23.2 4.0 -10.0 -0.2 17.8 17.4 13.0 -0.1 24.3 1.4 -3.4 -3.6 16.5 
47 40 18.5 3.2 5.4 1.4 -12.1 0.3 8.5 1.3 9.4 -25.7 -3.0 0.7 -24.9 
44 14 18.1 -23.1 -13.6 -2.3 18.3 -3.2 -11.6 -1.7 10.4 -13.9 -18.7 -3.0 1.5 
36 23 18.0 4.8 6.0 0.5 8.9 1.6 8.8 -0.3 -37.7 -25.4 -23.1 -0.1 -23.5 
166 8 17.5 1.4 10.9 -3.5 2.5 -13.6 2.5 -10.8  5.6 -15.9 0.1 -4.7 
Colour code outcome QCI: light green if mean excess prob is not significantly higher than P75; dark green:  
significantly higher than P75; Colour code process QCI: dark red: negative mean excess prob; dark green: positive mean excess prob 
 
 
                                                     
15   Overall about one third of patients in the BCR database are represented in PROCARE, the apparent assignment of more patients to the PROCARE database for some centers is due 
to the different center assignment procedures used by both registers, as explained in section 3.1 and Appendix 7.   
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Table 47: Average center size for the 5 centers with highest and lowest 
estimated adjusted excess chance of 3 year survival.  
Ranking BCR 
Center size 
PROCARE 
Center-size 
Top-5 61 20 
Bottom-5 36 11 
Univariate weighted least squares linear regression with excess survival chance as an 
outcome yields a significant (at the nominal .05 level) linear association with process 
QCI 1272 (%TME_Qual_Rep). The univariate regression models are summarized in 
Table 48. QCI 1221 (%Preop_RT) and center size (the number of patients included in 
either the BCR or the PROCARE database) are significant at the nominal .1 level. 
Table 48: Univariate associations with excess 3-year survival chance as an 
outcome 
Predictor Estimate StdErr Pr > |t| 
PROCARE size 0.03 0.02 0.081 
BCR size 0.02 0.01 0.059 
QCI 1211 0.07 0.11 0.545 
QCI 1213 0.13 0.09 0.140 
QCI 1214 0.46 0.39 0.238 
QCI 1217 0.10 0.09 0.280 
QCI 1221 0.10 0.05 0.077 
QCI 1232a -0.17 0.12 0.165 
QCI 1271 0.08 0.22 0.708 
QCI 1272 0.15 0.05 0.004 
QCI 1273 -0.16 0.11 0.141 
QCI 1273b -0.02 0.14 0.863 
QCI 1274 -0.15 0.45 0.744 
QCI 1275 0.10 0.09 0.305 
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5.4 FORWARD STEPWISE REGRESSION  
After stepwise selection of predictors (with and without center size included), a model 
with 1 significant predictor was selected, i.c. excess probability on process QCI 1272 
(see Table 49). To support the linearity assumption of the fitted model, Figure 24 shows 
observed versus predicted excess outcomes with the locally smoothed regression line. 
Table 49: Parameter estimates for the significant (at the .05 level) predictors 
in the model for excess probability of 3 year survival.  
Variable 
Parameter 
Estim. 
Standard 
Error Type II SS F Value Pr > F 
Intercept 1.09 1.06 2.55 1.05 0.310 
QCI 1272 (%TME_Qual_Rep) 0.14 0.05 20.02 8.26 0.006 
 
Figure 24: Model predictions for the adjusted excess probability of 3 year 
survival. 
 
We note at this stage that data for this outcome QCI are still immature and the limited 
information implies relatively little power for the detection of significant effects.  
For the purpose of explanation, we also added interaction effects between center and 
age to the final explanatory model at the patient level that had been reached for 
individual QCI111 measures. The added terms did not significantly improve the model 
(P=0.2038). Again, with limited data, this is at present not to be taken as evidence of the 
fact that no differences could exist between centers and their treatment of different age 
groups. There is at present however no evidence that such interaction indeed exists. 
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Summary points 
• Center performance, measured as adjusted excess probability of an 
outcome QCI or aggregate outcome QI, may be explained in terms of 
center characteristics using (generalized) linear models. Such analysis is of a 
hypothesis generating nature. 
• Explanatory factors of  interest include performance on process Q(C)Is, 
center size, region, treatment facilities, case load per surgeon, …  some of 
these require more detailed knowledge about the center. 
• Interactions between center and baseline characteristics of the patient, 
measured at the patient level, may point to different centers caring better 
for specific subpopulations.  
• Limited center sizes and errors in measurement both contribute to reduced 
power to detect explanatory factors.  
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6 DISCUSSION 
The present report documents results of the study, development and application of 
methods for the evaluation of quality of care among rectal cancer centers entering 
information on quality indicators for some of their patients in the voluntary PROCARE 
registry. With its focus on causal inference, the methodology developed is generic in 
nature and the approach applicable for the monitoring of care in a whole range of 
cancers and other areas of disease.   
The monitoring and evaluation of care envisaged here primarily serves an educational 
purpose, realized through confidential feedback on quality indicators to individual care 
centers on their performance - adjusted for patient mix when necessary. This is 
accompanied by a flagging of lower performance which is not overly conservative since 
it provides foremost an early warning signal for individual center use. While this effort is 
expected to lead to improved care, no specific monitoring of response to this feedback 
is currently conducted. Whether and how feedback indeed (best) leads to the desired 
response resulting in an optimization of care is yet to be addressed explicitly and is 
work for further study. 
Feedback takes the form of domain-specific (or more global) presentations of center 
performance expressed as an excess probability: the expected percentage of patients in 
the center, beyond that in the average center, for which all relevant quality indicators in 
the composite index are met. Centers are plotted in order from the highest to the 
lowest estimated excess probability and presented with the 95% CI on this excess 
probability. Overlapping confidence intervals emphasize that the plotting order should 
not be seen as an indication of the intrinsic rank order of the centers. Substantial 
uncertainty on the relative quality index performance remains, particularly in centers 
which contributed few patients to the database so far. By choosing this presentation, we 
place ourselves on the sceptical side in the debate on the value of ranks in evaluating 
performance of care in line with Lilford et al. 53. 
Ideally, confidence intervals on the quality indexes should be compared to absolute 
bench marks of good quality care. In practice, such objective bench marks are not yet 
available and hence the intervals are simply related to observed percentiles (quartiles) of 
performance over the centers. Relative benchmarks have the obvious drawback that 1) 
stricter demands are made in domains which generally perform better (i.e. with less 
variability over the centers) and 2) the bench marks are likely changing over time and 
cannot be used in an international comparison.  
Domain-specific aggregate scores allow the comparison of specific services across 
centers. Their construction is designed to involve fewer QCIs than the original set of 
QCIs in the database without losing much information. The obtained reduction in QCIs 
for this evaluation thus suggests more economic ways of gathering data. A word of 
caution is in place, however, when interpreting current results of the implementation of 
this strategy. In some instances, the most clinically meaningful and important variables 
lacked the quality required for entry into the construction of the aggregate quality 
index. This was the case for example in the domain `diagnosing and staging’, where such 
indexes did not reach the quality threshold criteria. This problem is expected to be 
resolved once the methods developed here are re-applied to a more mature database.  
In general, the question of whether or not to reduce the number of QCIs to be 
measured is a difficult one, with several dimensions: 
• How much information is lost? This is the line we followed and targeted in 
the report: retaining a sufficient amount of variation in the full set of 
indicators. One could alternatively focus more directly on the impact of a 
reduced number of QCIs on the accurate ranking of centers either in relative 
terms or in terms of absolute bench marks 
• Would the recording of fewer QCIs lead to more accurate and complete 
data?  
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• Will fewer QCIs make it more difficult to diagnose the reasons for center 
underperformance and to intervene successfully?  
• Are there other ways of retrieving the latter information post hoc in a more 
cost-efficient way, for instance through linking with administrative databases? 
The application of the proposed methods to the PROCARE database demonstrates the 
feasibility of the approach in this setting, but also indicates the limitations caused by 
incompleteness and data quality of the database. Results should not uncritically be used 
to objectively judge the quality of rectal cancer care in Belgium at present. For instance, 
while the database structure and maturity is evolving, one expects a growing number of 
variables will hit the quality threshold and be allowed to enter the construction for the 
aggregated quality index. As a result these indexes and the corresponding models for 
adjustment are expected to change over a period to come. Once the database structure 
is stable one should be able to work with a given derived model for quite a while 
without need for rebuilding the model for each feedback application.  
Notwithstanding the database limitations, certain conclusions emerge with some clarity. 
In Chapter 4 (and appendix 8) we learn, for instance, that the efforts towards 
standardizing surgical treatment appear to have paid off among the selected surgeons 
contributing to the PROCARE database. This emerges as the quartiles of the adjusted 
performance on the all-or-none score range from a mere 6% below to 6% above the 
center average performance. In addition, even with these narrow margins, just 1 center 
stays significantly below the P25 (and two above the P75).  This is in contrast with 
results for Domain 4 (diagnosing and staging) and Domain 8 (histopathology) where 
much more variation is seen with a distance between quartiles of adjusted excess 
probabilities of 25% and 24%, respectively. The unadjusted ranges are even wider. 
Notwithstanding the wide margins, we found that 5 and 2 centers, respectively, have 
indicators that are significantly below the P25. This indicates that there is room for 
improvement in this domain. An educational system as put in place for surgery could be 
considered as a fruitful way forward.  
We note that - in a continuous effort to protect confidentiality - the report contains 
marginal presentations of performance on separate QCIs or quality indexes. An 
inspection of the joint performance on several indexes could point more strongly to 
generalized drop of quality in some centers. While we have not presented that link in 
the report, it is present in the feedback to centers since each is presented with its own 
performance on several indexes. Clearly, centers featuring in the tail of the distribution 
of several indicators should be especially concerned about improving their performance 
in those areas. 
Lessons have been learned that suggest ways for improvement as one builds on results 
on this report both for data gathering and analysis.  
On the data: issues of completeness and reliability.  
Currently, about one third of the targeted patient population is registered in the 
PROCARE database. Less than a sixth of them contribute to all QCIs. This is not only 
the consequence of specific eligibility criteria, but also a symptom of a considerable 
amount of missing data. It comes as no surprise, therefore, that the request for more 
comprehensive coverage of all relevant patients and centers has been echoed by most 
stakeholders in the quality improvement process. This will be a continued concern. 
Even when coverage is more comprehensive the care for data quality remains 
important. This project was unfortunately not able to work with some important 
variables because their data quality was not good enough. Ideally both preventive and 
curative action can be taken.  
• the amount of data to enter should be limited to what is necessary and not 
excessively time-consuming to enter to avoid registration fatigue 
• whenever possible a two-stage data entry procedure may be considered 
whereby more detailed information is requested only once a certain quality 
threshold is hit, 
110 PROCARE – phase III : benchmarking KCE Report 161 
• a system of peer review should be put in place (on a voluntary basis) that 
allows for regular random audits of data records. 
• (if all else fails) some compulsory data entry could be considered 
This work would benefit further in particular from linking to administrative databases to 
improve the quality of data gathering and reduce the registration efforts for the centers. 
The availability of further predictors of center choice, such as distance between the 
patient’s residence and the centers, and predictors of outcome, such as socio-economic 
factors, would enhance the assessment of effects truly due to centers rather than 
factors confounded with the patient choice. The available resource was rather poor in 
that sense which is an important reason why concrete results beyond the 
methodological approach should be considered as quite tentative here and still 
confounded with patient characteristics to some degree.  
On model building quality 
The current project was charged to analyze a total of 44 QCIs and aggregated quality 
indexes. For several of them (16 outcome QCIs) and for the aggregated quality indexes 
(8 per domain + 3 global ones (+1 modified build up)) full models have been built for 
the correction of QCIs for baseline covariates, on the currently still immature data. 
These prediction models have no ambition of showing causal effects of patient 
characteristics, but do aim to predict expected QCIs in function of these characteristics 
such that the additional center effects can be interpreted causally if the predictive value 
of baseline confounders for center effects has been well captured by the model. 
While we have sought to provide methods that are readily adaptable in the routine 
practice of an institution like the Belgian Cancer Register, and we believe we have 
succeeded, the models and the database are complex, and the model building cannot yet 
be automated in standard statistical software.  
On a more technical note:  
The working logistic and Cox regression models involved a Firth Bias correction which 
cannot be used in combination with an automated stepwise regression procedure in 
SAS. For the construction of confidence intervals on the resulting center-specific 
predictions a delta method was developed and implemented in R for the production of 
caterpillar plots. This involves an extra ‘manual’ step in the production of the analysis. 
The combination of sample size and number of patients registered, means that several 
methods have hit their limit of applicability which could lead to extra convergence and 
coverage issues. The same is true for the missing data that contaminate this database, 
and every other one like it (voluntary based). The model building procedure applied 
here could be subject to more detailed scrutiny and more sophisticated adaptation if it 
did not have to be developed for so many different outcomes with the limited 
resources of time and staff. We encourage future users to expand on this once the 
means are available. In particular we advocate the selection of a single (or a few) key 
measures of evaluation which can be modeled in much more detail than here possible. 
Cross validation can then also be applied for instance for evaluation of the stability of 
the models.  
Another area for further research concerns the burden of evidence to put on small 
centers. Due to their typically large confidence intervals small centers have relatively 
little chance of producing `evidence of significant underperformance’ even though there 
are indications of a volume outcome relationship in the literature. One might therefore 
consider demanding varying levels of confidence for crossing relative (and ideally 
absolute) bench marks in this regard. In particular, approaches as developed in Uno et 
al. 54 would lead to an average confidence level of 95% whereby smaller centers be 
presented with lower confidence levels than larger centers. 
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In conclusion, we emphasize that the present report presents first and foremost a 
methodological approach to the problem of assessing quality of care. Secondly, the 
application to the current PROCARE database demonstrates practical feasibility of the 
selected methods in this context. On both accounts methodology as well as application 
is not ‘the final answer’, but several important steps were achieved and a feasible 
approach was presented for work that will continue to progress. There are important 
open questions about some of the candidate methods, questions that will benefit from 
further targeted statistical research. The application to and results on the PROCARE 
database inherit all the limitations of the current database. Selectiveness of the recorded 
patients, missing data, and uneven data quality all contribute to results that must be 
interpreted with caution. 
More generally, we have presented work that will evolve with increased experience 
with the data and the methods. Our current developments have similarly built on the 
previous PROCARE reports which resulted in several recommendations for adapted or 
refined definitions of previously validated quality of care indicators. For instance, upon 
analyzing QCIs and correspondingly studying them in more detail, it emerged that some 
of the previously validated QCIs needed revised definitions. Some QCIs have also 
changed because they turned out harder to measure than anticipated.  
We finally conclude that registration, analysis and feedback on quality of care indicators 
form an important and irreplaceable instrument for quality of care improvement. It is 
essential for evidence-based assessments of the performance of health care centers and 
for the design of intervention strategies to improve care. Imperfect data are better than 
no data when approached with appropriate care. 
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